



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**
(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2017/10/20	(51) Cl.Int./Int.Cl. <i>A61K 31/444</i> (2006.01), <i>A61K 31/4545</i> (2006.01), <i>A61K 31/496</i> (2006.01), <i>A61K 31/5355</i> (2006.01), <i>A61P 17/00</i> (2006.01), <i>A61P 17/06</i> (2006.01), <i>A61P 21/00</i> (2006.01)
(87) Date publication PCT/PCT Publication Date: 2018/04/26	(71) Demandeur/Applicant: SAMUMED, LLC, US
(85) Entrée phase nationale/National Entry: 2019/04/18	(72) Inventeurs/Inventors: DESHMUKH, VISHAL, US; MURPHY, ERIC ANTHONY, US; HOOD, JOHN, US...
(86) N° demande PCT/PCT Application No.: US 2017/057536	(74) Agent: SMART & BIGGAR
(87) N° publication PCT/PCT Publication No.: 2018/075858	
(30) Priorité/Priority: 2016/10/21 (US62/411,478)	

(54) Titre : PROCEDES D'UTILISATION D'INDAZOLE-3-CARBOXAMIDES ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE LA VOIE DE SIGNALISATION WNT/S-CATENINE
(54) Title: METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS




FIG. 1

(57) **Abrégé/Abstract:**
This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis,

(57) **Abrégé(suite)/Abstract(continued):**

morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
26 April 2018 (26.04.2018)



(10) International Publication Number
WO 2018/075858 A1

(51) International Patent Classification:

A61K 31/444 (2006.01) A61P 17/00 (2006.01)
A61K 31/4545 (2006.01) A61P 17/06 (2006.01)
A61K 31/496 (2006.01) A61P 21/00 (2006.01)
A61K 31/5355 (2006.01)

(21) International Application Number:

PCT/US2017/057536

(22) International Filing Date:

20 October 2017 (20.10.2017)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/411,478 21 October 2016 (21.10.2016) US

(71) Applicant: SAMUMED, LLC [US/US]; 9381 Judicial Drive, Suite 160, San Diego, California 92121 (US).

(72) Inventors; and

(71) Applicants: DESHMUKH, Vishal [IN/US]; 3887 Pell Place, 106, San Diego, California 92130 (US). MURPHY, Eric Anthony [US/US]; 727 Via Cafetal, San Marcos, Cal-

ifornia 92069 (US). HOOD, John [US/US]; 5124 Seagrove Court, San Diego, California 92130 (US).

(74) Agent: KENDALL, John T. et al.; Fish & Richardson P.C., PO Box 1022, Minneapolis, Minnesota 55440-1022 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,

(54) Title: METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS




FIG. 1

(57) Abstract: This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

WO 2018/075858 A1



TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

RELATED APPLICATIONS

[001] This application claims the benefit of U.S. Provisional Application No. 62/411,478, filed October 21, 2016, which is incorporated herein by reference in its entirety.

BACKGROUND

Technical Field

[002] This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

Background

[003] Pattern formation is the activity by which embryonic cells form ordered spatial arrangements of differentiated tissues. Speculation on the mechanisms underlying these patterning effects usually centers on the secretion of a signaling molecule that elicits an appropriate response from the tissues being patterned. More recent work aimed at the identification of such signaling molecules implicates secreted proteins encoded by individual members of a small number of gene families.

[004] The Wnt growth factor family includes more than 10 genes identified in the mouse and at least 19 genes identified in the human. Members of the Wnt family of signaling molecules mediate many important short-and long-range patterning processes during invertebrate and vertebrate development. The Wnt signaling pathway is known for its important role in the inductive interactions that regulate growth and differentiation, and plays important roles in the homeostatic maintenance of post-embryonic tissue integrity. Wnt stabilizes cytoplasmic β -catenin, which stimulates the expression of genes including c-myc, c jun, fra-1, and cyclin D1. In addition, misregulation of Wnt signaling can cause developmental defects and is implicated in the genesis of several human cancers. More recently, the Wnt pathway has been implicated in the maintenance of stem or progenitor cells in a growing list of adult tissues that now includes skin, blood, gut, prostate, muscle and the nervous system.

[005] Pathological activation of the Wnt pathway is also believed to be the initial event leading to colorectal cancer in over 85% of all sporadic cases in the Western world. Activation of the Wnt pathway has also been extensively reported for hepatocellular carcinoma, breast cancer, ovarian cancer, pancreatic cancer, melanomas, mesotheliomas, lymphomas and leukemias. In addition to cancer, inhibitors of the Wnt pathway can be used for stem cell research or for the treatment of any diseases characterized by aberrant Wnt activation such as diabetic retinopathy, pulmonary fibrosis, rheumatoid arthritis, scleroderma as well as mycotic and viral infections and bone and cartilage diseases. As such, it is a therapeutic target that is of great interest to the field.

[006] In addition to cancer, there are many cases of genetic diseases due to mutations in Wnt signaling components. Examples of some of the many diseases are Alzheimer's disease [*Proc. Natl. Acad. Sci. U S A* (2007), 104(22), 9434-9], osteoarthritis, polyposis coli [*Science* (1991), 253(5020), 665-669], bone density and vascular defects in the eye (osteoporosis-pseudoglioma syndrome, OPPG) [*N. Engl. J. Med.* (2002), 346(20), 1513-21], familial exudative vitreoretinopathy [*Hum. Mutat.* (2005), 26(2), 104-12], retinal angiogenesis [*Nat. Genet.* (2002), 32(2), 326-30], early coronary disease [*Science* (2007), 315(5816), 1278-82], tetra-amelia syndrome [*Am. J. Hum. Genet.* (2004), 74(3), 558-63], Müllerian-duct regression and virilization [*Engl. J. Med.* (2004), 351(8), 792-8], SERKAL syndrome [*Am. J. Hum. Genet.* (2008), 82(1), 39-47], diabetes mellitus type 2 [*Am. J. Hum. Genet.* (2004), 75(5), 832-43; *N. Engl. J. Med.* (2006), 355(3), 241-50], Fuhrmann syndrome [*Am. J. Hum. Genet.* (2006), 79(2), 402-8], Al-Awadi/Raas-Rothschild/Schinzel phocomelia syndrome [*Am. J. Hum. Genet.* (2006), 79(2), 402-8], odonto-onycho-dermal dysplasia [*Am. J. Hum. Genet.* (2007), 81(4), 821-8], obesity [*Diabetologia* (2006), 49(4), 678-84], split-hand/foot malformation [*Hum. Mol. Genet.* (2008), 17(17), 2644-53], caudal duplication syndrome [*Am. J. Hum. Genet.* (2006), 79(1), 155-62], tooth agenesis [*Am. J. Hum. Genet.* (2004), 74(5), 1043-50], Wilms tumor [*Science* (2007), 315(5812), 642-5], skeletal dysplasia [*Nat. Genet.* (2009), 41(1), 95-100], focal dermal hypoplasia [*Nat. Genet.* (2007), 39(7), 836-8], autosomal recessive anonychia [*Nat. Genet.* (2006), 38(11), 1245-7], neural tube defects [*N. Engl. J. Med.* (2007), 356(14), 1432-7], alpha-thalassemia (ATRX) syndrome [*The Journal of Neuroscience* (2008), 28(47), 12570-12580], fragile X syndrome [*PLoS Genetics* (2010), 6(4), e1000898], ICF syndrome, Angelman syndrome [*Brain Research Bulletin* (2002), 57(1), 109-119], Prader-Willi syndrome [*Journal of Neuroscience* (2006), 26(20), 5383-5392], Beckwith-Wiedemann Syndrome [*Pediatric and Developmental Pathology* (2003), 6(4), 299-306] and Rett syndrome.


[007] Regulation of cell signaling by the Wnt signaling pathway is critical for the formation of neuronal circuits. Wnt pathway modulates in neural tissue, among other things, axon pathfinding, dendritic development, and synaptic assembly. Through different receptors,

Wnt pathway activates and/or regulates diverse signaling pathways and other processes that lead to local changes on the cytoskeleton or global cellular changes involving nuclear function. Recently, a link between neuronal activity, essential for the formation and refinement of neuronal connections, and Wnt signaling has been uncovered. Indeed, neuronal activity regulates the release of various Wnt proteins and the localization of their receptors. Wnt pathway mediates synaptic structural changes induced by neuronal activity or experience. Evidence suggests that dysfunction in Wnt signaling contributes to neurological disorders [*Brain Research Reviews* (2000), 33(1), 1–12; *Oncogene* (2006) 25(57), 7545–7553; *Molecular Neurodegeneration* (2008), 3, 9; *Neurobiology of Disease* (2010), 38(2), 148–153; *Journal of Neurodevelopmental Disorders* (2011), 3(2), 162–174 and *Cold Spring Harbor Perspectives in Biology February* (2012), 4(2)].

[008] Tendinopathies are chronic disorders or injuries of the tendons, that typically result from gradual wear and tear to the tendon, e.g., from overuse or aging, and leading to is tendon degeneration, weakness, tearing, and pain. Individuals who tend to make multiple, repeated motions in their jobs, sports, or regular daily activities tend to be more likely to develop tendinopathies. Tendinopathy usually causes pain, stiffness, and loss of strength in the affected area.

[009] Skin disorders are common afflictions for many people. Some of the most common are dermatitis (also known as eczema) and psoriasis. Both dermatitis and psoriasis can cause serious physical and/or psychological suffering to the subject regardless of the location on the body that these conditions occur.

[010] WO 2013/040215 describes indazole-3-carboxamides having Formula (I) and their use as Wnt/B-catenin signaling pathway inhibitors.




SUMMARY

[011] This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a

therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

[012] One embodiment disclosed herein includes administering an indazole-3-carboxamide compound having the structure of Formula I:



as well as prodrugs and pharmaceutically acceptable salts thereof.

[013] In some embodiments of Formula (I):

R^1 , R^2 and R^4 are independently selected from the group consisting of H, C_{1-9} alkyl, halide, $-N(R^{10})_2$, $-XR^{10}$, CN, $-OCF_3$ and $-CF_3$;

R^3 is selected from the group consisting of carbocyclyl R^6 , heterocyclyl R^6 , aryl R^6 and heteroaryl R^6 ;

R^5 is selected from the group consisting of $-(C_{1-9} \text{ alkyl})_n \text{carbocyclyl}R^7$, $-(C_{1-9} \text{ alkyl})_n \text{heterocyclyl}R^7$, $-(C_{1-9} \text{ alkyl})_n \text{aryl}R^7$ and $-(C_{1-9} \text{ alkyl})_n \text{heteroaryl}R^7$;

each R^6 is 1-5 substituents each selected from the group consisting of H, C_{1-9} alkyl, halide, amino, $-OCF_3$, $-CF_3$, $-CN$, $-XR^{10}$, $-(C_{1-9} \text{ alkyl})_n \text{carbocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n \text{heterocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n \text{aryl}R^8$, $-(C_{1-9} \text{ alkyl})_n \text{heteroaryl}R^8$, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1-9} \text{ alkyl})_n N(R^{10})_2$, $-(C_{1-9} \text{ alkyl})_n N(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$;

each R^7 is 1-5 substituents each selected from the group consisting of H, C_{1-9} alkyl, halide, amino, $-OCF_3$, $-CF_3$, $-CN$, $-XR^{10}$, $-(C_{1-9} \text{ alkyl})_n \text{carbocyclyl}R^9$, $-(C_{1-9} \text{ alkyl})_n \text{heterocyclyl}R^9$, $-(C_{1-9} \text{ alkyl})_n \text{aryl}R^9$, $-(C_{1-9} \text{ alkyl})_n \text{heteroaryl}R^9$, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1-9} \text{ alkyl})_n N(R^{10})_2$, $-(C_{1-9} \text{ alkyl})_n N(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$;














each R^8 is 1-5 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, OCF_3 , $-CF_3$, $-CN$, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1-9} \text{ alkyl})_n N(R^{12})_2$, $-(C_{1-9} \text{ alkyl})_n N(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$;

each R^9 is 1-5 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$, $-CN$, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1-9} \text{ alkyl})_n N(R^{12})_2$, $-(C_{1-9} \text{ alkyl})_n N(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$;




each R^{10} is independently selected from the group consisting of H, C_{1-9} alkyl, $-(C_{1-9} \text{ alkyl})_n N(R^{14})_2$, $-(C_{1-9} \text{ alkyl})_n \text{carbocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n \text{heterocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n \text{aryl}R^8$ and $-(C_{1-9} \text{ alkyl})_n \text{heteroaryl}R^8$;

in some embodiments, it is provided that R^5 is not phenyl R^7 when R^1 , R^2 and R^4 are H, R^3 is 4-pyridyl R^6 and R^6 and R^7 are both H;



in some embodiments, it is provided that R^3 is not 3-pyridyl R^6 when R^1 , R^2 and R^4 are

H, R^5 is selected from the group consisting of phenyl R^7 , , , , , , , , , , , ,  and , and R^6 and R^7 are both H;

in some embodiments, it is provided that R^3 is not oxazole R^6 when R^1 , R^2 and R^4 are

H, R^5 is selected from the group consisting of ,  and , and R^6 is H;

in some embodiments, it is provided that R^3 is not thiazole R^6 when R^1 , R^2 and R^4 are

H, R^5 is selected from the group consisting of  and , and R^6 is H;

each R^6 is 1-5 substituents each selected from the group consisting of H, C_{1-9} alkyl, halide, amino, $-OCF_3$, $-CF_3$, $-CN$, $-XR^{10}$, $-(C_{1-9} \text{ alkyl})_n\text{carbocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n\text{heterocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n\text{aryl}R^8$, $-(C_{1-9} \text{ alkyl})_n\text{heteroaryl}R^8$, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$;

each R^7 is 1-5 substituents each selected from the group consisting of H, C_{1-9} alkyl, halide, amino, $-OCF_3$, $-CF_3$, $-CN$, $-XR^{10}$, $-(C_{1-9} \text{ alkyl})_n\text{carbocyclyl}R^9$, $-(C_{1-9} \text{ alkyl})_n\text{heterocyclyl}R^9$, $-(C_{1-9} \text{ alkyl})_n\text{aryl}R^9$, $-(C_{1-9} \text{ alkyl})_n\text{heteroaryl}R^9$, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$;

each R^8 is 1-5 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, OCF_3 , $-CF_3$, $-CN$, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1-9} \text{ alkyl})_nN(R^{12})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$;

each R^9 is 1-5 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$, $-CN$, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1-9} \text{ alkyl})_nN(R^{12})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$;

each R^{10} is independently selected from the group consisting of H, C_{1-9} alkyl, $-(C_{1-9} \text{ alkyl})_n N(R^{14})_2$, $-(C_{1-9} \text{ alkyl})_n \text{carbocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n \text{heterocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n \text{aryl}R^8$ and $-(C_{1-9} \text{ alkyl})_n \text{heteroaryl}R^8$;

each R^{11} is independently selected from the group consisting of C_{1-9} alkyl, $-N(R^{14})_2$, $-(C_{1-9} \text{ alkyl})_n \text{carbocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n \text{heterocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n \text{aryl}R^8$ and $-(C_{1-9} \text{ alkyl})_n \text{heteroaryl}R^8$;

each R^{12} is independently selected from the group consisting of H, C_{1-9} alkyl, $-(C_{1-9} \text{ alkyl})_n N(R^{14})_2$, $-(C_{1-9} \text{ alkyl})_n \text{carbocyclyl}$, $-(C_{1-9} \text{ alkyl})_n \text{heterocyclyl}$, $-(C_{1-9} \text{ alkyl})_n \text{aryl}$ and $-(C_{1-9} \text{ alkyl})_n \text{heteroaryl}$;

each R^{13} is independently selected from the group consisting of C_{1-9} alkyl, $-N(R^{14})_2$, $-(C_{1-9} \text{ alkyl})_n \text{carbocyclyl}$, $-(C_{1-9} \text{ alkyl})_n \text{heterocyclyl}$, $-(C_{1-9} \text{ alkyl})_n \text{aryl}$ and $-(C_{1-9} \text{ alkyl})_n \text{heteroaryl}$;

each R^{14} is independently selected from the group consisting of H, C_{1-3} alkyl, carbocyclyl and aryl;

each X is selected from the group consisting of a bond, -O- and -S-; and

each n is 0 or 1.

[015] Some embodiments include administering stereoisomers and pharmaceutically acceptable salts of a compound of general Formula (I).

[016] Some embodiments include administering pro-drugs of a compound of general Formula (I).

[017] Some embodiments include administering pharmaceutical compositions comprising a compound of general Formula (I) or in a pharmaceutically acceptable carrier, diluent, or excipient.

[018] It is to be understood that both the foregoing general description and the following detailed description are exemplary and explanatory only and are not restrictive of the invention, as claimed.

BRIEF DESCRIPTION OF THE FIGURES

[019] FIG. 1 depicts a plot showing that exposure of a human colorectal cancer cell line (SW480) to compound 175 inhibited Wnt/ β -catenin activity in these cells in a dose-dependent manner (EC_{50} = 152.9 nM). The human colorectal cancer cell line (SW480) with constitutive activation of the Wnt pathway and engineered to express a Wnt responsive promoter linked to luciferase were treated with compound 175 at test concentrations of 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001 and 0.0003 μ M.

[020] FIGS. 2A-C depict plots of the percentage of human mesenchymal stem cells (hMSC) expressing SCXA, tenascinC, and tenomodulin, respectively vs. concentration of compound 175. Human Mesenchymal Stem Cells were treated with compound 175 at test concentrations of 750, 333.3, 166.6, 83.3, 41.7, 21.7, 10.8 and 5.8 nM. Exposure of the cells

to compound **175** for 7 days induced the expression of markers of tenocyte differentiation-SCXA, TenacinC and Tenomodulin in a dose-dependent manner (EC_{50} = 139- 189 nM).

[021] **FIG. 3** are images of the expression of SCXA, tenacinC, and tenomodulin in hMSCs treated with DMSO, bone morphogenic protein (BMP) and fibroblast growth factor (FGF), and compound **175** at 333 nM concentration.

[022] **FIGS. 4A-B** depict plots of tumor necrosis factor alpha concentration in THP-1 cells vs. the logarithm of the concentration of compound **175** the THP-1 cells were exposed to, and interleukin-6 concentration in THP-1 cells vs. the logarithm of the concentration of compound **175** the THP-1 cells were exposed to, respectively. THP-1 cells, a human monocyte cell line (6×10^4 cells/well in a 96-well plate) were treated with DMSO (vehicle) or compound **175** at concentrations of 10, 3.5, 1, 0.5, 0.1, 0.035, 0.01, 0.005 μ M. After 2 hours, treated cells were stimulated with LPS (50 ng/mL for 5 hours [TNF α] and 500 ng/ml for 22 hours [IL6]) at 37°C to induce production of the cytokines. Supernatants (diluted 1:1 or 1:4) were collected and analyzed for TNF α and IL6 levels using the TNF α and IL6 ELISA kits. Inhibition profile and EC_{50} was calculated using Prism 5. Representative images indicate that exposure of the cells to compound **175** inhibited the production of TNF α (**4A**) and IL6 (**4B**) in THP-1 cells in a dose-dependent manner, with an average EC_{50} of 342 - 547 nM for TNF α and 356 - 629 nM for IL6 (2 independent assays and 3 replicates per assay).

[023] **FIG. 5** is a grid of images of a rat Achilles tendon; a rat Achilles tendon treated with a collagenase with a vehicle; a rat Achilles tendon treated with a collagenase, compound **175**, and benzyl alcohol; and a rat Achilles tendon treated with a collagenase and compound **175**. Tendinopathy in rats was induced by injecting collagenase (50 μ l, 10 mg/ml Type IA in PBS, pH 7.4, ~469 units/mg) or sham needle puncture for control in the Achilles tendon. After 1 day, rats were dosed once daily for 21 days via topical application with vehicle control or compound **175** (10 mg/ml). 24 hours after the last dose, tendons were isolated, fixed with 10% buffered formalin, sectioned and stained with H&E. Group 1 (sham injection), Group 2 (Collagenase-Vehicle), Group 3 (Collagenase-compound **175** with 1% BA) and Group 4 (Collagenase-compound **175** with 0.5% Tween 80, without BA).

[024] **FIG. 6** is a plot of tendon histology scores of rat Achilles tendon; a rat Achilles tendon treated with a collagenase with a vehicle; a rat Achilles tendon treated with a collagenase, compound **175**, and benzyl alcohol; and a rat Achilles tendon treated with a collagenase and compound **175**. Tendinopathy in rats was induced by injecting collagenase (50 μ l, 10 mg/ml Type IA in PBS, pH 7.4, ~469 units/mg) or sham needle puncture for control in the Achilles tendon. After 1 day, rats were dosed once daily for 21 days via topical application with vehicle control or compound **175** (10 mg/ml). 24 hours after the last dose, tendons were isolated, fixed with 10% buffered formalin, sectioned and stained with H&E. Group 1 (sham injection), Group 2 (Collagenase-Vehicle), Group 3 (Collagenase-compound

175 with 1% BA) and Group 4 (Collagenase-compound 175 with 0.5% Tween 80, without BA). Blinded histology scoring of tendon injury and inflammation indicated that compound 175 with or without BA preservative significantly ameliorated collagenase-induced tendinopathy (** $p < 0.01$ and * $p < 0.05$ respectively) by student's t test. For this study, a total of 64 sections were scored for Group 1 and ~96 sections each for Group 2-4.

[025] FIG. 7 is series of plots of plasma concentrations of KC/GRO in rats vs. the number of days elapsed after administration of a vehicle, compound 175 with benzyl alcohol, and compound 175. Tendinopathy in rats was induced by injecting collagenase (50 μ l, 10 mg/ml Type IA in PBS, pH 7.4, ~469 units/mg) in the Achilles tendon. After 1 day, rats were dosed once daily for 21 days via topical application with vehicle control or compound 175 (10 mg/ml). Blood was collected at various timepoints and plasma was analyzed for KC/GRO by ELISA. Measurement of inflammatory cytokine KC/GRO in the plasma of rats from Group 2 (Collagenase-Vehicle), Group 3 (Collagenase-compound 175 10 mg/mL with 1% BA) and Group 4 (Collagenase- compound 175 10 mg/mL without BA, with 0.5% Tween 80). Compound 175 with or without BA preservative significantly decreased the levels of KC/GRO in plasma ($p < 0.05$, student's t test as indicated in **Error! Reference source not found.**), indicating an anti-inflammatory effect of compound 175. These data were generated from 3 replicates per timepoint per group ($n=3$).

[026] FIG. 8 is a grid of images of a rat Achilles tendon; a rat Achilles tendon treated with a collagenase with a vehicle; a rat Achilles tendon treated with a collagenase, 3 mg/ml compound 175, and benzyl alcohol; a rat Achilles tendon treated with a collagenase, 10 mg/ml compound 175 and benzyl alcohol; a rat Achilles tendon treated with a collagenase, 3 mg/ml compound 175, and Phx; and a rat Achilles tendon treated with a collagenase, 10 mg/ml compound 175, and Phx. Tendinopathy in rats was induced by injecting collagenase (50 μ l, 10 mg/ml Type IA in PBS, pH 7.4, ~469 units/mg) or sham needle puncture for control in the Achilles tendon. After 1 day, rats were dosed once daily for 21 days via topical application with vehicle or compound 175 topical formulations. 24 hours after the last dose, tendons were isolated, fixed with 10% buffered formalin, sectioned and stained with H&E. Group 1 (sham injection), Group 2 (Collagenase-Vehicle with 0.5% Phx), Group 3 (Collagenase-compound 175 3 mg/ml with 0.5% BA), Group 4 (Collagenase-compound 175 10 mg/ml with 0.5% BA), Group 5 (Collagenase-compound 175 3 mg/ml with 0.5% Phx) and Group 6 (Collagenase-COMPOUND 175 10 mg/ml with 0.5% Phx).

[027] FIG. 9 is a plot of tendon histology scores of a rat Achilles tendon; a rat Achilles tendon treated with a collagenase with a vehicle; a rat Achilles tendon treated with a collagenase, 3 mg/ml compound 175, and benzyl alcohol; a rat Achilles tendon treated with a collagenase, 10 mg/ml compound 175, and benzyl alcohol; a rat Achilles tendon treated with a collagenase, 3 mg/ml compound 175, and Phx; and a rat Achilles tendon treated with a

collagenase, 10 mg/ml compound 175, and Phx. Tendinopathy in rats was induced by injecting collagenase (50 μ l, 10 mg/ml Type IA in PBS, pH 7.4, ~469 units/mg) or sham needle puncture for control in the Achilles tendon. After 1 day, rats were dosed once daily for 21 days via topical application with vehicle or COMPOUND 175 topical formulations. 24 hours after the last dose, tendons were isolated, fixed with 10% buffered formalin, sectioned and stained with H&E. Group 1 (sham injection), Group 2 (Collagenase-Vehicle with 0.5% Phx), Group 3 (Collagenase-compound 175 3 mg/ml with 0.5% BA), Group 4 (Collagenase-compound 175 10 mg/ml with 0.5% BA), Group 5 (Collagenase-compound 175 3 mg/ml with 0.5% Phx) and Group 6 (Collagenase-compound 175 10 mg/ml with 0.5% Phx). Blinded histology scoring of tendon injury and inflammation indicates that compound 175 at both 3 and 10mg/mL, with either BA or Phx as a preservative, significantly ameliorated collagenase-induced tendinopathy (** $p < 0.01$ and *** $p < 0.001$) by student's t test. For this study, a total of 94 sections were scored for Group 1 and 92-116 sections for Groups 2-6.

[028] FIG. 10 is series of plots of plasma concentrations of KC/GRO in rats vs. the number of days elapsed after administration of a vehicle, 3 mg/ml COMPOUND 175 with benzyl alcohol, 10 mg/ml COMPOUND 175 with benzyl alcohol, 3 mg/ml COMPOUND 175 with Phx, and 10 mg/ml compound 175 with Phx. Tendinopathy in rats was induced by injecting collagenase (50 μ l, 10 mg/ml Type IA in PBS, pH 7.4, ~469 units/mg) in the Achilles tendon. After 1 day, rats were dosed once daily for 21 days via topical application with vehicle control or topical compound 175. Blood was collected at various timepoints and plasma was analyzed for KC/GRO by ELISA. Measurement of inflammatory cytokine KC/GRO in the plasma of rats from Group 2 (Collagenase-Vehicle containing 0.5% Phx), Group 3 (Collagenase-compound 175 3 mg/mL with 0.5% BA), Group 4 (Collagenase-compound 175 10 mg/mL with 0.5% BA), Group 5 (Collagenase-compound 175 3 mg/mL with 0.5% Phx) and Group 6 (Collagenase-compound 175 10 mg/mL with 0.5% Phx). Compound 175 at both 3 and 10mg/mL dose concentrations, with either BA or Phx as preservative significantly decreased the levels of KC/GRO in plasma compared to vehicle ($p < 0.05$ and $p < 0.01$, student's t test as indicated in Table 5), indicating an anti-inflammatory effect of compound 175. These data were generated from 3 replicates per timepoint per group ($n=3$).

[029] FIG. 11 is a series of plots of compound 175 concentrations vs. time in Sprague-Dawley rat tendons, plasma, and skin after a topical application of 1 mg/mL compound 175 and benzyl alcohol, 10 mg/mL compound 175 and benzyl alcohol, and 10 mg/mL compound 175.

DETAILED DESCRIPTION

[030] This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions

independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

Definitions

[031] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as is commonly understood by one of ordinary skill in the art to which this disclosure belongs. All patents, applications, published applications, and other publications are incorporated by reference in their entirety. In the event that there is a plurality of definitions for a term herein, those in this section prevail unless stated otherwise.

[032] In this specification and in the claims, the following terms have the meanings as defined. As used herein, "alkyl" means a branched, or straight chain chemical group containing only carbon and hydrogen, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and pentyl. Alkyl groups can either be unsubstituted or substituted with one or more substituents, e.g., halide, alkoxy, acyloxy, amino, amido, cyano, nitro, hydroxyl, mercapto, carboxy, carbonyl, benzyloxy, aryl, heteroaryl, or other functionality that may be suitably blocked, if necessary for purposes of the invention, with a protecting group. Alkyl groups can be saturated or unsaturated (e.g., containing $-C=C-$ or $-C\equiv C-$ subunits), at one or several positions. Typically, alkyl groups will comprise 1 to 9 carbon atoms, preferably 1 to 6, more preferably 1 to 4, and most preferably 1 to 2 carbon atoms.

[033] As used herein, "carbocyclyl" means a cyclic ring system containing only carbon atoms in the ring system backbone, such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cyclohexenyl. Carbocyclyls may include multiple fused rings. Carbocyclyls may have any degree of saturation provided that at least one ring in the ring system is not aromatic. Carbocyclyl groups can either be unsubstituted or substituted with one or more substituents, e.g., alkyl, halide, alkoxy, acyloxy, amino, amido, cyano, nitro, hydroxyl, mercapto, carboxy, carbonyl, benzyloxy, aryl, heteroaryl, or other functionality that may be suitably blocked, if necessary for purposes of the invention, with a protecting group. Typically, carbocyclyl groups will comprise 3 to 10 carbon atoms, preferably 3 to 6.

[034] As used herein, "lower alkyl" means a subset of alkyl having 1 to 3 carbon atoms, and thus is a hydrocarbon substituent, which is linear, or branched. Examples of lower alkyl include methyl, ethyl, n-propyl and isopropyl. Likewise, radicals using the terminology "lower" refer to radicals preferably with 1 to about 3 carbons in the alkyl portion of the radical.

[035] As used herein, “amido” means a H-CON- or alkyl-CON-, carbocycl-CON-, aryl-CON-, heteroaryl-CON- or heterocycl-CON group wherein the alkyl, carbocycl, aryl or heterocycl group is as herein described.

[036] As used herein, “aryl” means an aromatic radical having a single-ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl) with only carbon atoms present in the ring backbone. Aryl groups can either be unsubstituted or substituted with one or more substituents, e.g., alkyl, amino, cyano, hydroxyl, lower alkyl, haloalkyl, alkoxy, nitro, halo, mercapto, and other substituents. A preferred carbocyclic aryl is phenyl.

[037] As used herein, the term “heteroaryl” means an aromatic radical having one or more heteroatom(s) (e.g., N, O, or S) in the ring backbone and may include a single ring (e.g., pyridine) or multiple condensed rings (e.g., quinoline). Heteroaryl groups can either be unsubstituted or substituted with one or more substituents, e.g., amino, cyano, hydroxyl, lower alkyl, haloalkyl, alkoxy, nitro, halo, mercapto, and other substituents. Examples of heteroaryl include thienyl, pyridinyl, furyl, oxazolyl, oxadiazolyl, pyrrolyl, imidazolyl, triazolyl, thiodiazolyl, pyrazolyl, isoxazolyl, thiadiazolyl, pyranyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, thiazolyl, benzothienyl, benzoxadiazolyl, benzofuranyl, benzimidazolyl, benzotriazolyl, cinnolinyl, indazolyl, indolyl, isoquinolinyl, isothiazolyl, naphthyridinyl, purinyl, thienopyridinyl, pyrido[2,3-*d*]pyrimidinyl, pyrrolo[2,3-*b*]pyridinyl, quinazolinyl, quinolinyl, thieno[2,3-*c*]pyridinyl, pyrazolo[3,4-*b*]pyridinyl, pyrazolo[3,4-*c*]pyridinyl, pyrazolo[4,3-*c*]pyridine, pyrazolo[4,3-*b*]pyridinyl, tetrazolyl, and others.

[038] In these definitions it is clearly contemplated that substitution on the aryl and heteroaryl rings is within the scope of certain embodiments. Where substitution occurs, the radical is called substituted aryl or substituted heteroaryl. Preferably one to three and more preferably one or two substituents occur on the aryl ring. Though many substituents will be useful, preferred substituents include those commonly found in aryl compounds, such as alkyl, cycloalkyl, hydroxy, alkoxy, cyano, halo, haloalkyl, mercapto and the like.

[039] As used herein, “amide” includes both RNR'CO- (in the case of R = alkyl, alkaminocarbonyl-) and RCONR'- (in the case of R = alkyl, alkyl carbonylamino-).

[040] As used herein, the term “ester” includes both ROCO- (in the case of R = alkyl, alkoxycarbonyl-) and RCOO- (in the case of R = alkyl, alkylcarbonyloxy-).

[041] As used herein, “acyl” means an H-CO- or alkyl-CO-, carbocycl-CO-, aryl-CO-, heteroaryl-CO- or heterocycl-CO- group wherein the alkyl, carbocycl, aryl or heterocycl group is as herein described. Preferred acyls contain a lower alkyl. Exemplary alkyl acyl groups include formyl, acetyl, propanoyl, 2-methylpropanoyl, t-butylacetyl, butanoyl and palmitoyl.

[042] As used herein, "halo", "halide" or "halogen" is a chloro, bromo, fluoro or iodo atom radical. Chloro, bromo and fluoro are preferred halides. Most preferred halide is fluorine.

[043] As used herein, "haloalkyl" means a hydrocarbon substituent, which is linear or branched or cyclic alkyl, alkenyl or alkynyl substituted with chloro, bromo, fluoro or iodo atom(s). Most preferred of these are fluoroalkyls, wherein one or more of the hydrogen atoms have been substituted by fluoro. Preferred haloalkyls are of 1 to about 3 carbons in length, more preferred haloalkyls are 1 to about 2 carbons, and most preferred are 1 carbon in length. The skilled artisan will recognize then that as used herein, "haloalkylene" means a diradical variant of haloalkyl, such diradicals may act as spacers between radicals, other atoms, or between the parent ring and another functional group.

[044] As used herein, "heterocyclyl" means a cyclic ring system comprising at least one heteroatom in the ring system backbone. Heterocyclyls may include multiple fused rings. Heterocyclyls may have any degree of saturation provided that at least one ring in the ring system is not aromatic. Heterocyclyls may be substituted or unsubstituted with one or more substituents, e.g., alkyl, halide, alkoxy, acyloxy, amino, amido, cyano, nitro, hydroxyl, mercapto, carboxy, carbonyl, benzyloxy, aryl, heteroaryl, and other substituents, and are attached to other groups via any available valence, preferably any available carbon or nitrogen. More preferred heterocycles are of 5-7 members. In six membered monocyclic heterocycles, the heteroatom(s) are selected from one up to three of O, N or S, and wherein when the heterocycle is five membered, preferably it has one or two heteroatoms selected from O, N, or S. Examples of heterocyclyl include aziriny, aziridinyl, azetidiny, oxetanyl, thietanyl, 1,4,2-dithiazolyl, 1,3-benzodioxolyl, dihydroisoindolyl, dihydroisoquinoliny, dihydrocinnoliny, dihydrobenzodioxiny, dihydro[1,3]oxazolo[4,5-b]pyridiny, benzothiazolyl, dihydroindolyl, dihydropyridiny, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-dioxolanyl, isoindoliny, morpholiny, thiomorpholiny, piperaziny, pyranly, pyrrolidinyl, tetrahydrofuryl, tetrahydropyridiny, oxazinyl, thiazinyl, thiiny, thiazolidiny, isothiazolidiny, oxazolidiny, isoxazolidiny, piperidinyl, pyrazolidiny, imidazolidiny, thiomorpholiny, and others.

[045] As used herein, "substituted amino" means an amino radical which is substituted by one or two alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl groups, wherein the alkyl, aryl, heteroaryl or heterocyclyl are defined as above.

[046] As used herein, "substituted thiol" means RS- group wherein R is an alkyl, an aryl, heteroaryl or a heterocyclyl group, wherein the alkyl, cycloalkyl, aryl, heteroaryl or heterocyclyl are defined as above.

[047] As used herein, "sulfonyl" means an alkylSO₂, arylSO₂, heteroarylSO₂, carbocyclylSO₂, or heterocyclyl-SO₂ group wherein the alkyl, carbocyclyl, aryl, heteroaryl or heterocyclyl are defined as above.

[048] As used herein, "sulfamido" means an alkyl-N-S(O)₂N-, aryl-NS(O)₂N-, heteroaryl-NS(O)₂N-, carbocyclyl-NS(O)₂N- or heterocyclyl-NS(O)₂N- group wherein the alkyl, carbocyclyl, aryl, heteroaryl or heterocyclyl group is as herein described.

[049] As used herein, "sulfonamido" means an alkyl-S(O)₂N-, aryl-S(O)₂N-, heteroaryl-S(O)₂N-, carbocyclyl-S(O)₂N- or heterocyclyl-S(O)₂N- group wherein the alkyl, carbocyclyl, aryl, heteroaryl or heterocyclyl group is as herein described.

[050] As used herein, "ureido" means an alkyl-NCON-, aryl-NCON-, heteroaryl-NCON-, carbocyclyl-NCON- or heterocyclyl-NCON- group wherein the alkyl, carbocyclyl, aryl, heteroaryl or heterocyclyl group is as herein described.

[051] As used herein, when two groups are indicated to be "linked" or "bonded" to form a "ring," it is to be understood that a bond is formed between the two groups and may involve replacement of a hydrogen atom on one or both groups with the bond, thereby forming a carbocyclyl, heterocyclyl, aryl, or heteroaryl ring. The skilled artisan will recognize that such rings can and are readily formed by routine chemical reactions, and it is within the purview of the skilled artisan to both envision such rings and the methods of their formations. Preferred are rings having from 3-7 members, more preferably 5 or 6 members. As used herein the term "ring" or "rings" when formed by the combination of two radicals refers to heterocyclic, carbocyclic, aryl, or heteroaryl rings.

[052] The skilled artisan will recognize that some structures described herein may be resonance forms or tautomers of compounds that may be fairly represented by other chemical structures, even when kinetically; the artisan recognizes that such structures are only a very small portion of a sample of such compound(s). Such compounds are clearly contemplated within the scope of this invention, though such resonance forms or tautomers may not be explicitly represented herein.

[053] The compounds provided herein may encompass various stereochemical forms. The compounds also encompass diastereomers as well as optical isomers, e.g. mixtures of enantiomers including racemic mixtures, as well as individual enantiomers and diastereomers, which arise as a consequence of structural asymmetry in certain compounds. Separation of the individual isomers or selective synthesis of the individual isomers is accomplished by application of various methods which are well known to practitioners in the art. Unless otherwise indicated, when a disclosed compound is named or depicted by a structure without specifying the stereochemistry and has one or more chiral centers, it is understood to represent all possible stereoisomers of the compound.

[054] The term "administration" or "administering" refers to a method of giving a dosage of a compound or pharmaceutical composition to a vertebrate or invertebrate, including a mammal, a bird, a fish, or an amphibian, where the method is, e.g., orally, subcutaneously, intravenously, intranasally, topically, transdermally, intraperitoneally,

intramuscularly, intrapulmonarily, vaginally, rectally, ontologically, neuro-otologically, intraocularly, subconjunctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intracisternally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic devices. The preferred method of administration can vary depending on various factors, *e.g.*, the components of the pharmaceutical composition, the site of the disease, the disease involved, and the severity of the disease.

[055] A “diagnostic” as used herein is a compound, method, system, or device that assists in the identification and characterization of a health or disease state. The diagnostic can be used in standard assays as is known in the art.

[056] The term “mammal” is used in its usual biological sense. Thus, it specifically includes humans, cattle, horses, dogs, and cats, but also includes many other species.

[057] The term “pharmaceutically acceptable carrier” or “pharmaceutically acceptable excipient” includes any and all solvents, co-solvents, complexing agents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like which are not biologically or otherwise undesirable. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions. In addition, various adjuvants such as are commonly used in the art may be included. These and other such compounds are described in the literature, *e.g.*, in the Merck Index, Merck & Company, Rahway, NJ. Considerations for the inclusion of various components in pharmaceutical compositions are described, *e.g.*, in Gilman *et al.* (Eds.) (2010); Goodman and Gilman’s: The Pharmacological Basis of Therapeutics, 12th Ed., The McGraw-Hill Companies.

[058] The term “pharmaceutically acceptable salt” refers to salts that retain the biological effectiveness and properties of the compounds of the preferred embodiments and, which are not biologically or otherwise undesirable. In many cases, the compounds of the preferred embodiments are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto. Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid,

nitric acid, phosphoric acid, and the like. Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like. Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases. Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts. Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. Many such salts are known in the art, as described in World Patent Publication 87/05297, Johnston et al., published September 11, 1987 (incorporated by reference herein).

[059] “Solvate” refers to the compound formed by the interaction of a solvent and a Wnt pathway inhibitor, a metabolite, or salt thereof. Suitable solvates are pharmaceutically acceptable solvates including hydrates.

[060] “Subject” as used herein, means a human or a non-human mammal, *e.g.*, a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate or a bird, *e.g.*, a chicken, as well as any other vertebrate or invertebrate.

[061] By “therapeutically effective amount” or “pharmaceutically effective amount” is one which is sufficient to achieve the desired effect and may vary according to the nature and severity of the disease condition, and the potency of the compound. “Therapeutically effective amount” is also intended to include one or more of the compounds of Formula (I) in combination with one or more other agents that are effective to inhibit Wnt related diseases and/or conditions. The combination of compounds is preferably a synergistic combination. Synergy, as described, for example, by Chou and Talalay, *Advances in Enzyme Regulation* (1984), 22, 27-55, occurs when the effect of the compounds when administered in combination is greater than the additive effect of the compounds when administered alone as a single agent. In general, a synergistic effect is most clearly demonstrated at sub-optimal concentrations of the compounds. It will be appreciated that different concentrations may be employed for prophylaxis than for treatment of an active disease. This amount can further depend upon the patient’s height, weight, sex, age and medical history.

[062] A therapeutic effect relieves, to some extent, one or more of the symptoms of the disease, and includes curing a disease. “Curing” means that the symptoms of active disease are eliminated. However, certain long-term or permanent effects of the disease may exist even after a cure is obtained (such as extensive tissue damage).

[063] “Treat,” “treatment,” or “treating,” as used herein refers to administering a pharmaceutical composition for therapeutic purposes. The term “therapeutic treatment” refers to administering treatment to a patient already suffering from a disease thus causing a therapeutically beneficial effect, such as ameliorating existing symptoms, preventing additional symptoms, ameliorating or preventing the underlying metabolic causes of symptoms, postponing or preventing the further development of a disorder and/or reducing the severity of symptoms that will or are expected to develop.

[064] “Morphea” as used herein refers to a skin condition wherein discolored and/or hardened patches appear on the skin (e.g., one or more outer layers of the skin) resulting from excessive collagen deposition.

[065] “Raynaud’s syndrome” as used herein refers to a disease in which certain parts of the body (e.g., fingers and/or toes) feel numb and/or cold in response to various stimuli (e.g., cold temperatures and/or stress) due to arterial narrowing.

[066] “Darier’s disease” as used herein refers to an autosomal dominant disorder characterized by the appearance of dark crusty patches on the skin (e.g., keratotic papules, keratosis follicularis or dyskeratosis follicularis) that may contain pus.

[067] “Wound healing” as used herein refers to a process by which skin and/or other bodily tissue repairs itself after experiencing, for example, damage and/or trauma.

[068] “Ichthyosis” as used herein refers to a group of genetic skin disorders characterized by the presence of dry, scaly, cracked, and/or flaky skin.

[069] “Tendinopathy” as used herein refers to a disease or disorder of a tendon characterized by inflammation, deterioration, and/or injury of the tendon and/or tissue contacting, near, or associated with the tendon. Tendinopathy includes, for example, inflammation of the tendon (e.g., tendonitis), non-inflammatory degeneration of, for example, the structure and/or composition of a tendon (e.g., tendinosis), inflammation of the paratenon near or in contact with a tendon (e.g., paratenonitis), micro-trauma to the tendon, and rupture of the tendon (e.g., acute, chronic, partial and/or complete rupture). The term also encompasses tenosynovitis, a tendinopathy of the outer lining of the tendon which occurs in certain tendons such as flexor tendons and the Achilles tendon. Symptoms of tendinopathy include pain at rest, upon palpation of the tendon, and/or with movement of, for example, the tendon, tissue, joint, or bone near or associated with the tendon; joint stiffness; difficulty moving; weakness of the joint or muscles surrounding the tendon; redness of the skin near the tendon; swelling of the tendon and/or of tissue near the tendon; and/or crepitus.

[070] “Tendinosis” as used herein, refers to a non-inflammatory injury to the tendon characterized by intratendinous degeneration of the tendon typically in the form of microtears in the tissue in and around the tendon caused by overuse, leading to an increase in the number of tendon repair cells around the area of damage. Degeneration of the tendon is

caused by damage to or disorganization of the collagen fibers, cells, and vascular components of the tendon, which can reduce the tendon's tensile strength and can lead to tendon rupture if not treated.


[071] "Tendinitis" as used herein refers to an inflammatory injury to the tendon, characterized by degeneration like that observed in tendinosis, but also accompanied by inflammation of the tendon, vascular disruption and an inflammatory repair response. Tendinitis is often associated with fibroblastic and myofibroblastic proliferation, as well as hemorrhage and organizing granulation tissue. Generally, tendinitis is referred to by the body part involved, such as Achilles tendinitis (affecting the Achilles tendon), or patellar tendinitis (also known as "jumper's knee," affecting the patellar tendon), though there are certain exceptions, such as lateral epicondylitis (also known as "tennis elbow," affecting the Extensor Carpi Radialis Brevis tendon). Symptoms can vary from aches or pains and local stiffness to a burning sensation surrounding the entire joint around the inflamed tendon. In some cases, tendonitis is characterized by swelling, sometimes accompanied by heat and redness; there may also be visible knots surrounding the joint. For many patients, the pain is usually worse during and after activity, and the tendon and joint area can become stiffer the following day as muscles tighten from the movement of the tendon.

[072] "Psoriasis" as used herein refers to an autoimmune disease in which skin cells build up and causes raised, red, scaly patches to appear on the skin.

[073] "Dermatitis" (also known as eczema) as used herein refers to generic inflammation of the skin. Specific types of dermatitis include atopic, contact, nummular, photo-induced, and stasis dermatitis. These diseases are characterized by itchiness, red skin, and a rash.


Compounds

[074] Some embodiments of the present invention include compounds, salts, pharmaceutically acceptable salts or pro-drug thereof of Formula (I):






[075] In some embodiments of Formula I, R¹, R² and R⁴ are independently selected from the group consisting of H, C₁₋₉ alkyl, halide, -N(R¹⁰)₂, -XR¹⁰, CN, -OCF₃ and -CF₃.



[079] In some embodiments of Formula I, R⁵ is not 4-pyridylR⁷ when R¹, R² and R⁴ are H, R³ is selected from the group consisting of 3-pyridylR⁶, 4-pyridylR⁶, 2-pyridylR⁶,



[083] In some embodiments of Formula I, R^3 is not oxazole R^6 when R^1 , R^2 and

R^4 are H, R^5 is selected from the group consisting of ,  and , and R^6 is H.

[084] In some embodiments of Formula I, R^3 is not thiazole R^6 when R^1 , R^2 and

R^4 are H, R^5 is selected from the group consisting of  and , and R^6 is H.

[085] In some embodiments of Formula I, each R^6 is 1-5 substituents each selected from the group consisting of H, C_{1-9} alkyl, halide, amino, $-OCF_3$, $-CF_3$, $-CN$, $-XR^{10}$, $-(C_{1-9} \text{ alkyl})_n\text{carbocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n\text{heterocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n\text{aryl}R^8$, $-(C_{1-9} \text{ alkyl})_n\text{heteroaryl}R^8$, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$.

[086] In some embodiments of Formula I, each R^7 is 1-5 substituents each selected from the group consisting of H, C_{1-9} alkyl, halide, amino, $-OCF_3$, $-CF_3$, $-CN$, $-XR^{10}$, $-(C_{1-9} \text{ alkyl})_n\text{carbocyclyl}R^9$, $-(C_{1-9} \text{ alkyl})_n\text{heterocyclyl}R^9$, $-(C_{1-9} \text{ alkyl})_n\text{aryl}R^9$, $-(C_{1-9} \text{ alkyl})_n\text{heteroaryl}R^9$, $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$.

[087] In some embodiments of Formula I, each R^8 is 1-5 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, OCF_3 , $-CF_3$, $-CN$, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1-9} \text{ alkyl})_nN(R^{12})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$.

[088] In some embodiments of Formula I, each R^9 is 1-5 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$, $-CN$, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1-9} \text{ alkyl})_nN(R^{12})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$.

[089] In some embodiments of Formula I, each R^{10} is independently selected from the group consisting of H, C_{1-9} alkyl, $-(C_{1-9} \text{ alkyl})_nN(R^{14})_2$, $-(C_{1-9} \text{ alkyl})_n\text{carbocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n\text{heterocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n\text{aryl}R^8$ and $-(C_{1-9} \text{ alkyl})_n\text{heteroaryl}R^8$.

[090] In some embodiments of Formula I, each R^{11} is independently selected from the group consisting of C_{1-9} alkyl, $-N(R^{14})_2$, $-(C_{1-9} \text{ alkyl})_n\text{carbocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n\text{heterocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n\text{aryl}R^8$ and $-(C_{1-9} \text{ alkyl})_n\text{heteroaryl}R^8$.

[091] In some embodiments of Formula I, each R^{12} is independently selected from the group consisting of H, C_{1-9} alkyl, $-(C_{1-9} \text{ alkyl})_nN(R^{14})_2$, $-(C_{1-9} \text{ alkyl})_n\text{carbocyclyl}$, $-(C_{1-9} \text{ alkyl})_n\text{heterocyclyl}$, $-(C_{1-9} \text{ alkyl})_n\text{aryl}$ and $-(C_{1-9} \text{ alkyl})_n\text{heteroaryl}$.

[092] In some embodiments of Formula I, each R^{13} is independently selected from the group consisting of C_{1-9} alkyl, $-N(R^{14})_2$, $-(C_{1-9} \text{ alkyl})_n\text{carbocyclyl}$, $-(C_{1-9} \text{ alkyl})_n\text{heterocyclyl}$, $-(C_{1-9} \text{ alkyl})_n\text{aryl}$ and $-(C_{1-9} \text{ alkyl})_n\text{heteroaryl}$.

[093] In some embodiments of Formula I, each R^{14} is independently selected from the group consisting of H, C_{1-3} alkyl, carbocyclyl and aryl.


[094] In some embodiments of Formula I, each X is selected from the group consisting of a bond, -O- and -S-.

[095] In some embodiments of Formula I, each n is 0 or 1.

[096] In some embodiments of Formula I, X is O.

[097] In some embodiments of Formula I, R^1 , R^2 and R^4 are H.

[098] Some embodiments of the present invention include compounds, salts, pharmaceutically acceptable salts or pro-drug thereof of Formula (Ia):



Ia

wherein:

R^3 is selected from the group consisting of 3-pyridyl R^6 , 5-pyrimidinyl R^6 , and 4-pyridazinyl R^6 ;

R^5 is selected from the group consisting of -heteroaryl R^7 ;

R^6 is a substituent selected from the group consisting of $-(C_{1-2} \text{ alkyl})\text{heterocyclyl}$ R^8 and -heterocyclyl R^8 ;

R^7 is 1-2 substituents each independently selected from the group consisting of H, C_{1-3} alkyl, halide, $-NH_2$, $-OCF_3$, $-CF_3$, $-CN$, $-OR^{10}$, $-(C_{1-2} \text{ alkyl})\text{heterocyclyl}$ R^9 , -heterocyclyl R^9 , and $-SO_2R^{11}$;

R^8 is 1-2 substituents each independently selected from the group consisting of H, C_{1-3} alkyl, halide, and $-OR^{12}$;


each R^9 is 1-2 substituents each independently selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$, $-CN$, and $-OR^{12}$;

R^{10} is selected from the group consisting of H and C_{1-3} alkyl;

R^{11} is C_{1-3} alkyl; and

each R^{12} is independently selected from the group consisting of H and C_{1-3} alkyl.

[099] Some embodiments of the present invention include compounds, salts, pharmaceutically acceptable salts or pro-drug thereof of Formula (Ia):




wherein:

R³ is 3-pyridylR⁶;

R⁵ is selected from the group consisting of pyridylR⁷, -pyrimidinylR⁷, and -pyridazinylR⁷;

R⁶ is -CH₂heterocyclylR⁸;

R⁷ is 1-2 substituents each independently selected from the group consisting of H, F,



R⁸ is 1-2 substituents each independently selected from the group consisting of H and halide.

[0100] In some embodiments of Formula **Ia**, R³ is selected from the group consisting of 3-pyridylR⁶, 5-pyrimidinylR⁶, and 4-pyridazinylR⁶;

[0101] In some embodiments of Formula **Ia**, R⁵ is selected from the group consisting of -heteroarylR⁷.

[0102] In some embodiments of Formula **Ia**, R⁵ is selected from the group consisting of -piperazinylR⁷, -tetrahydropyranylR⁷, -piperidinylR⁷, pyrazolylR⁷, pyrimidinylR⁷, pyridazinylR⁷, benzo[*d*][1,3]dioxolylR⁷, 2,3-dihydrobenzo[*b*][1,4]dioxinylR⁷, pyrazinylR⁷, and 3-pyridylR⁷.

[0103] In some embodiments of Formula **Ia**, R⁶ is a substituent selected from the group consisting of -(C₁-₂ alkyl)heterocyclylR⁸ and -heterocyclylR⁸.

[0104] In some embodiments of Formula **Ia**, R^6 is each R^6 is 1-2 substituents each selected from the group consisting of $-(C_{1-2} \text{ alkyl})\text{heterocyclyl}R^8$, $-\text{heterocyclyl}R^8$, $-(C_{1-2} \text{ alkyl})\text{aryl}R^8$, $-\text{N}(R^{10})\text{C}(=\text{O})R^{11}$ and $-(C_{1-2} \text{ alkyl})\text{N}(R^{10})_2$.

[0105] In some embodiments of Formula **Ia**, R^7 is 1-2 substituents each independently selected from the group consisting of H, C_{1-3} alkyl, halide, $-\text{NH}_2$, $-\text{OCF}_3$, $-\text{CF}_3$, $-\text{CN}$, $-\text{OR}^{10}$, $-(C_{1-2} \text{ alkyl})\text{heterocyclyl}R^9$, $-\text{heterocyclyl}R^9$, and $-\text{SO}_2R^{11}$.

[0106] In some embodiments of Formula **Ia**, each R^7 is 1-2 substituents each selected from the group consisting of unsubstituted C_{1-3} alkyl, halide, amino, $-\text{OCF}_3$, $-\text{CF}_3$, $-\text{CN}$, $-\text{OR}^{10}$, $-\text{C}(=\text{O})R^{11}$, $-\text{N}(R^{10})\text{C}(=\text{O})R^{11}$, $-\text{N}(R^{10})_2$, $-(C_{1-2} \text{ alkyl})\text{N}(R^{10})_2$, and $-\text{N}(R^{10})\text{SO}_2R^{11}$.

[0107] In some embodiments of Formula **Ia**, R^8 is 1-2 substituents each independently selected from the group consisting of H, C_{1-3} alkyl, halide, and $-\text{OR}^{12}$.

[0108] In some embodiments of Formula **Ia**, each R^9 is 1-2 substituents each independently selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-\text{OCF}_3$, $-\text{CF}_3$, $-\text{CN}$, and $-\text{OR}^{12}$.

[0109] In some embodiments of Formula **Ia**, R^{10} is selected from the group consisting of H and C_{1-3} alkyl.

[0110] In some embodiments of Formula **Ia**, each R^{10} is independently selected from the group consisting of H, C_{1-3} alkyl, $-(C_{1-3} \text{ alkyl})\text{N}(R^{14})_2$ and $-\text{aryl}R^8$.

[0111] In some embodiments of Formula **Ia**, R^{11} is C_{1-3} alkyl.

[0112] In some embodiments of Formula **Ia**, R^{11} is each R^{11} is independently selected from the group consisting of C_{1-3} alkyl, $-\text{N}(R^{14})_2$, $-\text{carbocyclyl}R^8$ and $-\text{heterocyclyl}R^8$.


[0113] In some embodiments of Formula **Ia**, each R^{12} is independently selected from the group consisting of H and C_{1-3} alkyl.

[0114] In some embodiments of Formula **Ia**, R^3 is selected from the group consisting of $\text{aryl}R^6$ and $\text{heteroaryl}R^6$.

[0115] In some embodiments of Formula **Ia**, when R^3 is heteroaryl, the heteroaryl is not selected from the group consisting of isoquinoline, 1H-pyrrolo[2,3-*c*]pyridine and tetrazole.

[0116] In some embodiments of Formula **Ia**, R^5 is selected from the group consisting of $-\text{carbocyclyl}R^7$, $-\text{heterocyclyl}R^7$, $-\text{aryl}R^7$, $-\text{heteroaryl}R^7$, and $-(C_{1-2} \text{ alkyl})\text{heteroaryl}R^7$.

[0117] In some embodiments of Formula **Ia**, R^5 is not 4-pyridyl R^7 when R^3 is selected from the group consisting of 3-pyridyl R^6 , 4-pyridyl R^6 , 2-pyridyl R^6 , phenyl R^6 ,



(C₁₋₂ alkyl)heterocyclylR⁹, -heterocyclylR⁹, -arylR⁹, -(C₁₋₂ alkyl)arylR⁹, -C(=O)R¹¹, -N(R¹⁰)C(=O)R¹¹, -N(R¹⁰)₂, -(C₁₋₂ alkyl)N(R¹⁰)₂, -N(R¹⁰)SO₂R¹¹ and -SO₂R¹¹.

[0125] In some embodiments of Formula **Ia**, each R⁸ is 1-2 substituents each selected from the group consisting of H, C₁₋₃ alkyl, halide, amino, OCF₃, -CF₃ -CN and -OR¹².

[0126] In some embodiments of Formula **Ia**, each R⁹ is 1-2 substituents each selected from the group consisting of H, C₁₋₃ alkyl, halide, amino, -OCF₃, -CF₃ -CN and -OR¹².

[0127] In some embodiments of Formula **Ia**, each R¹⁰ is independently selected from the group consisting of H, C₁₋₃ alkyl, -(C₁₋₃ alkyl)N(R¹⁴)₂ and -arylR⁸.

[0128] In some embodiments of Formula **Ia**, each R¹¹ is independently selected from the group consisting of C₁₋₃ alkyl, -N(R¹⁴)₂, -carbocyclylR⁸ and -heterocyclylR⁸.

[0129] In some embodiments of Formula **Ia**, each R¹² is independently selected from the group consisting of H and C₁₋₃ alkyl.

[0130] In some embodiments of Formula **Ia**, each R¹⁴ is independently selected from the group consisting of H, C₁₋₃ alkyl and carbocyclyl.

[0131] In some embodiments of Formula **I** or Formula **Ia**, halide is fluorine.

[0132] In some embodiments of Formula **I** or Formula **Ia**, R³ is -arylR⁶.

[0133] In some embodiments of Formula **I** or Formula **Ia**, R³ is -heteroarylR⁶.

[0134] In some embodiments of Formula **I** or Formula **Ia**, R⁵ is -arylR⁷.

[0135] In some embodiments of Formula **I** or Formula **Ia**, R⁵ is -heteroarylR⁷.

[0136] In some embodiments of Formula **I** or Formula **Ia**, R⁵ is -heterocyclylR⁷.

[0137] In some embodiments of Formula **I** or Formula **Ia**, R³ is -heteroarylR⁶ and R⁵ is -heteroarylR⁷.

[0138] In some embodiments of Formula **I** or Formula **Ia**, R³ is -phenylR⁶ and R⁵ is -heteroarylR⁷.

[0139] In some embodiments of Formula **I** or Formula **Ia**, R³ is -heteroarylR⁶ and R⁵ is -phenylR⁷.

[0140] In some embodiments of Formula **I** or Formula **Ia**, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷.

[0141] In some embodiments of Formula **I** or Formula **Ia**, R³ is -3-pyridylR⁶ and R⁵ is -CH₂-3-pyridylR⁷.

[0142] In some embodiments of Formula **I** or Formula **Ia**, R³ is -3-pyridylR⁶ and R⁵ is -pyridazinylR⁷.

[0143] In some embodiments of Formula **I** or Formula **Ia**, R³ is -3-pyridylR⁶ and R⁵ is -pyrazinylR⁷.

[0144] In some embodiments of Formula **I** or Formula **Ia**, R³ is -3-pyridylR⁶ and R⁵ is -pyrimidinylR⁷.

[0145] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is benzo[*d*][1,3]dioxolyl.

[0146] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is 2,3-dihydrobenzo[*b*][1,4]dioxinyl.

[0147] In some embodiments of Formula I or Formula Ia, the aryl is phenyl.

[0148] In some embodiments of Formula I or Formula Ia, when R³ is heteroaryl, the heteroaryl is 3-pyridyl.

[0149] In some embodiments of Formula I or Formula Ia, when R⁵ is heteroaryl, the heteroaryl is 3-pyridyl.

[0150] In some embodiments of Formula I or Formula Ia, when R⁵ is heteroaryl, the heteroaryl is 5-pyrimidinyl.

[0151] In some embodiments of Formula I or Formula Ia, when R⁵ is heteroaryl, the heteroaryl is 4-pyridazinyl.

[0152] In some embodiments of Formula I or Formula Ia, when R⁵ is heteroaryl, the heteroaryl is pyrazolyl.

[0153] In some embodiments of Formula I or Formula Ia, when R⁵ is heteroaryl, the heteroaryl is benzo[*d*][1,3]dioxolyl.

[0154] In some embodiments of Formula I or Formula Ia, when R⁵ is heteroaryl, the heteroaryl is 2,3-dihydrobenzo[*b*][1,4]dioxinyl.

[0155] In some embodiments of Formula I or Formula Ia, R⁶ is a heterocyclyl. For example, the heterocyclyl can be selected from the group consisting of morpholinyl, piperazinyl, piperidinyl, tetrahydropyranyl, azetidiny and pyrrolidinyl. In certain embodiments, R⁶ is morpholinyl. In another embodiment, R⁶ is piperazinyl. In another embodiment, R⁶ is piperidinyl. In another embodiment, R⁶ is pyrrolidinyl.

[0156] In some embodiments of Formula I or Formula Ia, R⁷ is a heterocyclyl. For example, the heterocyclyl can be selected from the group consisting of morpholinyl, piperazinyl, piperidinyl, tetrahydropyranyl, azetidiny and pyrrolidinyl. In certain embodiments, R⁷ is morpholinyl. In another embodiment, R⁷ is piperazinyl. In another embodiment, R⁷ is piperidinyl. In another embodiment, R⁷ is pyrrolidinyl. In another embodiment, R⁷ is azetidiny.

[0157] In some embodiments of Formula I or Formula Ia, R¹⁰ is a carbocyclyl. For example, the carbocyclyl can be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In certain embodiments, R¹⁰ is cyclopropyl. In another embodiment, R¹⁰ is cyclobutyl. In another embodiment, R¹⁰ is cyclopentyl. In another embodiment, R¹⁰ is cyclohexyl.

[0158] In some embodiments of Formula I or Formula Ia, R¹¹ is a heterocyclyl. For example, the heterocyclyl can be selected from the group consisting of morpholinyl,

piperazinyl, piperidinyl, tetrahydropyranyl, azetidiny and pyrrolidinyl. In certain embodiments, R¹¹ is morpholinyl. In another embodiment, R¹¹ is piperazinyl. In another embodiment, R¹¹ is piperidinyl. In another embodiment, R¹¹ is pyrrolidinyl. In another embodiment, R¹¹ is azetidiny.

[0159] In some embodiments of Formula I or Formula Ia, R¹¹ is a carbocyclyl. For example, the carbocyclyl can be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In certain embodiments, R¹¹ is cyclopropyl. In another embodiment, R¹¹ is cyclobutyl. In another embodiment, R¹¹ is cyclopentyl. In another embodiment, R¹¹ is cyclohexyl.

[0160] In some embodiments of Formula I or Formula Ia, R¹² is a carbocyclyl. For example, the carbocyclyl can be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In certain embodiments, R¹² is cyclopropyl. In another embodiment, R¹² is cyclobutyl. In another embodiment, R¹² is cyclopentyl. In another embodiment, R¹² is cyclohexyl.

[0161] In some embodiments of Formula I or Formula Ia, R¹³ is a heterocyclyl. For example, the heterocyclyl can be selected from the group consisting of morpholinyl, piperazinyl, piperidinyl, tetrahydropyranyl, azetidiny and pyrrolidinyl. In certain embodiments, R¹³ is morpholinyl. In another embodiment, R¹³ is piperazinyl. In another embodiment, R¹³ is piperidinyl. In another embodiment, R¹³ is pyrrolidinyl. In another embodiment, R¹³ is azetidiny.

[0162] In some embodiments of Formula I or Formula Ia, R¹³ is a carbocyclyl. For example, the carbocyclyl can be selected from the group consisting of cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl. In certain embodiments, R¹³ is cyclopropyl. In another embodiment, R¹³ is cyclobutyl. In another embodiment, R¹³ is cyclopentyl. In another embodiment, R¹³ is cyclohexyl.

[0163] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent.

[0164] In some embodiments of Formula I or Formula Ia, R⁶ is 1-2 substituents.

[0165] In some embodiments of Formula I, R⁶ is 1-3 substituents.

[0166] In some embodiments of Formula I, R⁶ is 1-4 substituents.

[0167] In some embodiments of Formula I or Formula Ia, R⁶ is H.

[0168] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is a halide.

[0169] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -NH₂.

[0170] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -OCF₃.

[0171] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -OCH₃.

[0172] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -CF₃.

[0173] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -heterocyclylR⁸.

[0174] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -(CH₂)heterocyclylR⁸.

[0175] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -(CH₂)pyrrolidinylR⁸.


[0176] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -(CH₂)pyrrolidinylR⁸ where R⁸ is two substituents and both substituents are halides.

[0177] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -(CH₂)piperidinylR⁸.

[0178] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -(CH₂)phenylR⁸.

[0179] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is - phenoxyR⁸.

[0180] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent



and the substituent is

[0181] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -N(R¹⁰)₂.

[0182] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -N(R¹⁰)₂ where each R¹⁰ is independently selected from C₁₋₃ alkyl.

[0183] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -(CH₂)N(R¹⁰)₂.

[0184] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -(CH₂)N(R¹⁰)₂ where each R¹⁰ is independently selected from C₁₋₃ alkyl.

[0185] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -N(R¹⁰)SO₂R¹¹.

[0186] In some embodiments of Formula I or Formula Ia, R⁶ is one substituent and the substituent is -N(R¹⁰)C(=O)R¹¹.

[0187] In some embodiments of Formula I or Formula Ia, R^6 is one substituent and the substituent is $-N(R^{10})C(=O)R^{11}$ where R^{11} is a heterocyclyl.


[0188] In some embodiments of Formula I or Formula Ia, R^6 is one substituent and the substituent is $-N(R^{10})C(=O)R^{11}$ where R^{11} is a carbocyclyl.

[0189] In some embodiments of Formula I, R^6 is two substituents and the substituents are fluorine and $-(C_{1-9} \text{ alkyl})_n \text{ heterocyclyl} R^8$.

[0190] In some embodiments of Formula Ia, R^6 is two substituents and the substituents are fluorine and $-\text{heterocyclyl} R^8$.

[0191] In some embodiments of Formula Ia, R^6 is two substituents and the substituents are fluorine and $-(C_{1-2} \text{ alkyl}) \text{ heterocyclyl} R^8$.

[0192] In some embodiments of Formula I or Formula Ia, R^6 is one substituent and the substituent is select from the group consisting of



[0193] In some embodiments of Formula I or Formula Ia, R^7 is one substituent.

[0194] In some embodiments of Formula I or Formula Ia, R^7 is 1-2 substituents.

[0195] In some embodiments of Formula I, R^7 is 1-3 substituents.

[0196] In some embodiments of Formula I, R^7 is 1-4 substituents.

[0197] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is a halide.

[0198] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-\text{NH}_2$.

[0199] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-\text{OH}$.

[0200] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-\text{CF}_3$.

[0201] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is -CN.

[0202] In some embodiments of Formula I, R^7 is one substituent and the substituent is $-XR^{10}$ where X is O and R^{10} is C_{1-3} alkyl.

[0203] In some embodiments of Formula Ia, R^7 is one substituent and the substituent is $-OR^{10}$ and R^{10} is C_{1-3} alkyl.

[0204] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-\text{phenyl}R^9$.

[0205] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-(CH_2)N(R^{10})_2$.

[0206] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-(CH_2)N(R^{10})_2$ where each R^{10} is independently selected from C_{1-3} alkyl.

[0207] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-(CH_2)\text{heterocycl}R^9$.

[0208] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-(CH_2)\text{pyrrolidin}R^9$.

[0209] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-\text{heterocycl}R^9$.

[0210] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-\text{phenoxy}R^9$.

[0211] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-(CH_2)\text{phenyl}R^9$.

[0212] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-\text{phenyl}R^9$.

[0213] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-N(R^{10})C(=O)R^{11}$.

[0214] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-N(R^{10})C(=O)R^{11}$ where R^{11} is a carbocycl.


[0215] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-N(R^{10})_2$.

[0216] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-C(=O)R^{11}$ where R^{11} is select from the group consisting of $-\text{heterocycl}R^8$ and $-N(R^{10})_2$.

[0217] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-\text{SO}_2R^{11}$.

[0218] In some embodiments of Formula I or Formula Ia, R^7 is one substituent and the substituent is $-\text{SO}_2R^{11}$; and R^{11} is C_{1-3} alkyl.

[0220] In some embodiments of Formula I or Formula Ia, R⁷ is one substituent and the substituent is select from the group consisting of



[0232] In some embodiments of Formula I or Formula Ia, R⁹ is 1-2 substituents.

[0233] In some embodiments of Formula I, R⁹ is 1-3 substituents.

[0234] In some embodiments of Formula I, R⁹ is 1-4 substituents.

[0235] In some embodiments of Formula I or Formula Ia, R⁹ is H.

[0236] In some embodiments of Formula I or Formula Ia, R⁹ is one substituent and the substituent is C₁₋₃ alkyl.

[0237] In some embodiments of Formula I or Formula Ia, R⁹ is one substituent and the substituent is -OH.

[0238] In some embodiments of Formula I or Formula Ia, R⁹ is one substituent and the substituent is a halide.

[0239] In some embodiments of Formula I or Formula Ia, R⁹ is two substituents and the substituents are halides.

[0240] In some embodiments of Formula I or Formula Ia, R⁸ is a -C₁₋₃ alkyl. For example, the -C₁₋₃ alkyl can be selected from the group consisting of methyl, ethyl, n-propyl and isopropyl. In certain embodiments, R⁸ is methyl. In another embodiment, R⁸ is ethyl.

[0241] In some embodiments of Formula I or Formula Ia, R¹⁰ is a -C₁₋₃ alkyl. For example, the -C₁₋₃ alkyl can be selected from the group consisting of methyl, ethyl, n-propyl and iso-propyl. In certain embodiments, R¹⁰ is methyl. In another embodiment, R¹⁰ is ethyl. In another embodiment, R¹⁰ is n-propyl. In another embodiment, R¹⁰ is iso-propyl.

[0242] In some embodiments of Formula I or Formula Ia, R¹¹ is a -C₁₋₃ alkyl. For example, the -C₁₋₃ alkyl can be selected from the group consisting of methyl, ethyl, n-propyl and iso-propyl. In certain embodiments, R¹¹ is methyl. In another embodiment, R¹¹ is ethyl. In another embodiment, R¹¹ is n-propyl. In another embodiment, R¹¹ is iso-propyl.

[0243] In some embodiments of Formula I or Formula Ia, R¹⁴ is a -C₁₋₃ alkyl. For example, the -C₁₋₃ alkyl can be selected from the group consisting of methyl, ethyl, n-propyl and iso-propyl. In certain embodiments, R¹⁴ is methyl. In another embodiment, R¹⁴ is ethyl. In another embodiment, R¹⁴ is n-propyl. In another embodiment, R¹⁴ is iso-propyl.

[0244] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)N(R¹⁰)₂; and R⁷ is one substituent consisting of -CF₃; and each R¹⁰ is -C₁₋₃ alkyl.

[0245] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)heterocyclylR⁸; R⁷ and R⁸ are both H; and the heterocycle is a 5-member ring.

[0246] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)heterocyclylR⁸; R⁷ and R⁸ are both H; and the heterocycle is a 6-member ring.

[0247] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)heterocyclylR⁸; R⁷ is one substituent consisting of CN; R⁸ is H; and the heterocycle is a 5-member ring.

[0248] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)heterocyclylR⁸; R⁷ is one substituent consisting of CN; R⁸ is H; and the heterocycle is a 6-member ring.

[0249] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)heterocyclylR⁸; R⁷ is one substituent consisting of CF₃; R⁸ is H; and the heterocycle is a 6-member ring.

[0250] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)heterocyclylR⁸; R⁷ is one substituent consisting of -heterocyclylR⁸; each R⁸ is H; and the heterocycles are independently selected from a 5 or 6-member ring.

[0251] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)N(R¹⁰)₂; and R⁷ is one substituent consisting of -CN; and each R¹⁰ is -C₁₋₃ alkyl.

[0252] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)N(R¹⁰)₂; and R⁷ is one substituent consisting of -(C₁₋₂ alkyl)heterocyclylR⁸; R⁸ is H; each R¹⁰ is -C₁₋₃ alkyl; and the heterocycle is a 6-member ring.

[0253] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)heterocyclylR⁸; R⁷ is one substituent consisting of -heterocyclylR⁸; each R⁸ is one substituent independently selected from H and -OH; and the heterocycles are independently selected from a 5 or 6-member ring.

[0254] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)heterocyclylR⁸; R⁷ is one substituent consisting of -C(=O)R¹¹; R¹¹ is -heterocyclylR⁸; each R⁸ is H; and the heterocycles are independently selected from a 5 or 6-member ring.

[0255] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)heterocyclylR⁸; R⁷ is one substituent consisting of -heterocyclylR⁸; each R⁸ is 1-3 substituents independently selected from H and F with the proviso that at least one substituent on one heterocycle is fluorine; and each heterocycle is a 5-member ring.













[0256] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)heterocyclylR⁸; R⁷ is one substituent consisting of -C(=O)R¹¹; R¹¹ is -NHR¹⁰; R¹⁰ is heterocyclylR⁸; each R⁸ is H; and the heterocycles are independently selected from a 5 or 6-member ring.



















[0257] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)heterocyclylR⁸; R⁷ is one substituent consisting of -SO₂R¹¹; R⁸ is H; R¹¹ is -C₁₋₃ alkyl; and the heterocycle is a 6-member ring.

[0258] In some embodiments of Formula I or Formula Ia, R³ is -3-pyridylR⁶ and R⁵ is -3-pyridylR⁷; R⁶ is one substituent consisting of -(C₁₋₂ alkyl)heterocyclylR⁸; R⁷ is H; R⁸ is 1-4 substituents independently selected from H and F with the proviso that at least one substituent is fluorine; and the heterocycle is a 5-member ring.

[0259] Illustrative compounds of Formula (I) are shown in Table 1.

Table 1.



















1		2		3	
4		5		6	
7		8		9	
10		11		12	



















13		14		15	
16		17		18	
19		20		21	
22		23		24	
25		26		27	
28		29		30	

31		32		33	
34		35		36	
37		38		39	
40		41		42	
43		44		45	
46		47		48	
49		50		51	

52		53		54	
55		56		57	
58		59		60	
61		62		63	
64		65		66	
67		68		69	
70		71		72	

73		74		75	
76		77		78	
79		80		81	
82		83		84	
85		86		87	
88		89		90	
91		92		93	



















94		95		96	
97		98		99	
100		101		102	
103		104		105	
106		107		108	
109		110		111	

112		113		114	
115		116		117	
118		119		120	
121		122		123	
124		125		126	
127		128		129	

130		131		132	
133		134		135	
136		137		138	
139		140		141	
142		143		144	
145		146		147	



















148		149		150	
151		152		153	
154		155		156	
157		158		159	
160		161		162	
163		164		165	






















166		167		168	
169		170		171	
172		173		174	
175		176		177	
178		179		180	
181		182		183	

184		185		186	
187		188		189	
190		191		192	
193		194		195	
196		197		198	
199		200		201	

202		203		204	
205		206		207	
208		209		210	
211		212		213	
214		215		216	
217		218		219	

220		221		222	
223		224		225	
226		227		228	
229		230		231	
232		233		234	
235		236		237	
238		239		240	

241		242		243	
244		245		246	
247		248		249	
250		251		252	
253		254		255	
256		257		258	

259		260		261	
262		263		264	
265		266		267	
268		269		270	
271		272		273	
274		275		276	
277		278		279	

280		281		282	
283		284		285	
286		287		288	
289		290		291	
292		293		294	
295		296		297	
298		299		300	
301		302		303	






















304		305		306	
307		308		309	
310		311		312	
313		314		315	
316		317		318	
319		320		321	
322		323		324	

325		326		327	
328		329		330	
331		332		333	
334		335		336	
337		338		339	
340		341		342	
343		344		345	



















346		347		348	
349		350		351	
352		353		354	
355		356		357	
358		359		360	
361		362		363	
364		365		366	



















367		368		369	
370		371		372	
373		374		375	
376		377		378	
379		380		381	
382		383		384	
385		386		387	



















388		389		390	
391		392		393	
394		395		396	
397		398		399	
400		401		402	
403		404		405	
406		407		408	






















409		410		411	
412		413		414	
415		416		417	
418		419		420	
421		422		423	
424		425		426	
427		428		429	

430		431		432	
433		434		435	
436		437		438	
439		440		441	
442		443		444	
445		446		447	






















448		449		450	
451		452		453	
454		455		456	
457		458		459	
460		461		462	
463		464		465	






















466		467		468	
469		470		471	
472		473		474	
475		476		477	
478		479		480	
481		482		483	






















484		485		486	
487		488		489	
490		491		492	
493		494		495	
496		497		498	
499		500		501	

502		503		504	
505		506		507	
508		509		510	
511		512		513	
514		515		516	
517		518		519	
520		521		522	



















523		524		525	
526		527		528	
529		530		531	
532		533		534	
535		536		537	
538		539		540	
541		542		543	
544		545		546	

547		548		549	
550		551		552	
553		554		555	
556		557		558	
559		560		561	
562		563		564	
565		566		567	

























568		569		570	
571		572		573	
574		575		576	
577		578		579	
580		581		582	
583		584		585	
586		587		588	

589		590		591	
592		593		594	
595		596		597	
598		599		600	
601		602		603	
604		605		606	
607		608		609	

610		611		612	
613		614		615	
616		617		618	
619		620		621	
622		623		624	
625		626		627	
628		629		630	






















631		632		633	
634		635		636	
637		638		639	
640		641		642	
643		644		645	
646		647		648	






















649		650		651	
652		653		654	
655		656		657	
658		659		660	
661		662		663	
664		665		666	
667		668		669	






















670		671		672	
673		674		675	
676		677		678	
679		680		681	
682		683		684	
685		686		687	
688		689		690	
691		692		693	

694		695		696	
697		698		699	
700		701		702	
703		704		705	
706		707		708	
709		710		711	
712		713		714	
715		716		717	






















718		719		720	
721		722		723	
724		725		726	
727		728		729	
730		731		732	
733		734		735	
736		737		738	





739		740		741	
742		743		744	
745		746		747	
748		749		750	
751		752		753	
754		755		756	
757		758		759	

760		761		762	
763		764		765	
766		767		768	
769		770		771	
772		773		774	
775		776		777	
778		779		780	

781		782		783	
784		785		786	
787		788		789	
790		791		792	
793		794		795	
796		797		798	
799		800		801	

802		803		804	
805		806		807	
808		809		810	
811		812		813	
814		815		816	
817		818		819	
820		821		822	
823		824		825	

826		827		828	
829		830		831	
832		833		834	
835		836		837	
838		839		840	
841		842		843	
844		845		846	

847		848		849	
850					

Compound preparation

[0260] The starting materials used in preparing the compounds of the invention are known, made by known methods, or are commercially available. It will be apparent to the skilled artisan that methods for preparing precursors and functionality related to the compounds claimed herein are generally described in the literature. The skilled artisan given the literature and this disclosure is well equipped to prepare any of the compounds.

[0261] It is recognized that the skilled artisan in the art of organic chemistry can readily carry out manipulations without further direction, that is, it is well within the scope and practice of the skilled artisan to carry out these manipulations. These include reduction of carbonyl compounds to their corresponding alcohols, oxidations, acylations, aromatic substitutions, both electrophilic and nucleophilic, etherifications, esterification and saponification and the like. These manipulations are discussed in standard texts such as *March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure* 6th Ed., John Wiley & Sons (2007), Carey and Sundberg, *Advanced Organic Chemistry* 5th Ed., Springer (2007), *Comprehensive Organic Transformations: A Guide to Functional Group Transformations*, 2nd Ed., John Wiley & Sons (1999) (incorporated herein by reference in its entirety) and the like.

[0262] The skilled artisan will readily appreciate that certain reactions are best carried out when other functionality is masked or protected in the molecule, thus avoiding any undesirable side reactions and/or increasing the yield of the reaction. Often the skilled artisan utilizes protecting groups to accomplish such increased yields or to avoid the undesired reactions. These reactions are found in the literature and are also well within the scope of the skilled artisan. Examples of many of these manipulations can be found for example in T. Greene and P. Wuts *Protecting Groups in Organic Synthesis*, 4th Ed., John Wiley & Sons (2007), incorporated herein by reference in its entirety.

[0263] To further illustrate this invention, the following examples are included. The examples should not, of course, be construed as specifically limiting the invention. Variations of these examples within the scope of the claims are within the purview of one

skilled in the art and are considered to fall within the scope of the invention as described, and claimed herein. The reader will recognize that the skilled artisan, armed with the present disclosure, and skill in the art is able to prepare and use the invention without exhaustive examples.

[0264] Trademarks used herein are examples only and reflect illustrative materials used at the time of the invention. The skilled artisan will recognize that variations in lot, manufacturing processes, and the like, are expected. Hence the examples, and the trademarks used in them are non-limiting, and they are not intended to be limiting, but are merely an illustration of how a skilled artisan may choose to perform one or more of the embodiments of the invention.

[0265] (^1H) nuclear magnetic resonance spectra (NMR) were measured in the indicated solvents on a Bruker NMR spectrometer (Avance TM DRX300, 300 MHz for ^1H or Avance TM DRX500, 500 MHz for ^1H) or Varian NMR spectrometer (Mercury 400BB, 400 MHz for ^1H). Peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane. The peak multiplicities are denoted as follows, s, singlet; d, doublet; t, triplet; q, quartet; ABq, AB quartet; quin, quintet; sex, sextet; sep, septet; non, nonet; dd, doublet of doublets; d/ABq, doublet of AB quartet; dt, doublet of triplets; td, triplet of doublets; m, multiplet.

[0266] The following abbreviations have the indicated meanings:

brine = saturated aqueous sodium chloride

CDCl_3 = deuterated chloroform

DCE = dichloroethane

DCM = dichloromethane

DHP = dihydropyran

DIPEA = diisopropylethylamine

DMF = N,N-dimethylformamide

DMSO- d_6 = deuterated dimethylsulfoxide

ESIMS = electron spray mass spectrometry

EtOAc = ethyl acetate

EtOH = ethanol

h = hour

HATU = 2-(1H-7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium

hexafluorophosphate

HCl = hydrochloric acid

HOAc = acetic acid

H_2SO_4 = sulfuric acid

iPrOH = iso-propyl alcohol

KOAc = potassium acetate

K₃PO₄ = potassium phosphate

LAH = lithium aluminum hydride

mCPBA = meta-Chloroperoxybenzoic acid

MeOH = methanol

MgSO₄ = magnesium sulfate

min. = minute

MW = microwave

NaBH(OAc)₃ = sodium triacetoxymborohydride

NaHCO₃ = sodium bicarbonate

NaHSO₃ = sodium bisulfite

NaHSO₄ = sodium bisulfate

NaOH = sodium hydroxide

NH₄OH = ammonium hydroxide

NMR = nuclear magnetic resonance

Pd/C = palladium(0) on carbon

PdCl₂(dppf)₂ = 1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride

Pd₂(dba)₃ = tris(dibenzylideneacetone)dipalladium(0)

Pd(PPh₃)₄ = tetrakis(triphenylphosphine)palladium(0)

PPTS = pyridinium p-toluenesulfonate

r.t. = room temperature

sat^d. = saturated

solⁿ. = solution

Reflux. = heated to reflux

TEA = triethylamine

TFA = trifluoroacetic acid

THF = tetrahydrofuran

TLC = thin layer chromatography


Tr-Cl = trityl chloride or triphenylmethyl chloride

[0267] The following example schemes are provided for the guidance of the reader, and collectively represent an example method for making the compounds provided herein. Furthermore, other methods for preparing compounds of the invention will be readily apparent to the person of ordinary skill in the art in light of the following reaction schemes and examples. The skilled artisan is thoroughly equipped to prepare these compounds by those methods given the literature and this disclosure. The compound numberings used in the synthetic schemes depicted below are meant for those specific schemes only, and should not be

construed as or confused with same numberings in other sections of the application. Unless otherwise indicated, all variables are as defined above.

General procedures


[0268] Compounds of Formula I of the present invention can be prepared as depicted in Scheme 1.



Scheme 1

[0269] Scheme 1 describes a method for preparation of indazole-3-carboxamide derivatives (I) by first forming the Weinreb amide (III) of a 1*H*-indazole-3-carboxylic acid (II). The Weinreb amide (III) is reacted with (bis(trifluoroacetoxy)iodo)benzene to produce the 5-iodo-1*H*-indazole-3-carboxylic acid (IV) followed by THP protection of the indazole nitrogen. The Weinreb amide of protected indazole V is reduced to aldehyde VI followed by reaction with bis(pinacolato)diboron to give the pinacol ester (VII). Suzuki coupling with a variety of aromatic and nonaromatic bromides yields the R³ substituted indazole VIII. Oxidation of the aldehyde to the acid (IX) followed by HATU mediated coupling of a variety of amines and sequent deprotection produces the desired indazole-3-carboxamide derivatives (I).


[0270] Compounds of Formula I of the present invention can also be prepared as depicted in Scheme 2.



Scheme 2

[0271] Scheme 2 describes an alternative method for preparation of indazole-3-carboxamide derivatives (I) by bromination of the indazole 5-position followed by esterification to form ester XII. The indazole nitrogen is THP protected and the ester is hydrolyzed to acid XVII. The acid is coupled with a variety of amines to produce amide XVIII which is then coupled with a variety of boronic acids (Route 1) to give XIX. Alternatively, XVIII can be converted to the boronate ester and then couple to a variety of bromides (Route 2) to yield XIX. Final deprotection of the indazole nitrogen yields the desired indazole-3-carboxamide derivatives (I).

[0272] Compounds of Formula I of the present invention can also be prepared as depicted in Scheme 3.




Scheme 3

[0273] Scheme 3 describes another alternative method for preparation of indazole-3-carboxamide derivatives (I) by bromination of the indazole 5-position followed by either Route 1: esterification to form ester XII, then trityl protection of the indazole nitrogen and then finally hydrolyzed of the ester to acid XVII; or Route 2: trityl protection of the indazole nitrogen directly to acid XVII. The acid is coupled with a variety of amines to produce amide XVIII which is then coupled with a variety of boronic acids (Route 3) to give XIX. Alternatively, XVIII can be converted to the boronate ester and then couple to a variety of bromides (Route 4) to yield XIX. Final deprotection of the indazole nitrogen yields the desired indazole-3-carboxamide derivatives (I).

Illustrative Compound Examples

[0274] Preparation of intermediate 3-(5-bromopyridin-3-yl)-1,1-dimethylurea (XXII) is depicted below in Scheme 4.




Scheme 4


Step 1

[0275] 3-Amino-5-bromo pyridine (XX) (1.0 g, 5.78 mmol) was dissolved in pyridine and cooled to 0°C before adding dimethyl carbamyl chloride (XXI) (0.683 g, 6.35 mmol). The reaction mixture was stirred at room temperature for 2 h and then heated overnight at 60°C under argon. The solution was cooled to room temperature, poured into ice water and extracted with EtOAc. The organic extract was dried over MgSO₄, filtered and concentrated to a residue to afford 3-(5-bromopyridin-3-yl)-1,1-dimethylurea (XXII) as a brown solid, (1.24 g, 5.09 mmol, 88% yield). ¹H NMR (DMSO-d₆) δ ppm 8.67-8.64 (m, 2H), 8.23 (d, *J* = 7.8 Hz, 1H), 2.93 (s, 6H); ESIMS found for C₈H₁₀BrN₃O *m/z* 245.05(M+H).

[0276] The following intermediates were prepared in accordance with the procedure described in the above Scheme 4.



[0277] N-(5-bromopyridin-3-yl)morpholine-4-carboxamide (XXIII): Tan solid (0.82 g, 48%). ^1H NMR (DMSO- d_6) 3.43-3.45 (m, 4H), 3.60-3.62 (m, 4H), 8.21 (t, $J = 2.0$ Hz, 1H), 8.26 (d, $J = 2.0$ Hz, 1H), 8.62 (d, $J = 2.2$ Hz, 1H), 8.91 (s, 1H); ESIMS found for $\text{C}_{10}\text{H}_{12}\text{BrN}_3\text{O}_2$ m/z 286 (M+H).



XXIV

[0278] N-(5-bromopyridin-3-yl)cyclopropanecarboxamide (XXIV): Off white solid, (83% yield), ^1H NMR (CDCl_3 , 400 MHz) δ ppm 8.46-8.39 (m, 3H), 7.54 (bs, 1H), 1.56-1.50 (m, 1H), 1.13-1.07 (m, 2H), 0.96-0.90 (m, 2H); ESIMS found for $\text{C}_9\text{H}_9\text{BrN}_2\text{O}$ m/z 240.85 (M+H).

[0279] Preparation of intermediate (XXVI) is depicted below in Scheme 5.




Scheme 5

Step 1


[0280] To a solution of 5-bromonicotinaldehyde (XXV) (5.0 g, 26.9 mmol) in DCE (108 mL) was added dimethylamine-HCl (4.39 g, 53.8 mmol) and TEA (7.5 g, 53.8 mmol). The reaction was stirred at room temperature for 1 h. $\text{NaBH}(\text{OAc})_3$ was added and the reaction was stirred overnight at room temperature. The reaction was diluted with DCM and sat. aq. NaHCO_3 . The organic layer was separated, washed with water, brine, dried and concentrated under vacuum to produce 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (XXVI) as a brown liquid (92.6% yield). ^1H NMR (CDCl_3) δ ppm 2.15 (s, 6H), 3.43 (s, 2H), 7.94 (s, 1H), 8.47 (d, $J=2\text{Hz}$, 1H), 8.59 (d, $J=3\text{Hz}$, 1H); ESIMS found for $\text{C}_8\text{H}_{11}\text{BrN}_2$ m/z 215 ($\text{M}^{\text{Br}79} + \text{H}$) and 217 ($\text{M}^{\text{Br}81} + \text{H}$).

[0281] The following intermediates were prepared in accordance with the procedure described in the above Scheme 5.




XXVII

[0282] 3-Bromo-5-(pyrrolidin-1-ylmethyl)pyridine (XXVII): Golden liquid (1.35 g, 97% yield). ^1H NMR (DMSO- d_6) 1.68-1.71 (m, 4H), 2.42-2.44 (m, 4H), 3.60 (s, 2H), 7.96 (s, 1H), 8.48 (d, $J=2\text{Hz}$, 1H), 8.58 (d, $J=3\text{Hz}$, 1H); ESIMS found for $\text{C}_{10}\text{H}_{13}\text{BrN}_2$ m/z 242 (M+H).




XXVIII

[0283] 3-Bromo-5-(piperidin-1-ylmethyl)pyridine (XXVIII): Brown liquid (13.1 g, 94% yield). ^1H NMR (DMSO- d_6) 1.36-1.39 (m, 2H), 1.46-1.51 (m, 4H), 2.31-2.32 (m, 4H), 3.46 (s, 2H), 7.94 (s, 1H), 8.47 (d, $J=2\text{Hz}$, 1H), 8.58 (d, $J=3\text{Hz}$, 1H); ESIMS found for $\text{C}_{11}\text{H}_{15}\text{BrN}_2$ m/z 257 (M+H).




XXIX

[0284] 4-((5-Bromopyridin-3-yl)methyl)morpholine (XXIX): Brown oil (1.02 g, 35.6% yield). ESIMS found for $\text{C}_{10}\text{H}_{13}\text{BrN}_2\text{O}$ m/z 258 (M+H).




XXX

[0285] 1-((5-Bromopyridin-3-yl)methyl)-4-methylpiperazine (XXX): Brown oil (0.93 g, 64% yield). ^1H NMR (DMSO- d_6) 2.14 (s, 3H), 2.27-2.37 (m, 8H), 3.49 (s, 2H), 7.95 (s, 1H), 8.47 (d, $J=1.7\text{Hz}$, 1H), 8.59 (d, $J=2.2\text{Hz}$, 1H); ESIMS found for $\text{C}_{11}\text{H}_{16}\text{BrN}_3$ m/z 272 (M+H).




XXXI

[0286] 1-(3-Bromo-5-fluorobenzyl)-4-methylpiperazine (XXXI): Light yellow oil (2.07 g, 68% yield). ^1H NMR (DMSO- d_6) 2.14 (s, 3H), 2.28-2.40 (m, 8H), 3.46 (s, 2H), 7.15-7.17 (m, 1H), 7.35 (s, 1H), 7.40-7.42 (m, 1H); ESIMS found for $\text{C}_{12}\text{H}_{16}\text{BrFN}_2$ m/z 288 (M+H).



XXXII


[0287] 1-(5-Bromopyridin-3-yl)piperidin-4-ol (**XXXII**): Brown oil (2.15 g, 7.93mmol, 72.7% yield). ^1H NMR (DMSO- d_6) 1.34-1.41 (m, 2H), 1.67-1.71 (m, 2H), 2.03-2.07 (m, 2H), 2.62-2.64 (m, 2H), 3.42-3.46 (m, 1H), 3.47 (s, 2H), 4.55 (d, $J=4.2\text{Hz}$, 1H), 7.93-7.94 (m, 1H), 8.46 (d, $J=1.6\text{Hz}$, 1H), 8.58 (d, $J=2.2\text{Hz}$, 1H); ESIMS found for $\text{C}_{11}\text{H}_{15}\text{BrN}_2\text{O}$ m/z 272 (M+H).



XXXIII

[0288] 3-Bromo-5-((3,3-difluoropyrrolidin-1-yl)methyl)pyridine (**XXXIII**): Brown liquid (7.38 g, 26.64 mmol, 94.9% yield). ^1H NMR (DMSO- d_6) 2.21-2.30 (m, 2H), 2.70 (t, $J=7\text{Hz}$, 2H), 2.89 (t, $J=13\text{Hz}$, 2H), 3.66 (s, 2H), 7.95-7.98 (m, 1H), 8.57 (d, $J=1.7\text{Hz}$, 1H), 8.61 (d, $J=2.2\text{Hz}$, 1H); ESIMS found for $\text{C}_{10}\text{H}_{11}\text{BrF}_2\text{N}_2$ m/z 276 (M+H).

[0289] Preparation of 3-benzyl-5-bromopyridine (**XXXVI**) is depicted below in Scheme 6.




Scheme 6

Step 1

[0290] To a solution of 3,5-dibromopyridine (**XXXIV**) (1.03 g, 4.36 mmol) in THF (7 mL) under argon was added CuI (50 mg, 0.26 mmol) and $\text{PdCl}_2(\text{dppf})_2$ (178 mg, 0.22 mmol). Benzylzinc(II) bromide (**XXXV**) (0.5M in THF) (13.09 mL, 6.55 mmol) was slowly added by syringe. The reaction was heated at 50°C over the weekend. The reaction was quenched with water and extracted with EtOAc. The EtOAc was separated, washed with water, brine, dried over MgSO_4 and concentrated under vacuum. The residue was purified on a silica gel column (100% hexanes $\rightarrow$ 5:95 EtOAc:hexanes) to afford 3-benzyl-5-bromopyridine (**XXXVI**) (0.614 g, 2.47 mmol, 57% yield) as a light brown oil. ^1H NMR (DMSO- d_6) δ ppm 3.98 (s, 2H), 7.19-7.23 (m, 1H), 7.27-7.32 (m, 4H), 7.92-7.93 (m, 1H), 8.51 (d, $J=2\text{Hz}$, 1H), 8.54 (d, $J=3\text{Hz}$, 1H); ESIMS found for $\text{C}_{12}\text{H}_{10}\text{BrN}$ m/z 248 (M+H).

[0291] Preparation of 3-bromo-5-phenoxy pyridine (**XXXIX**) is depicted below in Scheme 7.




Scheme 7

Step 1

[0292] To a solution of 3,5-dibromopyridine (XXXVII) (1.00 g, 4.24 mmol) in NMP (11 mL) was added phenol (XXXVIII) (398 mg, 4.24 mmol) and CsCO₃ (1.38 g, 4.24 mmol). The reaction was heated at 100°C over the weekend. The reaction was then partitioned between Et₂O/water. The Et₂O was separated, washed with 2x water, brine, dried over MgSO₄ and concentrated under vacuum. The residue was purified on a silica gel column (100% hexanes → 2:98 EtOAc:hexanes) to afford 3-bromo-5-phenoxy pyridine (XXXIX) (535 mg, 2.14 mmol, 50% yield) as a clear oil. ¹H NMR (DMSO-d₆) δ ppm 7.13-7.15 (m, 2H), 7.23-7.26 (m, 1H), 7.43-7.46 (m, 2H), 7.69-7.70 (m, 1H), 8.37 (d, *J*=3Hz, 1H), 8.49 (d, *J*=2Hz, 1H); ESIMS found for C₁₁H₈BrNO *m/z* 250 (M+H).

[0293] Preparation of 1-(5-bromopyridin-3-yl)-4-methylpiperazine (XL) is depicted below in Scheme 8.




Scheme 8

Step 1

[0294] To a solution of 3,5-dibromopyridine (XXXVIII) (2.90 g, 12.24 mmol) in dry DMF (20 mL) was added 1-methylpiperazine (2.987 mL, 26.93 mmol) and K₂CO₃ (5.58 g, 40.39 mmol). The reaction was heated at 120°C overnight. An additional portion of 1-methylpiperazine (6 mL) was added and heating was continued for another 24 h. The reaction was poured into ice water and filtered. The filtrate was extracted with 66% MeOH/CHCl₃. The organic layer was dried over MgSO₄, filtered and concentrated under vacuum to yield 1-(5-bromopyridin-3-yl)-4-methylpiperazine (XL) as a brown viscous oil (2.49 g, 9.76 mmol, 79.8% yield). ESIMS found for C₁₀H₁₄BrN₃ *m/z* 256 (M+H).


[0295] The following intermediate was prepared in accordance with the procedure described in the above Scheme 8.



XLI

[0296] 4-(5-Bromopyridin-3-yl)morpholine (XLI): Yellow solid (1.12 g, 4.61 mmol, 64.9% yield). ESIMS found for $C_9H_{11}BrN_2O$ m/z 244.1 (M+H).

[0297] Preparation of 5-bromo-N-cyclohexylnicotinamide (XLIV) is depicted below in Scheme 9.




Scheme 9

Step 1

[0298] To a solution of 5-bromonicotinic acid (XLII) (500 mg, 2.49 mmol) in DMF (8 mL) was added cyclohexylamine (XLIII) (247 mg, 2.49 mmol) and DIPEA (643 mg, 4.98 mmol). The reaction was cooled at 0°C before adding HATU (947 mg, 2.49 mmol). The reaction was warmed to room temperature and stirred for 4 hrs. The reaction was diluted with EtOAc, washed with 2x water, brine, dried over $MgSO_4$ and concentrated under vacuum to yield crude 5-bromo-N-cyclohexylnicotinamide (XLIV). The product was used without further purification. ESIMS found for $C_{12}H_{15}BrN_2O$ m/z 283 (M+H).

[0299] Preparation of 3-bromo-5-(((2R,6S)-2,6-dimethylpiperidin-1-yl)methyl)pyridine (XLVII) is depicted below in Scheme 10.



Scheme 10

Step 1

[0300] To a solution of 5-bromonicotinaldehyde (XXV) (2.05 g, 11.0 mmol) in MeOH (85 mL) was added NaBH₄ (832 mg, 21.99 mmol). The reaction was stirred at room temperature for 1 h. The reaction was quenched with saturated aqueous NH₄Cl (5 mL). The reaction was concentrated under vacuum and the residue was partitioned between saturated aqueous NH₄Cl/EtOAc. The organic layer was separated, washed with water, brine, dried over MgSO₄ and concentrated under vacuum to yield crude (5-bromopyridin-3-yl)methanol (XLV) as a golden oil (1.54 g, 8.2 mmol, 74% yield). The product was used without further purification. ESIMS found for C₆H₆BrNO *m/z* 188 (M+H).


Step 2

[0301] (5-Bromopyridin-3-yl)methanol (XLV) (1.54 g, 8.2 mmol) was treated with 4M HCl in dioxane (10 mL) at 0°C and then evaporated. The residue was dissolved in SOCl₂ (4 mL) and refluxed for 2 hrs. The SOCl₂ was removed and the residue was triturated with hexane to produce HCl salt of 3-bromo-5-(chloromethyl)pyridine (XLVI) as a brown solid (1.30 g, 5.4 mmol, 66% yield). The product was used without further purification. ESIMS found for C₆H₅BrClN *m/z* 206 (M+H).

Step 3

[0302] To a solution of 3-bromo-5-(chloromethyl)pyridine (XLVI) (1.17 g, 4.8 mmol) in MeCN (0.2 mL) and (2S,6R)-2,6-dimethylpiperidine (2.6 mL, 19.3 mmol) was added K₂CO₃ (667 mg, 4.8 mmol). The reaction was refluxed for 5 hrs. TLC showed the presence of starting material so additional (2S,6R)-2,6-dimethylpiperidine (2.0 mL, 14.8 mmol) was added and the reaction was refluxed for an additional 5 hrs. The solvent was removed and the residue was partitioned between EtOAc/water. The EtOAc was separated and washed with brine, dried over MgSO₄ and concentrated under vacuum. The residue was purified on a silica gel column (100% hexanes → 6:94 EtOAc:hexanes) to afford 3-bromo-5-(((2R,6S)-2,6-dimethylpiperidin-1-yl)methyl)pyridine (XLVII) as a clear oil (728 mg, 2.57 mmol, 53% yield). ¹H NMR (DMSO-d₆) δ ppm 0.92 (d, *J*=8Hz, 6H), 1.21-1.32 (m, 3H), 1.52-1.55 (m, 2H), 1.59-1.63 (m, 1H), 2.42-2.46 (m, 2H), 3.73 (s, 2H), 7.97-7.98 (m, 1H), 8.50 (d, *J*=3Hz, 1H), 8.55-8.56 (m, 1H); ESIMS found for C₁₃H₁₉BrN₂ *m/z* 283 (M+H).

[0303] Preparation of intermediate 3'-fluorobiphenyl-3-amine (LI) is depicted below in Scheme 11.



Scheme 11


Step 1

[0304] A 25 mL microwave vessel was charged with 1-bromo-3-nitrobenzene (XLVIII) (0.61 g, 3.0 mmol), 3-fluorophenylboronic acid (XLIX) (0.46 g, 3.3 mmol), potassium phosphate tribasic (0.95 g, 4.5 mmol), 1,4-dioxane (15.0 mL), and water (3.0 mL). Tetrakis(triphenylphosphine)palladium(0) (0.17 g, 0.15 mmol) was added, and the reaction was placed in a microwave reactor for 1 h at $95^\circ C$. An additional 3-fluorophenylboronic acid (0.20 g) and tetrakis(triphenylphosphine)palladium(0) (0.05 g) were added, and the reaction was heated for another 1 h at $95^\circ C$ in a microwave reactor. The organic solvent was separated from the water and concentrated to a residue. The residue was then purified by flash chromatography using a 25 g Thomson normal phase silica gel cartridge (100% hexanes $\rightarrow$ 1:99 EtOAc:hexanes) to afford 3'-fluoro-3-nitrobiphenyl (L) (0.63 g, 2.91 mmol, 97% yield) as a white solid. ^1H NMR (DMSO- d_6) δ ppm 8.48 (t, $J=2.0$ Hz, 1H), 8.26-8.24 (m, 1H), 8.20-8.18 (m, 1H), 7.78 (t, $J=8$ Hz, 1H), 7.70-7.68 (m, 1H), 7.67-7.65 (m, 1H), 7.59-7.56 (m, 1H), 7.32-7.28 (m, 1H).

Step 2

[0305] 10% Palladium on carbon (0.095g) was added to a solution of 3'-fluoro-3-nitrobiphenyl (L) (0.63 g, 2.88 mmol) in EtOH (20.0 mL). The flask was evacuated and replaced with a hydrogen atmosphere. The solution was stirred at room temperature for 5 h under hydrogen. The catalyst was filtered through a pad of Celite, and the solvent was removed under reduced pressure. The residue was purified by flash chromatography using a 40 g Thomson normal phase silica gel cartridge (100% hexanes $\rightarrow$ 15:85 EtOAc:hexanes) to afford 3'-fluorobiphenyl-3-amine (LI) (0.34 g, 1.81 mmol, 63% yield) as a light yellow oil. ^1H NMR (DMSO- d_6) δ ppm 7.47-7.44 (m, 1H), 7.40-7.39 (m, 1H), 7.36-7.33 (m, 1H), 7.15-7.14 (m, 1H), 7.10 (t, $J=7.7$ Hz, 1H), 6.85-6.84 (m, 1H), 6.80-6.79 (m, 1H), 6.60-6.58 (m, 1H), 5.18 (s, 2H); ESIMS found for $C_{12}H_{10}FN$ m/z 188 (M+H).

[0306] Preparation of intermediate 5-(3-fluorophenyl)pyridin-3-amine (LIII) is depicted below in Scheme 12.




Scheme 12

Step 1

[0307] To a microwave vial was added 3-amino-5-bromopyridine (**LII**) (0.400 g, 2.31 mmol), 3-fluorophenyl boronic acid (**XLIX**) (0.356 g, 2.54 mmol), tetrakis(triphenylphosphine)palladium(0) (0.133 g, 0.116 mmol), potassium phosphate (0.736 g, 3.47 mmol), water (1 mL), and DMF (5 mL). The reaction vial was capped, purged with argon and heated under microwave irradiation for 1 h at $180^\circ C$. The solution was filtered through a pad of Celite and concentrated under vacuum. The residue was purified by column chromatography (4:6 EtOAc:hexanes $\rightarrow$ 7:3 EtOAc:hexanes) to afford the 5-(3-fluorophenyl)pyridin-3-amine (**LIII**) (0.360 g, 1.92 mmol, 83% yield) as a yellow-white solid. ESIMS found for $C_{11}H_9FN_2$ m/z 189.1 (M+H).

[0308] Preparation of intermediate 5-((dimethylamino)methyl)pyridin-3-amine (**LVII**) is depicted below in Scheme 13.



Scheme 13

Step 1

[0309] 5-Bromonicotinaldehyde (XXV) (5.01g, 26.9 mmol) and dimethylamine hydrochloride (4.39 g, 53.8 mmol) were suspended in 1,2-dichloroethane (108 mL). Triethylamine (7.50 mL, 53.8 mmol) was added, and the reaction was stirred at room temperature for 1 h. Sodium triacetoxyborohydride (8.56 g, 40.4 mmol) was added, and the reaction was further stirred at room temperature overnight. The reaction was diluted with saturated sodium bicarbonate solution and DCM. The organic layer was separated, washed sequentially with water and brine, dried over MgSO₄, filtered and concentrated to give 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (LIV) (1.19 g, 23.9 mmol, 89% yield) as a brown oil: ¹H NMR (DMSO-d₆) δ ppm 8.59 (d, *J*=3Hz, 1H), 8.47 (d, *J*=2Hz, 1H), 7.94 (s, 1H), 3.43 (s, 2H), 2.15 (s, 6H); ESIMS found for C₈H₁₁BrN₂ *m/z* 215 (M+H).


Step 2

[0310] In a 25 mL microwave vessel, 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine (LIV) (1.27 g, 5.92 mmol), 4-methoxybenzylamine (LV) (0.77 mL, 5.92 mmol), cesium carbonate (2.70 g, 8.29 mmol) and xanthphos (0.17g, 0.30 mmol) were suspended in xylenes (12.0 mL). The solvent was degassed, and tris(dibenzylideneacetone)dipalladium(0) (0.27 g, 0.30 mmol) was added. The vessel was sealed, and the reaction was heated to 130°C for 5 h in a microwave reactor. The solvent was decanted away from the solid material and concentrated to a residue. The residue was purified by silica gel chromatography using a 40 g Thomson normal-phase silica gel cartridge (100% CHCl₃ → 3:97 MeOH[7N NH₃]:CHCl₃) to afford 5-((dimethylamino)methyl)-N-(4-methoxybenzyl)pyridin-3-amine (LVI) (0.68 g, 2.49 mmol, 42% yield) as a yellow solid. ¹H NMR (DMSO-d₆) δ ppm 7.84 (d, *J*=3Hz, 1H), 7.64 (d, *J*=2Hz, 1H), 7.27 (d, *J*=11Hz, 2H), 6.88 (d, *J*=11Hz, 2H), 6.83-6.82 (m, 1H), 6.35 (t, *J*=8Hz, 1H), 4.20 (d, *J*=8Hz, 2H), 3.72 (s, 3H), 3.24 (s, 2H), 2.08 (s, 6H); ESIMS found for C₁₆H₂₁N₃O *m/z* 272 (M+H).

Step 3

[0311] 5-((dimethylamino)methyl)-N-(4-methoxybenzyl)pyridin-3-amine (LVI) (0.15 g, 0.56 mmol) was dissolved in TFA (2.0 mL) and stirred at room temperature for 1 h. The TFA was removed, and the residue was treated with 7N ammonia in MeOH/chloroform mixture (7/93) to neutralize the TFA and concentrated again to a residue. The residue was purified by flash silica gel chromatography utilizing a 4 g Thomson normal-phase silica gel cartridge (100% CHCl₃ → 3:97 MeOH[7N NH₃]:CHCl₃) to afford 5-((dimethylamino)methyl)pyridin-3-amine (LVII) (0.044 g, 0.29 mmol, 52% yield) as a brown oil. ESIMS found for C₈H₁₃N₃ *m/z* 152 (M+H).


[0312] The following intermediate was prepared in accordance with the procedure described in the above Scheme 13.



LVIII

[0313] 5-((4-Methylpiperazin-1-yl)methyl)pyridin-3-amine (LVIII): Dark yellow solid (138 mg, 0.67 mmol, 71% yield). ESIMS found for $C_{11}H_{18}N_4$ m/z 207 (M+H).

[0314] Preparation of intermediate 6-(pyrrolidin-1-ylmethyl)pyridin-3-amine (LXIII) is depicted below in Scheme 14.



Scheme 14

Step 1

[0315] To a suspension of methyl 5-nitropicolinate (LIX) (1.282 g, 7.03 mmol) in DCM (25 mL) stirred at -78°C under argon was slowly added DIBAL (1M in toluene) (9.14 mL, 9.14 mmol). The solution was allowed to warm to room temperature over 3 h. An aqueous solution of potassium sodium tartrate was added, diluted further with water and DCM. The solution was stirred at room temperature for another 30 min before the organic layer was separated. The aqueous layer was extracted 2x DCM, combined with the organic layer, dried over MgSO_4 , filtered and evaporated under reduced pressure. The residue was purified by column chromatography to produce 5-nitropicolinaldehyde (LX) as a brown oil (0.64 g, 4.2 mmol, 60% yield). ^1H NMR ($\text{DMSO}-d_6$) δ ppm 8.17 (d, $J=9\text{Hz}$, 1H), 8.81 (dd, $J=9\text{Hz}$, $J=2\text{Hz}$, 1H), 9.56 (d, $J=2\text{Hz}$, 1H), 10.08 (s, 1H).

Step 2


[0316] Preparation of 5-nitro-2-(pyrrolidin-1-ylmethyl)pyridine (LXII) was performed following the procedure listed in Scheme 5, Step 1. Purple oil (0.41 g, 1.98 mmol,

86% yield). ^1H NMR (DMSO- d_6) δ ppm 9.28 (d, $J=3\text{Hz}$, 1H), 8.56 (dd, $J=11\text{Hz}$, 3Hz, 1H), 7.72 (d, $J=11\text{Hz}$, 1H), 3.85 (s, 2H), 2.53-2.50 (m, 4H), 1.75-1.70 (m, 4H).

Step 3


[0317] Preparation of intermediate 6-(pyrrolidin-1-ylmethyl)pyridin-3-amine (LXIII) was performed following the procedure listed in Scheme 11, Step 2. Dark brown oil (0.35 g, 1.97 mmol, quantitative). ESIMS found for $\text{C}_{10}\text{H}_{15}\text{N}_3$ m/z 178 (M+H).

[0318] The following intermediate was prepared in accordance with the procedure described in the above Scheme 14.



[0319] 6-((4-Methylpiperazin-1-yl)methyl)pyridin-3-amine (LXIV): Brown oil (120 mg, 0.58 mmol, 100% yield). ESIMS found for $\text{C}_{11}\text{H}_{18}\text{N}_4$ m/z 207 (M+H).

[0320] Preparation of intermediate 6-(3-fluorophenoxy)pyridin-3-amine (LXVIII) is depicted below in Scheme 15.



Step 1


[0321] A solution of 2-chloro-5-nitropyridine (LXV) (1.98 g, 12.5 mmol) and 3-fluorophenol (LXVI) (1.4 g, 12.5 mmol) in pyridine (20 mL) was heated at 120°C overnight under argon. The solution was cooled to room temperature and concentrated under vacuum. The residue was dissolved in EtOAc, washed with water, brine, dried over MgSO_4 and evaporated. The residue was purified by silica gel column chromatography (100% hexane $\rightarrow$ 2:98 EtOAc:hexane) to give 2-(3-fluorophenoxy)-5-nitropyridine (LXVII) as a yellow viscous oil (2.27 g, 9.7 mmol, 77% yield). ^1H NMR (DMSO- d_6) δ ppm 7.11 (dd, $J=8\text{Hz}$, $J=2\text{Hz}$, 1H),

7.17 (dt, $J=8\text{Hz}$, $J=6\text{Hz}$, 1H), 7.23 (td, $J=10\text{Hz}$, $J=2\text{Hz}$, 1H), 7.31 (d, $J=9\text{Hz}$, 1H), 7.52 (q, $J=9\text{Hz}$, 1H), 8.64 (dd, $J=9\text{Hz}$, $J=3\text{Hz}$, 1H), 9.05 (d, $J=3\text{Hz}$, 1H); ESIMS found for $\text{C}_{11}\text{H}_7\text{FN}_2\text{O}_3$ m/z 234.9 (M+H).

Step 2


[0322] Preparation of intermediate 6-(3-fluorophenoxy)pyridin-3-amine (LXVIII) was performed following the procedure listed in Scheme 11, Step 2. Black green viscous oil (1.90 g, 9.3 mmol, 96% yield). ^1H NMR (DMSO-d_6) δ ppm 5.18 (brs, 2H), 6.74-6.83 (m, 3H), 6.90 (dt, 1H), 7.09 (dd, $J=9\text{Hz}$, $J=3\text{Hz}$, 1H), 7.34 (q, $J=7\text{Hz}$, 1H), 7.57 (d, $J=3\text{Hz}$, 1H); ESIMS found for $\text{C}_{11}\text{H}_9\text{FN}_2\text{O}$ m/z 204.4 (M+).

[0323] The following intermediates were prepared in accordance with the procedure described in the above Scheme 15.



LXIX


[0324] 6-(4-Fluorophenoxy)pyridin-3-amine (LXIX): Dark brown oil (870 mg, 4.3 mmol, 100% yield). ^1H NMR (DMSO-d_6) δ ppm 5.08 (brs, 2H), 6.75 (d, $J=15\text{Hz}$, 1H), 6.90-7.01 (m, 2H), 7.07 (dd, $J=9\text{Hz}$, $J=3\text{Hz}$, 1H), 7.16 (t, 9Hz, 1H), 7.26-7.30 (m, 1H), 7.73 (d, $J=3\text{Hz}$, 1H); ESIMS found for $\text{C}_{11}\text{H}_9\text{FN}_2\text{O}$ m/z 204.9 (M+H).



LXX

[0325] 6-(2-Fluorophenoxy)pyridin-3-amine (LXX): Dark brown oil (611 mg, 3.0 mmol, 91% yield). ESIMS found for $\text{C}_{11}\text{H}_9\text{FN}_2\text{O}$ m/z 204.9 (M+H).

[0326] Preparation of intermediate 6-phenylpyridin-3-amine (LXXIV) is depicted below in Scheme 16.



Scheme 16


Step 1

[0327] To a solution of 2-bromo-5-nitropyridine (LXXI) (302 mg, 1.49 mmol) in a mixture of dioxane (14 mL) and water (3 mL) was added phenylboronic acid (LXXII) (199 mg, 1.64 mmol), $\text{Pd(PPh}_3)_4$ (86 mg, 0.74 mmol) and K_3PO_4 (473 mg, 2.23 mmol). The reaction was microwaved at 95°C for 1h. The reaction was cooled and the organic phase was separated, dried over MgSO_4 and evaporated under vacuum. The residue was purified by silica gel column chromatography (100% hexane $\rightarrow$ 5:95 EtOAc:hexane) to give 5-nitro-2-phenylpyridine (LXXIII) as off-white needles (254 mg, 1.27 mmol, 85% yield). ESIMS found for $\text{C}_{11}\text{H}_8\text{N}_2\text{O}_2$ m/z 200.9 (M+H).

Step 2


[0328] Preparation of intermediate 6-phenylpyridin-3-amine (LXXIV) was performed following the procedure listed in Scheme 11, Step 2. Black green viscous oil (211 mg, 1.24 mmol, 98% yield). ^1H NMR (DMSO-d_6) δ ppm 5.45 (s, 2H), 6.99 (dd, $J=11\text{Hz}$, $J=3\text{Hz}$, 1H), 7.25-7.28 (m, 1H), 7.38-7.40 (m, 2H), 7.62 (d, $J=11\text{Hz}$, 1H), 7.89-7.91 (m, 1H), 8.02 (d, $J=3\text{Hz}$, 1H); ESIMS found for $\text{C}_{11}\text{H}_{10}\text{N}_2$ m/z 171 (M+H).

[0329] The following intermediates were prepared in accordance with the procedure described in the above Scheme 16.



LXXV


[0330] 6-(3-Fluorophenyl)pyridin-3-amine (LXXV): Brown oil (252 mg, 1.34 mmol, 98% yield). ESIMS found for $\text{C}_{11}\text{H}_9\text{FN}_2$ m/z 189 (M+H).



LXXVI

[0331] 6-(4-Fluorophenyl)pyridin-3-amine (LXXVI): Deep purple oil (202 mg, 1.07 mmol, 98% yield). ESIMS found for $C_{11}H_9FN_2$ m/z 189 (M+H).

[0332] Preparation of intermediate 5-benzylpyridin-3-amine (LXXX) is depicted below in Scheme 17.



Scheme 17


Step 1

[0333] To a solution of 3-bromo-5-nitropyridine (LXXVII) (295 mg, 1.45 mmol) in dioxane (14 mL) was added 2-benzyl-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (LXXVIII) (420 μ L, 1.89 mmol), $PdCl_2(dppf)_2$ (120 mg, 0.15 mmol) and 2M aqueous K_3PO_4 (2.2 mL, 4.36 mmol). The reaction was microwaved at 90°C for 2h. The reaction was cooled and the organic phase was separated, dried over $MgSO_4$ and evaporated under vacuum. The residue was purified by silica gel column chromatography (100% hexane $\rightarrow$ 6:94 EtOAc:hexane) to give 3-benzyl-5-nitropyridine (LXXIX) as brown oil (117 mg, 0.54 mmol, 37% yield). ^1H NMR (DMSO- d_6) δ ppm 4.16 (s, 2H), 7.21-7.25 (m, 1H), 7.31-7.33 (m, 4H), 8.45-8.46 (m, 1H), 8.93 (d, $J=2$ Hz, 1H), 9.21 (d, $J=3$ Hz, 1H); ESIMS found for $C_{12}H_{10}N_2O_2$ m/z 215 (M+H).

Step 2

[0334] Preparation of 5-benzylpyridin-3-amine (LXXX) was performed following the procedure listed in Scheme 11, Step 2. Black green viscous oil (139 mg, 0.75 mmol, 98% yield). ESIMS found for $C_{12}H_{12}N_2$ m/z 185 (M+H).

[0335] Preparation of intermediate 2-(4-methylpiperazin-1-yl)pyridin-3-amine (LXXXIV) is depicted below in Scheme 18.



Scheme 18


Step 1

[0336] To a microwave vial was added 2-chloro-3-nitropyridine (LXXXI) (1.00 g, 6.31 mmol), 1-methylpiperazine (LXXXII) (0.758 g, 7.57 mmol), cesium carbonate (2.88 g, 8.83 mmol), $\text{Pd}_2(\text{dba})_3$ (0.173 g, 0.189 mmol), xanthphos (0.109 g, 0.189 mmol), and dioxane (5 mL). The reaction vial was capped and purged with argon. The solution into the reaction vial was heated under microwave irradiation for 2 h at 90°C. The solution was filtered through a pad of Celite and concentrated to a residue under vacuum. The residue was purified by column chromatography (1:99 MeOH: $\text{CHCl}_3 \rightarrow$ 8:92 MeOH: CHCl_3) to afford 1-methyl-4-(3-nitropyridin-2-yl)-piperazine (LXXXIII) (1.30 g, 5.85 mmol, 93% yield) as a brown oil.

Step 2


[0337] To a stirring solution of 1-methyl-4-(3-nitropyridin-2-yl)-piperazine (LXXXIII) (1.30 g, 5.85 mmol) in MeOH (15 mL) was added 10% Pd/C. The solution was purged with hydrogen. The solution was stirred at room temperature for 16 h under hydrogen. The solution was filtered through a pad of Celite and concentrated to a residue under vacuum. The residue was purified by column chromatography (100% $\text{CHCl}_3 \rightarrow$ 2:98 MeOH[7N NH_3]: CHCl_3) to afford 2-(4-methylpiperazin-1-yl)pyridin-3-amine (LXXXIV) (0.466 g, 2.42 mmol, 52% yield) as a tan solid. ESIMS found for $\text{C}_{10}\text{H}_{16}\text{N}_4$ m/z 192.4 (M+H).

[0338] The following intermediates were prepared in accordance with the procedure described in the above Scheme 18.




LXXXV

[0339] 6-(Pyrrolidin-1-yl)pyridin-3-amine (LXXXV): Deep purple oil (1.43 g, 8.77 mmol, 100% yield). ESIMS found for $\text{C}_9\text{H}_{13}\text{N}_3$ m/z 164 (M+H).




LXXXVI

[0340] 6-(4-Methylpiperazin-1-yl)pyridin-3-amine (LXXXVI): Purple solid (598 mg, 3.11 mmol, 32% yield). ESIMS found for $C_{10}H_{16}N_4$ m/z 193 (M+H).



LXXXVII


[0341] 6-Morpholinopyridin-3-amine (LXXXVII): Purple solid (782 mg, 4.36 mmol, 95% yield). ESIMS found for $C_9H_{13}N_3O$ m/z 180 (M+H).



LXXXVIII

[0342] N^2 -(2-(Dimethylamino)ethyl)- N^2 -methylpyridine-2,5-diamine (LXXXVIII): Deep purple oil (1.55 g, 7.98 mmol, 96% yield). ESIMS found for $C_{10}H_{18}N_4$ m/z 195 (M+H).

[0343] Preparation of intermediate 1-(5-aminopyridin-2-yl)piperidin-4-ol (XCI) is depicted below in Scheme 19.



Scheme 19

Step 1


[0344] To a solution of 2-chloro-5-nitropyridine (LXV) (5.0 g, 31.5 mmol) in DMF (50 mL) was added piperidin-4-ol (LXXXIX) (3.5 g, 34.65 mmol) and K_2CO_3 (8.7 g, 63.0 mmol). The reaction was headed at 85°C overnight. The solution was poured into ice water,

stirred for 15 min and then filtered. The solid was washed with cold water and dried under vacuum to produce 1-(5-aminopyridin-2-yl)piperidin-4-ol (**XC**) as a yellow solid (6.62 g, 29.67 mmol, 94.2% yield). ^1H NMR (DMSO- d_6) δ ppm 1.34-1.42 (m, 2H), 1.77-1.83 (m, 2H), 3.40-3.56 (m, 2H), 3.76-3.83 (m, 1H), 4.12 (brd, 2H), 4.81 (d, $J=4\text{Hz}$, 1H), 6.94 (d, $J=10\text{Hz}$, 1H), 8.17 (dd, $J=10\text{Hz}$, $J=3\text{Hz}$, 1H), 8.94 (d, $J=3\text{Hz}$, 1H); ESIMS found for $\text{C}_{10}\text{H}_{13}\text{N}_3\text{O}_3$ m/z 224.1 (M+H).

Step 2


[0345] Preparation of intermediate 1-(5-aminopyridin-2-yl)piperidin-4-ol (**XCI**) was performed following the procedure listed in Scheme 11, Step 2. Dark brown oil (5.7 g, 29.5 mmol, 99.5% yield). ^1H NMR (DMSO- d_6) δ ppm 1.36 (tq, $J=13\text{Hz}$, $J=4\text{Hz}$, 2H), 1.72-1.76 (m, 2H), 2.79 (dt, $J=13\text{Hz}$, $J=3\text{Hz}$, 2H), 3.54-3.61 (m, 1H), 3.70-3.78 (m, 2H), 4.49 (s, 2H), 4.61 (d, $J=4\text{Hz}$, 1H), 6.61 (d, $J=9\text{Hz}$, 1H), 6.88 (dd, $J=9\text{Hz}$, $J=3\text{Hz}$, 1H), 7.57 (d, $J=3\text{Hz}$, 1H); ESIMS found for $\text{C}_{10}\text{H}_{15}\text{N}_3\text{O}$ m/z 194.1 (M+H).

[0346] The following intermediates were prepared in accordance with the procedure described in the above Scheme 19.




XCI

[0347] 6-(Piperidin-1-yl)pyridin-3-amine (**XCI**): Dark red viscous oil (4.93 g, 27.81 mmol, 95.9% yield). ^1H NMR (DMSO- d_6) δ ppm 1.48-1.71 (m, 8H), 3.42-3.53 (m, 2H), 4.48 (brs, 2H), 6.59 (d, $J=9\text{Hz}$, 1H), 6.89 (dd, $J=9\text{Hz}$, $J=3\text{Hz}$, 1H), 7.58 (d, $J=3\text{Hz}$, 1H); ESIMS found for $\text{C}_{10}\text{H}_{15}\text{N}_3$ m/z 178.0 (M+H).




XCII

[0348] 5-Methyl-6-(pyrrolidin-1-yl)pyridin-3-amine (**XCIII**): Dark blue viscous oil (2.06 g, 12.62 mmol, 100% yield). ^1H NMR (DMSO- d_6) δ ppm 1.76-1.82 (m, 4H), 2.13 (s, 3H), 3.15-3.20 (m, 4H), 4.53 (brs, 2H), 6.74 (d, $J=3.5\text{Hz}$, 1H), 7.42 (d, $J=2.7\text{Hz}$, 1H); ESIMS found for $\text{C}_{10}\text{H}_{15}\text{N}_3$ m/z 178.1 (M+H).



XCIII


[0349] 6-(Azetidin-1-yl)-5-methylpyridin-3-amine (XCIV): Dark red solid (2.0 g, 11.29 mmol, 86.9% yield). ^1H NMR (DMSO- d_6) δ ppm 2.11 (quin, $J=7\text{Hz}$, 2H), 3.76-3.87 (m, 4H), 4.50 (brs, 2H), 6.72 (d, $J=2.5\text{Hz}$, 1H), 7.38 (d, $J=2.5\text{Hz}$, 1H); ESIMS found for $\text{C}_9\text{H}_{13}\text{N}_3$ m/z 164.4 (M+H).



XCIV

[0350] 6-(Azetidin-1-yl)pyridin-3-amine (XCV): Burgundy solid (1.45 g, 9.70 mmol, 99.3% yield). ESIMS found for $\text{C}_8\text{H}_{11}\text{N}_3$ m/z 149.0 (M+H).

[0351] Preparation of intermediate *tert*-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate (XCVIII) is depicted below in Scheme 20.



Scheme 20


Step 1

[0352] To a solution of 2-chloro-5-nitropyridine (LXV) (2.0 g, 12.6 mmol) in EtOH (20 mL) was added *tert*-butyl piperazine-1-carboxylate (XCVI) (7.05 g, 37.9 mmol). The reaction was headed at 70°C for 16 h. The reaction was concentrated under vacuum and then dissolved in EtOAc. The EtOAc was washed with 1 M NaOH, brine and then dried over MgSO_4 to give *tert*-butyl 4-(5-nitropyridin-2-yl)piperazine-1-carboxylate (XCVII) as a yellow solid (4.94 g). ESIMS found for $\text{C}_{14}\text{H}_{20}\text{N}_4\text{O}_4$ m/z 309.0 (M+H).

Step 2

[0353] Preparation of intermediate *tert*-butyl 4-(5-aminopyridin-2-yl)piperazine-1-carboxylate (XCVIII) was performed following the procedure listed in Scheme 11, Step 2. Purple solid (990 mg, 3.56 mmol, quantitative). ESIMS found for $\text{C}_{14}\text{H}_{22}\text{N}_4\text{O}_2$ m/z 278.8 (M+H).

[0354] Preparation of intermediate N-(3-aminopyridin-4-yl) cyclopropanecarboxamide (**CII**) is depicted below in Scheme 21.



Scheme 21


Step 1

[0355] Preparation of N-(3-nitropyridin-4-yl)cyclopropanecarboxamide (**CI**) was performed following the procedure listed in Scheme 4, Step 1. Orange solid (130 mg, 0.93 mmol, 13% yield). ESIMS found for $\text{C}_9\text{H}_9\text{N}_3\text{O}_3$ m/z 207.8 ($\text{M}+\text{H}$).

Step 2

[0356] Preparation of intermediate N-(3-aminopyridin-4-yl) cyclopropanecarboxamide (**CII**) was performed following the procedure listed in Scheme 11, Step 2. Dark grey solid (100 mg, 0.56 mmol, quantitative). ESIMS found for $\text{C}_9\text{H}_{11}\text{N}_3\text{O}$ m/z 178.3 ($\text{M}+\text{H}$).

[0357] Preparation of intermediate (5-aminopyridin-2-yl)(pyrrolidin-1-yl)methanone (**CV**) is depicted below in Scheme 22.



Scheme 22


Step 1

[0358] To a solution of 5-nitropicolinic acid (**CIII**) (500 mg, 2.97 mmol) in DMF (15 mL) was added pyrrolidine (244 μ L, 2.47 mmol) and DIPEA (1.03 mL, 5.95 mmol). The reaction was cooled at 0°C before adding HATU (1.13 g, 2.47 mmol). The reaction was warmed to room temperature and stirred for 2 hrs. The reaction was concentrated under vacuum and then dissolved in a mixture of water and 10% iPrOH/ CHCl_3 . The organic layer was separated and the aqueous phase was washed again with 10% iPrOH/ CHCl_3 . The combined organic phases were washed with brine, dried over MgSO_4 and evaporated to yield (5-nitropyridin-2-yl)(pyrrolidin-1-yl)methanone (**CIV**) as a red solid (849 mg). ESIMS found for $\text{C}_{10}\text{H}_{11}\text{N}_3\text{O}_3$ m/z 222.1 (M+H).

Step 2


[0359] Preparation of intermediate (5-aminopyridin-2-yl)(pyrrolidin-1-yl)methanone (**CV**) was performed following the procedure listed in Scheme 11, Step 2. Yellow solid (708 mg, 7.3 mmol, 96.4% yield). ESIMS found for $\text{C}_{10}\text{H}_{13}\text{N}_3\text{O}$ m/z 191.4 (M+H).

[0360] The following intermediate was prepared in accordance with the procedure described in the above Scheme 22.



[0361] 5-Amino-N-cyclopentylpicolinamide (**CVI**): Yellow solid (450 mg, 2.19 mmol, 93.7% yield). ESIMS found for $\text{C}_{11}\text{H}_{15}\text{N}_3\text{O}$ m/z 206.1 (M+H).

[0362] Preparation of intermediate 6-(methylsulfonyl)pyridin-3-amine (**CIX**) is depicted below in Scheme 23.



Scheme 23

Step 1

[0363] To a solution of sodium thiomethoxide in THF (53 mL) and H₂O (20 mL) cooled to 0°C was added 2-chloro-5-nitropyridine (LXV) (5.09 g, 32.09 mmol). The reaction was warmed to room temperature and stirred for 2 hrs. The reaction was poured into ice water and stirred for 10 minutes, filtered, washed with water, dried under vacuum to yield 2-(methylthio)-5-nitropyridine (CVII) as a yellow solid (5.14 g, 30.20 mmol, 94.1%). ¹H NMR (DMSO-d₆) δ ppm 2.62 (s, 3H), 7.57 (d, *J*=8.9Hz, 1H), 8.38 (d, *J*=8.9Hz, 1H), 9.22 (d, *J*=2.7Hz, 1H); ESIMS found for C₆H₆N₂O₂S *m/z* 171.1 (M+H).


Step 2

[0364] To a solution of 2-(methylthio)-5-nitropyridine (CVII) (502 mg, 2.95 mmol) in DCM (60 mL) was mCPBA (1.33 g, 5.90 mmol). The reaction was stirred at room temperature for 1 hr. Two additional portions of mCPBA (2 x 250 mg) were added at 1 hr intervals for a total reaction time of 4 hr. The reaction was poured into saturated aqueous NaHCO₃. The organic phase was separated and washed with water, brine and then dried over MgSO₄. The solvent was removed under vacuum to produce crude 2-(methylsulfonyl)-5-nitropyridine (CVIII) (854 mg) which was used without purification for step 3. ESIMS found for C₆H₆N₂O₄S *m/z* 203.0 (M+H).

Step 3

[0365] Preparation of intermediate 6-(methylsulfonyl)pyridin-3-amine (CIX) was performed following the procedure listed in Scheme 11, Step 2. The crude product was used as is without purification. ESIMS found for C₆H₈N₂O₂S *m/z* 173.0 (M+H).

[0366] Preparation of intermediate 5-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carbaldehyde (CXIV) is depicted below in Scheme 24.



Step 1

[0367] 1*H*-indazole-3-carboxylic acid (**CX**) (100 g, 617 mmol) in DMF was treated with carbonyldiimidazole (110 g, 678 mmol) at room temperature until the evolution of gas ceased (ca. 15 minutes). The reaction was heated to 60-65°C for 2 h and then allowed to cool to room temperature. *N,O*-Dimethylhydroxylamine-HCl (66.2 g, 678 mmol) was added as a solid and the mixture was heated to 65°C for 3 h. The reaction was concentrated to a paste, taken up in DCM and washed subsequently with water and 2 N HCl. The product could be seen coming out of solution. The solid was filtered and rinsed separately with EtOAc. The EtOAc and DCM layers were separately washed with sodium bicarbonate followed by brine, dried over MgSO₄ and concentrated under reduced pressure. The resulting solids were combined, triturated with 1:1 mixture of DCM-ether, filtered, and dried to produce *N*-methoxy-*N*-methyl-1*H*-indazole-3-carboxamide (**CXI**) as a white solid (100 g, 487 mmol, 79% yield). ¹H NMR (DMSO-*d*₆) δ ppm 3.46 (s, 3H), 3.69-3.85 (m, 3H), 7.13-7.31 (m, 1H), 7.41 (t, *J*=7.25 Hz, 1H), 7.56-7.65 (m, 1H), 7.93-8.08 (m, 1H); ESIMS found for C₁₀H₁₁N₃O₂ *m/z* 206 (*M*+*H*).

Step 2

[0368] To *N*-methoxy-*N*-methyl-1*H*-indazole-3-carboxamide (**CXI**) (20 g, 97.4 mmol) in DCM (1 L) was added (Bis(trifluoroacetoxy)iodo)benzene (46 g, 107 mmol) followed by portionwise addition of iodine (14.84 g, 58.5 mmol) at room temperature. After 1 h, saturated aqueous NaHSO₃ (600 mL) was added and a solid began to precipitate which was filtered and rinsed with excess DCM. The filtrate was washed with brine, dried over MgSO₄, concentrated and the remaining solid was triturated with a minimal amount of DCM. The combined solids were dried under vacuum over KOH to produce 5-iodo-*N*-methoxy-*N*-methyl-1*H*-indazole-3-carboxamide (**CXII**) as a white solid (23.2 g, 70 mmol, 72% yield). ¹H NMR (DMSO-*d*₆) δ

ppm 3.45 (s, 3H), 3.77 (s, 3H), 7.45-7.54 (m, 1H), 7.66 (dd, $J=8.81, 1.51$ Hz, 1H), 8.40 (d, $J=1.01$ Hz, 1H); ESIMS found for $C_{10}H_{10}IN_3O_2$ m/z 331 (M+H).


Step 3

[0369] A mixture of 5-iodo-N-methoxy-N-methyl-1H-indazole-3-carboxamide (CXII) (16.5 g, 50 mmol), 3,4-dihydro-2H-pyran (10.3 mL, 113 mmol) and PPTS (0.12 g, 0.6 mmol) in DCM was heated to reflux for 5 h. The solution was poured into a saturated aqueous $NaHCO_3$ solution, the layers were separated, and the aqueous layer was extracted with DCM. The combined organic layers were washed with 5% aqueous citric acid and brine, dried over $MgSO_4$, and concentrated. The crude product was purified on a silica gel column (100% EtOAc $\rightarrow$ 3:97 MeOH:DCM) to provide 5-iodo-N-methoxy-N-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxamide (CXIII) as a white viscous oil (19.1 g, 46 mmol, 92% yield). ^1H NMR (DMSO- d_6) δ ppm 1.28-1.84 (m, 6H), 3.43 (s, 3H), 3.60-4.04 (s, 5H), 5.86-6.08 (m, 1H), 7.45-7.87 (m, 2H), 8.39 (s, 1H); ESIMS found for $C_{15}H_{18}IN_3O_3$ m/z 416 (M+H).

Step 4

[0370] Lithium aluminum hydride (160 mg, 4.21 mmol) was added in portions to a cooled (0°C) solution of 5-iodo-N-methoxy-N-methyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxamide (CXIII) (1.46 g, 3.5 mmol) in THF. Stirring was continued at 0°C until the reaction was completed, approximately 30 min. The reaction was quenched by the slow addition of EtOAc at 0°C, and the whole mixture was poured into 0.4 N aqueous $NaHSO_4$. The organic layer was washed with brine, dried over $MgSO_4$, concentrated, and purified on a silica gel column (100% EtOAc $\rightarrow$ 3:97 MeOH:DCM) to give 5-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carbaldehyde (CXIV) as a white solid (0.90 g, 3.15 mmol, 72% yield). ^1H NMR (DMSO- d_6) δ ppm 1.50-1.71 (m, 2H), 1.71-1.87 (m, 1H), 1.97-2.15 (m, 2H), 2.31-2.42 (m, 1H), 3.66-3.99 (m, 2H), 5.96-6.17 (m, 1H), 7.78 (d, $J=6$ Hz, 1H), 7.84 (d, $J=6$ Hz, 1H), 8.50 (s, 1H), 10.13 (s, 1H); ESIMS found for $C_{13}H_{13}IN_2O_2$ m/z 357 (M+H).

[0371] Preparation of intermediate 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid (CXVIII) is depicted below in Scheme 25.



Scheme 25

Step 1

[0372] A suspension of indazole-3-carboxylic acid (CX) (1.0 g, 6.16 mmol) in glacial acetic acid (60 mL) was heated at 120°C to get a clear solution. The solution was cooled to 90°C. A solution of bromine (0.633 mL, 12.33 mmol) in glacial acetic acid (2 mL) was added slowly to the solution while heating at 90°C. The solution was further heated 16 h at 90°C. The solution was cooled to room temperature, poured into ice water and further stirred at room temperature for 15 min. The solids formed were filtered, washed with cold water and dried under vacuum at room temperature to get 5-bromo-1H-indazole-3-carboxylic acid (CXV) as a white solid (1.30 g, 5.39 mmol, 87.5% yield). ¹H NMR (DMSO-d₆) δ ppm 13.95 (s, 1H), 13.18 (br s, 1H), 8.21 (d, *J* = 1.2 Hz, 1H), 7.65 (d, *J* = 7.0 Hz, 1H), 7.56 (dd, *J* = 7.0, 1.2 Hz, 1H); ESIMS found for C₈H₄BrN₂O₂ *m/z* 242.0 (M+H).

Step 2

[0373] Concentrated sulfuric acid (1 mL) was added to a suspension of 5-bromo-1H-indazole-3-carboxylic acid (CXV) (1.30 g, 5.39 mmol) in dry MeOH (50 mL) and heated to reflux for 4 h under argon. The solution was cooled to room temperature and the MeOH was evaporated under vacuum. The residue was dissolved in EtOAc and washed with water. The organic phase was dried over Na₂SO₄, filtered and concentrated to afford methyl 5-bromo-1H-indazole-3-carboxylate (CXVI) as a white solid (1.35 g, 5.29 mmol, 98% yield). ¹H NMR (DMSO-d₆) δ ppm 14.13 (s, 1H), 8.21 (d, *J* = 1.6 Hz, 1H), 7.67 (d, *J* = 7.2 Hz, 1H), 7.59 (dd, *J* = 7.2, 1.2 Hz, 1H), 3.92 (s, 3H); ESIMS found for C₉H₇BrN₂O₂ *m/z* 256.0 (M+H).

Step 3

[0374] A suspension of methyl 5-bromo-1H-indazole-3-carboxylate (CXVI) (1.35 g, 5.29 mmol), pyridinium p-toluenesulfonate (0.143 g, 0.56 mmol) and 3,4 dihydro-2H-pyran (1.02 mL, 11.90 mmol) in anhydrous dichloroethane (20 mL) was refluxed 5 h under argon. The suspension was turned into the clear solution. The solution was cooled and the excess solvent was evaporated under vacuum. The residue was dissolved in EtOAc and washed with dilute NaHCO₃ solution (sat^d. NaHCO₃ solⁿ/H₂O: 1:9). The organic layer was dried over Na₂SO₄, filtered and concentrated. The residue was purified by column chromatography (100% hexanes → 5:95 EtOAc:hexanes) to get methyl 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylate (CXVII) as a white solid (1.47 g, 4.34 mmol, 82% yield). ¹H NMR (DMSO-d₆) δ ppm 8.22 (d, *J* = 1.4 Hz, 1H), 7.89 (d, *J* = 7.2 Hz, 1H), 7.68 (dd, *J* = 7.2, 1.6 Hz, 1H), 6.02 (dd, *J* = 8.0, 2.4 Hz, 1H), 3.94 (s, 3H), 3.88 (m, 1H), 3.79 (m, 1H), 2.37-2.31 (m, 1H), 2.05-1.96 (m, 2H), 1.77-1.73 (m, 1H), 1.60-1.58 (m, 2H); ESIMS found for C₁₄H₁₅BrN₂O₃ *m/z* 340.0 (M+H).


Step 4

[0375] 2 N Aqueous NaOH solution (10 mL) was added to a suspension of methyl 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylate (CXVII) (1.30 g, 3.83 mmol) in water (20 mL) and heated at 90°C for 1 h. The solution was cooled to room temperature, diluted with ice water and acidified to pH 3.0 with 10% aqueous HCl. The solids formed were filtered, washed with cold water and dried under vacuum at room temperature to get 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid (CXVIII) as a white solid (0.87 g, 2.68 mmol, 70% yield). ESIMS found for C₁₃H₁₃BrN₂O₃ *m/z* 326.0 (M+H).

Step 5

[0376] To a solution of 5-bromo-1H-indazole-3-carboxylic acid (CXV) (59.8 g, 248 mmol) in THF (800 mL) under argon was added 3,4 dihydro-2H-pyran (50.6 mL, 558 mmol) and p-TsOH (4.72 g, 24.8 mmol). The reaction was heated to reflux at 60°C for 16 h. An additional portion of p-TsOH (0.025 eq) and 3,4 dihydro-2H-pyran (0.56 eq) was added and the reflux continued for 5 h. The solution was concentrated under vacuum. EtOAc was added to the residue and the suspension was filtered and dried under high vacuum overnight to produce 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid (CXVIII) as a white solid (49.07 g, 150.9 mmol, 60.8% yield). ESIMS found for C₁₃H₁₃BrN₂O₃ *m/z* 326.3 (M+H).

[0377] Preparation of intermediate 5-bromo-1-trityl-1H-indazole-3-carboxylic acid (CXXI) is depicted below in Scheme 26.



Scheme 26

Step 1

[0378] Preparation of intermediate ethyl 5-bromo-1H-indazole-3-carboxylate (CXIX) was performed following the procedure listed in Scheme 25, Step 2. White solid. (3.60 g, 13.38 mmol, 64.5% yield). ^1H NMR (DMSO- d_6) δ ppm 1.37 (t, $J=7\text{Hz}$, 3H), 4.40 (q, $J=7\text{Hz}$, 2H), 7.57 (dd, $J=9\text{Hz}$, $J=2\text{Hz}$, 1H), 7.66 (d, $J=9\text{Hz}$, 1H), 8.20 (d, $J=2\text{Hz}$, 1H), 14.11 (brs, 1H); ESIMS found for $\text{C}_{10}\text{H}_9\text{BrN}_2\text{O}_2$ m/z 269.0 (M+H).

Step 2

[0379] To a solution of ethyl 5-bromo-1H-indazole-3-carboxylate (CXIX) and trityl chloride in DCM was slowly added DIPEA. The solution was stirred at room temperature overnight. The reaction was poured into water and stirred for 5 min. The organic layer was separated, dried over MgSO_4 and concentrated under vacuum. The residue was purified by column chromatography using a ISCO 200RF system with a SiO_2 column (12 g) (100% hexanes $\rightarrow$ 10:90 EtOAc:hexanes) to produce a white solid. (357 mg, 0.70 mmol, 69.8% yield). ^1H NMR (DMSO- d_6) δ ppm 1.34 (t, $J=7\text{Hz}$, 3H), 4.38 (q, $J=7\text{Hz}$, 2H), 6.43 (d, $J=9.5\text{Hz}$, 1H), 7.11-7.14 (m, 6H), 7.31-7.35 (m, 10H), 8.23 (d, $J=2\text{Hz}$, 1H); ESIMS found for $\text{C}_{29}\text{H}_{23}\text{BrN}_2\text{O}_2$ m/z 511.0 (M+H).

Step 3


[0380] Preparation of intermediate 5-bromo-1-trityl-1H-indazole-3-carboxylic acid (CXXI) by hydrolysis of ethyl 5-bromo-1-trityl-1H-indazole-3-carboxylate (CXX) can be performed following the procedure listed in Scheme 25, Step 3.

Step 4

[0381] Preparation of intermediate 5-bromo-1-trityl-1H-indazole-3-carboxylic acid (CXXI) by tritylation of 5-bromo-1H-indazole-3-carboxylic acid (CXV) can be performed following the procedure listed in the *Journal of Medicinal Chemistry* (2003), 46(25), 5458-5470.

Example 1

[0382] Preparation of 5-(5-(3,3-dimethylureido)pyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide (1) is depicted below in Scheme 27.



Scheme 27

Step 1-2

[0383] A solution of 5-iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carbaldehyde (CXIV) (1.780 g, 5.0 mmol), bis(pinacolato)diboron (1.523 g, 6.0 mmol), KOAc (1.471 g, 15 mmol) and dry DMF (20 mL) was purged with argon. PdCl₂(dppf)₂ (0.245 g, 0.3 mmol) was added to the reaction and purged again with argon. The solution was heated at 90°C for 2 h. Once TLC showed the disappearance of (CXIV), the solution was cooled to room temperature. To this solution was added K₃PO₄ (1.592 g, 7.5 mmol), 3-(5-bromopyridin-3-yl)-1,1-dimethylurea (XXII) (1.220 g, 5.0 mmol), Pd(PPh₃)₄ (173 mg, 0.15 mmol) and water (2 mL). The solution was purged with argon and heated at 90°C for 3 h. The solution was cooled to room temperature and then concentrated under reduced pressure. The residue was dissolved in DCM and washed with water, dried over MgSO₄, filtered and then evaporated under vacuum. The residue was purified on a silica gel column (100% DCM → 2:98 MeOH:DCM) to give 3-

(5-(3-formyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl)pyridin-3-yl)-1,1-dimethylurea (**CXXIII**) as a brown viscous oil which solidified under vacuum at room temperature (354 mg, 0.90 mmol, 18% yield for 2 steps). ¹H NMR (DMSO-d₆) δ ppm 10.22 (s, 1H), 8.76 (d, *J* = 1.6 Hz, 1H), 8.63 (s, 1H), 8.52 (d, *J* = 1.6 Hz, 1H), 8.36 (s, 1H), 8.24 (m, 1H), 8.05 (d, *J* = 7.2 Hz, 1H), 7.91 (dd, *J* = 7.2, 1.4 Hz, 1H), 6.13 (dd, *J* = 7.6, 2.0 Hz, 1H), 3.93 (m, 1H), 3.85 (m, 1H), 2.98 (s, 6H), 2.47-2.42 (m, 1H), 2.11-2.06 (m, 2H), 1.82-1.79 (m, 1H) 1.64 (m, 2H); ESIMS found for C₂₁H₂₃N₅O₃ *m/z* 394.0(M+H).

Step 3

[0384] A solution of sodium hydroxide (0.173 g, 4.33 mmol) in water (5 mL) was added to a solution of silver nitrate (0.367 g, 2.16 mmol) in water (5 mL) to give a brown precipitate. 3-(5-(3-formyl-1-(tetrahydro-2H-pyran-2-yl)-1H-indazol-5-yl) pyridin-3-yl)-1,1-dimethylurea (**CXXIII**) (0.340 g, 0.86 mmol) was dissolved in 1,4-dioxane (10 mL) and added to the reaction which was stirred overnight at room temperature. The solution was diluted with water and then extracted with diethyl ether. The aqueous layer was separated and carefully brought to pH = 3 with aqueous HCl. The aqueous layer was then extracted with 10% iPrOH/chloroform. The combined organic layers were then dried (Na₂SO₄), filtered and concentrated to give 5-(5-(3,3-dimethylureido)pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid (**CXXIV**) as a brownish white solid (246 mg, 0.60 mmol, 70% yield). ¹H NMR (DMSO-d₆) δ ppm 13.26 (br. s, 1H), 8.87 (s, 1H), 8.63 (s, 1H), 8.41 (s, 1H), 8.34 (s, 1H), 8.03 (d, *J* = 7.1 Hz, 1H), 7.86 (dd, *J* = 7.2, 1.3 Hz, 1H), 6.06 (dd, *J* = 8.0, 4.0 Hz, 1H), 3.92 (m, 1H), 3.80 (m, 1H), 2.98 (s, 6H), 2.42-2.39 (m, 1H), 2.03-2.02 (m, 2H), 1.79-1.77 (m, 1H) 1.61 (m, 2H); ESIMS found for C₂₁H₂₃N₅O₄ *m/z* 410.0(M+H).

Step 4


[0385] HATU (0.190 g, 0.5 mmol) was added to a solution of 5-(5-(3,3-dimethylureido)pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid (**CXXIV**) (0.39 g, 1.21 mmol) and diisopropylethylamine (0.174 mL, 1.0 mmol) in DMF stirred at room temperature under argon. After stirring 5 min, the solution was added with 3-aminopyridine (**CXXV**) (0.047 g, 0.5 mmol). The solution was stirred overnight at room temperature under argon. The DMF was removed under reduced pressure, and the residue was treated with water, sonicated briefly and filtered. The solids were washed with cold water and dried at room temperature. The product was purified by column chromatography using a 4 g Thomson normal phase silica gel cartridge (100% DCM → 5:95 MeOH:DCM) to afford 5-(5-(3,3-dimethylureido)pyridin-3-yl)-N-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxamide (**CXXVI**) as an off white solid (323 mg, 0.67 mmol, 55% yield). ¹H NMR (DMSO-d₆) δ ppm 10.56 (s, 1H), 9.06 (d, *J* = 2.0 Hz, 1H), 8.75 (d, *J* = 1.6 Hz, 1H), 8.64

(s, 1H), 8.53 (d, $J = 1.6$ Hz, 1H), 8.46 (s, 1H), 8.34-8.29 (m, 2H), 8.26 (m, 1H), 8.03 (d, $J = 7.0$ Hz, 1H), 7.88 (dd, $J = 7.0, 1.2$ Hz, 1H), 7.43 (dd, $J = 6.64, 3.84$ Hz, 1H), 6.07 (dd, $J = 8.0, 1.8$ Hz, 1H), 3.98 (m, 1H), 3.82 (m, 1H), 2.98 (s, 6H), 2.63-2.60 (m, 1H), 2.11-2.06 (m, 2H), 1.83-1.81 (m, 1H) 1.52 (m, 2H); ESIMS found for $C_{21}H_{23}N_5O_4$ m/z 410.0(M+H).

Step 5

[0386] TFA (5 mL) was added to a solution of 5-(5-(3,3-dimethylureido)pyridin-3-yl)-N-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxamide (CXXVI) (0.134 g, 0.27 mmol) and triethylsilane (0.110 mL, 0.69 mmol) in DCM (5 mL) and stirred 3 h at room temperature. The solvent was removed under vacuum. The residue was treated with water, sonicated briefly to disperse the solids, basified to pH 9.0 with 5 N NH_4OH and sonicated again. The solids were filtered, washed with cold water and purified by column chromatography (100% DCM $\rightarrow$ 5:95 MeOH[7N NH_3]:DCM) to afford 5-(5-(3,3-dimethylureido)pyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide (1) as a white solid (35.8 mg, 0.09 mmol, 33% yield). ^1H NMR (DMSO- d_6) δ ppm 13.99 (s, 1H), 10.69 (s, 1H), 9.08 (d, $J = 1.2$ Hz, 1H), 8.74 (d, $J = 1.8$ Hz, 1H), 8.63 (s, 1H), 8.51 (d, $J = 1.5$ Hz, 1H), 8.47 (s, 1H), 8.33-8.30 (m, 2H), 8.26 (m, 1H), 7.80 (s, 2H), 7.41 (dd, $J = 6.6, 3.6$ Hz, 1H), 2.98 (s, 6H); ESIMS found for $C_{21}H_{19}N_7O_2$ m/z 402.3(M+H).

[0387] The following compound was prepared in accordance with the procedure described in the above Example 1.




[0388] N-(5-Fluoropyridin-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide 23.

[0389] Light tan solid. ^1H NMR (DMSO- d_6) δ ppm 7.53 (dd, $J=8$ Hz, $J=5$ Hz, 1H), 7.82-7.86 (m, 2H), 8.13-8.15 (m, 1H), 8.31-8.34 (m, 2H), 8.47-8.48 (m, 1H), 8.60 (dd, $J=5$ Hz, $J=2$ Hz, 1H), 8.94 (d, $J=2$ Hz, 1H), 8.99 (d, $J=2$ Hz, 1H), 10.97 (s, 1H), 14.05 (s, 1H); ESIMS found for $C_{18}H_{12}FN_5O$ m/z 334 (M+1).

Example 2

[0390] Preparation of 5-(5-fluoropyridin-3-yl)-N-(6-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide (2) is depicted below in Scheme 28.



Scheme 28

Step 1

[0391] HATU (1.125 g, 2.96 mmol) was added to a solution of 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid (CXVIII) (0.876 g, 2.69 mmol) and diisopropylethylamine (1.03 mL, 5.92 mmol) in DMF stirred at room temperature under argon. After stirring 5 min, the solution was added with 5-amino-2-(trifluoromethyl) pyridine (CXVII) (0.479 g, 2.96 mmol). The solution was stirred 24 h at room temperature under argon. The DMF was removed under reduced pressure, and the residue was treated with water, sonicated briefly and filtered. The solids were washed with cold water and dried at room temperature. The product was purified by silica gel column chromatography (100% hexanes → 7:93 EtOAc:hexanes) to afford 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-N-(6-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide (CXCVIII) as a white solid (1.17 g, 2.50 mmol, 93% yield). ¹H NMR (DMSO-d₆) δ ppm 10.93 (s, 1H), 9.23 (d, *J* = 1.9 Hz, 1H), 8.60 (dd, *J* = 6.8, 1.4 Hz, 1H), 8.38 (d, *J* = 4.4 Hz, 1H), 7.95 (m, 2H), 7.70 (dd, *J* = 7.1, 1.5 Hz, 1H), 6.04 (dd, *J* = 8.1, 1.9 Hz, 1H), 3.98 (m, 1H), 3.82 (m, 1H), 2.59-2.54 (m, 1H), 2.08-2.03 (m, 2H), 1.81-1.77 (m, 1H), 1.66-1.61 (m, 2H); ESIMS found for C₁₉H₁₆BrF₃N₄O₂ *m/z* 470.0 (M+H).

Step 2


[0392] A solution of 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-N-(6-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide (CXCVIII) (0.469 g, 1 mmol), 5-fluoropyridin-3-ylboronic acid (CXXIX) (0.156 g, 1.1 mmol), potassium phosphate tribasic (0.318 g, 1.5 mmol) and water (degassed, 1 mL) in DMF (10 mL) was purged with argon.

Tetrakis(triphenylphosphine)palladium(0) (0.034 g, 0.03 mmol) was added and the solution was purged again with argon. The reaction was heated to 90°C for 3 h when TLC showed disappearance of starting material. The solution was cooled to room temperature and excess solvent was removed under vacuum. The residue was treated with water, sonicated briefly and the solids formed were filtered. The solids were washed with cold water and dried under vacuum at room temperature which was purified by silica gel column chromatography (2:8 EtOAc:hexanes → 3:7 EtOAc:hexanes) to afford 5-(5-fluoropyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-N-(6-(trifluoromethyl) pyridin-3-yl)-1H-indazole-3-carboxamide (**CXXX**) as a white solid (427 mg, 0.88 mmol, 88% yield). ¹H NMR (DMSO-d₆) δ ppm 10.95 (s, 1H), 9.25 (d, *J* = 1.8 Hz, 1H), 8.85 (m, 1H), 8.63 (d, *J* = 1.8 Hz, 1H), 8.61 (d, *J* = 2.1 Hz, 1H), 8.53 (m, 1H), 8.16-8.13 (m, 1H), 8.08 (d, *J* = 7.1 Hz, 1H), 7.97-7.94 (m, 2H), 6.11 (dd, *J* = 8.1, 1.8 Hz, 1H), 4.01 (m, 1H), 3.88-3.83 (m, 1H), 2.63-2.60 (m, 1H), 2.11-2.07 (m, 2H), 1.83-1.80 (m, 1H), 1.69-1.65 (m, 2H); ESIMS found for C₂₄H₁₉F₄N₅O₂ *m/z* 486.0 (M+H).

Step 3

[0393] TFA (10 mL) was added to a solution of 5-(5-fluoropyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-N-(6-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide (**CXXX**) (0.420 g, 0.86 mmol) and triethylsilane (0.345 mL, 2.16 mmol) in DCM (10 mL) and stirred 5 h at room temperature. The solvent was removed under vacuum. The residue was treated with water, sonicated briefly to disperse the solids, basified to pH 9.0 with 5 N NH₄OH and sonicated again. The solids were filtered, washed with cold water and air dried at room temperature. The solids were suspended in DCM:MeOH (1:1) mixture and boiled to get a clear solution. The solution was cooled to room temperature. The solids formed were filtered washed with DCM and dried under vacuum at room temperature to get 5-(5-fluoropyridin-3-yl)-N-(6-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide (**2**) as a white solid (72.9 mg, 0.18 mmol, 21% yield). ¹H NMR (DMSO-d₆) δ ppm 14.13 (br. s, 1H), 11.11 (s, 1H), 9.27 (d, *J* = 1.8 Hz, 1H), 8.84 (m, 1H), 8.63 (dd, *J* = 6.8, 1.8 Hz, 1H), 8.60 (d, *J* = 2.0 Hz, 1H), 8.53 (m, 1H), 8.14-8.11 (m, 1H), 7.94 (d, *J* = 6.9 Hz, 1H), 7.90-7.83 (m, 2H); ESIMS found for C₁₉H₁₁F₄N₅O *m/z* 402.30 (M+H).


[0394] The following compound was prepared in accordance with the procedure described in the above Example 2.



3

[0395] 5-(Pyridin-3-yl)-N-(6-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **3**.


[0396] White solid (19% yield). ¹H NMR (DMSO-d₆) δ ppm 14.03 (br. s, 1H), 11.10 (s, 1H), 9.27 (d, *J* = 1.8 Hz, 1H), 8.94 (d, *J* = 1.6 Hz, 1H), 8.63 (dd, *J* = 6.8, 1.7 Hz, 1H), 8.60 (m, 1H), 8.48 (s, 1H), 8.15-8.13 (m, 1H), 7.93 (d, *J* = 6.9 Hz, 1H), 7.85 (s, 2H), 7.54 (m, 1H); ESIMS found for C₁₉H₁₂F₃N₅O *m/z* 384.0 (M+H).



37

[0397] N-(1-Methyl-5-(trifluoromethyl)-1H-pyrazol-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide **37**.

[0398] Light green solid (76.7 mg, 0.20 mmol, 48.4% yield). ¹H NMR (DMSO-d₆) δ ppm 3.93 (s, 3H), 7.18 (s, 1H), 7.55 (dt, *J* = 8Hz, *J* = 3Hz, 1H), 7.81 (dd, *J* = 15Hz, *J* = 9Hz, 2H), 8.16 (d, *J* = 8Hz, 1H), 8.45 (s, 1H), 8.61 (d, *J* = 4Hz, 1H), 8.95 (s, 1H), 10.81 (s, 1H), 13.96 (s, 1H); ESIMS found for C₁₈H₁₃F₃N₆O *m/z* 387.1 (M+H).




42

[0399] 5-(Pyridin-3-yl)-N-(pyridin-3-ylmethyl)-1H-indazole-3-carboxamide **42**.

[0400] White solid (54.5 mg, 0.17 mmol, 78% yield). ¹H NMR (DMSO-d₆) δ ppm 4.53 (d, *J* = 6Hz, 2H), 7.35 (dd, *J* = 8Hz, *J* = 5Hz, 1H), 7.49-7.52 (m, 1H), 7.74-7.78 (m, 3H), 8.09-8.11 (m, 1H), 8.41-8.42 (m, 1H), 8.45 (dd, *J* = 5Hz, *J* = 2Hz, 1H), 8.57 (dd, *J* = 5Hz, *J* = 2Hz, 1H),


8.59 (d, $J=2$ Hz, 1H), 8.90 (d, $J=2$ Hz, 1H), 9.16 (t, $J=6$ Hz, 1H), 13.77 (s, 1H); ESIMS found for $C_{19}H_{15}N_5O$ m/z 330 (M+H).



48

[0401] 5-(Pyridin-3-yl)-N-(4-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **48**.


[0402] White solid (67 mg, 0.17 mmol, 62% yield). ^1H NMR (DMSO- d_6) δ ppm 7.52 (dd, $J=8$ Hz, $J=5$ Hz, 1H), 7.83-7.87 (m, 3H), 8.12 (td, $J=8$ Hz, $J=2$ Hz, 1H), 8.41 (t, $J=1$ Hz, 1H), 8.59 (dd, $J=5$ Hz, $J=2$ Hz, 1H), 8.75 (d, $J=5$ Hz, 1H), 8.92 (d, $J=3$ Hz, 1H), 9.08 (s, 1H), 10.21 (s, 1H), 14.06 (brs, 1H); ESIMS found for $C_{19}H_{12}F_3N_5O$ m/z 384.0 (M+H).



53

[0403] 5-(Pyridin-3-yl)-N-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide **53**.


[0404] Beige solid (23.8 mg, 0.06 mmol, 44.5% yield). ^1H NMR (DMSO- d_6) δ ppm 1.92-1.97 (m, 4H), 3.38 (t, $J=7$ Hz, 4H), 6.46 (d, $J=9$ Hz, 1H), 7.52 (dd, $J=8$ Hz, $J=5$ Hz, 1H), 7.80 (dq, $J=9$ Hz, $J=2$ Hz, 2H), 7.97 (dd, $J=9$ Hz, $J=3$ Hz, 1H), 8.12 (dd, $J=8$ Hz, $J=4$ Hz, 1H), 8.47 (s, 1H), 8.50 (d, $J=3$ Hz, 1H), 8.59 (dd, $J=5$ Hz, $J=2$ Hz, 1H), 8.92 (d, $J=2$ Hz, 1H), 10.22 (s, 1H), 13.86 (s, 1H); ESIMS found for $C_{22}H_{20}N_6O$ m/z 385.1 (M+H).



58

[0405] N-(4-(Cyclopropanecarboxamido)pyridin-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide **58**.

[0406] White solid (32.7 mg, 0.08 mmol, 37.0% yield). ^1H NMR (DMSO- d_6) δ ppm 0.84-0.88 (m, 2H), 0.88-0.92 (m, 2H), 1.91-1.99 (m, 1H), 7.52 (dd, $J=8\text{Hz}$, $J=5\text{Hz}$, 1H), 7.73 (d, $J=6\text{Hz}$, 1H), 7.82 (dd, $J=12\text{Hz}$, $J=9\text{Hz}$, 2H), 8.12 (dt, $J=9\text{Hz}$, $J=4\text{Hz}$, 1H), 8.34 (d, $J=6\text{Hz}$, 1H), 8.44 (s, 1H), 8.59 (dd, $J=5\text{Hz}$, $J=2\text{Hz}$, 1H), 8.80 (s, 1H), 8.92 (d, $J=2\text{Hz}$, 1H), 10.03 (s, 1H), 10.31 (s, 1H), 13.98 (s, 1H); ESIMS found for $\text{C}_{22}\text{H}_{18}\text{N}_6\text{O}_2$ m/z 399.0 (M+H).




181

[0407] N-(6-(Cyclopentylcarbamoyl)pyridin-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide **181**.

[0408] Light yellow solid (18 mg, 0.04 mmol, 16.6% yield). ^1H NMR (DMSO- d_6) δ ppm 1.50-1.64 (m, 4H), 1.67-1.76 (m, 2H), 1.85-1.94 (m, 4H), 4.24 (quin, $J=8\text{Hz}$, 1H), 7.53 (dd, $J=8\text{Hz}$, $J=5\text{Hz}$, 1H), 7.84 (ABq, 2H), 8.03 (d, $J=9\text{Hz}$, 1H), 8.14 (d, $J=8\text{Hz}$, 1H), 8.45 (d, $J=8\text{Hz}$, 1H), 8.48 (s, 1H), 8.54 (dd, $J=9\text{Hz}$, $J=2.5\text{Hz}$, 1H), 8.60 (d, $J=4\text{Hz}$, 1H), 8.94 (d, $J=2\text{Hz}$, 1H), 9.16 (d, $J=2\text{Hz}$, 1H), 10.97 (s, 1H), 14.08 (brs, 1H); ESIMS found for $\text{C}_{24}\text{H}_{22}\text{N}_6\text{O}_2$ m/z 427.1 (M+H).

Example 3

[0409] Preparation of N,5-di(pyridin-3-yl)-1H-indazole-3-carboxamide (**4**) is depicted below in Scheme 29.



Scheme 29

Step 1

[0410] 5-Iodo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carbaldehyde (CXIV) (1.53 g, 4.30 mmol), pyridine-3-boronic acid (CXXXI) (0.58 g, 4.73 mmol), and potassium phosphate tribasic (1.37 g, 6.45 mmol) was dissolved in 1,4-dioxane (43.0 mL) and water (9.0 mL). Tetrakis(triphenylphosphine)palladium(0) (0.50 g, 0.4301 mmol) was added, and the reaction was heated to 95°C for 2.5 h. The solvent was removed, and the residue was partitioned between EtOAc and water. The organic phase was separated and washed sequentially with water and brine. The material was dried (MgSO₄), concentrated, and purified by flash chromatography using a 40 g Thomson normal phase silica gel cartridge (100% hexanes → 1:1 EtOAc:hexanes) to afford 5-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carbaldehyde (CXXXII) (0.62 g, 2.02 mmol, 47% yield) as a tan amorphous solid. ¹H NMR (DMSO-d₆) δ ppm 10.23 (s, 1H), 8.95 (d, *J* = 2.3 Hz, 1H), 8.61 (dd, *J* = 4.8, 1.5 Hz, 1H), 8.39 (d, *J* = 0.98 Hz, 1H), 8.17-8.14 (m, 1H), 8.06 (d, *J* = 8.8 Hz, 1H), 7.95-7.93 (m, 1H), 7.64-7.60 (m, 1H), 6.13 (dd, *J* = 9.4, 2.4 Hz, 1H), 3.93-3.90 (m, 1H), 3.86-3.81 (m, 1H), 2.45-2.41 (m, 1H), 2.11-2.07 (m, 2H), 1.82-1.78 (m, 1H), 1.66-1.62 (m, 2H); ESIMS found for C₁₈H₁₇N₃O₂ *m/z* 308 (M+H).

Step 2

[0411] To a solution of silver nitrate (0.55 g, 3.25 mmol) in water (10 mL) was added a solution of sodium hydroxide (0.26 g, 6.50 mmol) in water (5 mL) to give a brown precipitate. 5-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carbaldehyde (CXXXII) (0.40 g, 1.30 mmol) dissolved in 1,4-dioxane (3 mL) was added to the reaction

which was stirred at room temperature for 2 h. The reaction was then extracted with diethyl ether. The aqueous layer was separated and carefully brought to pH = 3 with 10% aqueous HCl. The aqueous layer was then extracted five times with iPrOH/chloroform (1/9). The combined organic layers were then dried (MgSO₄) and concentrated to afford 5-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid (**CXXXIII**) (0.30 g, 0.93 mmol, 70% yield) as a white solid. ¹H NMR (DMSO-d₆) δ ppm 13.28 (br, 1H), 8.93 (s, 1H), 8.60 (d, *J* = 4.1 Hz, 1H), 8.32 (d, *J* = 0.83 Hz, 1H), 8.14-8.12 (m, 1H), 8.00 (d, *J* = 8.8 Hz, 1H), 7.86 (dd, *J* = 8.8, 1.7 Hz, 1H), 7.52 (dd, *J* = 7.8, 4.7 Hz, 1H), 6.04 (dd, *J* = 9.3, 2.3 Hz, 1H), 3.92-3.90 (m, 1H), 3.83-3.78 (m, 1H), 2.44-2.37 (m, 1H), 2.08-2.02 (m, 2H), 1.79-1.76 (m, 1H), 1.63-1.61 (m, 2H).

Step 3


[0412] To a solution of 5-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid (**CXXXIII**) (0.39 g, 1.21 mmol) and 3-aminopyridine (**CXXVII**) (0.11 g, 1.21 mmol) in DMF (4.0 mL) was added N,N-diisopropylethylamine (0.42 mL, 1.21 mmol). The solution was cooled to 0°C before adding HATU (0.46 g, 1.21 mmol). The ice bath was removed, and the reaction warmed to room temperature and stirred for 2 h. The DMF was removed under reduced pressure, and the residue was partitioned between chloroform and water. The organic phase was separated and washed sequentially with water and brine, dried over MgSO₄, filtered, and concentrated. The product was purified by column chromatography using a 25 g Thomson normal phase silica gel cartridge (100% CHCl₃ → 2:98 MeOH:CHCl₃) to afford N,5-di(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxamide (**CXXXIV**) (0.36 g, 0.90 mmol, 75% yield) as an off-white solid. ¹H NMR (DMSO-d₆) δ ppm 10.56 (s, 1H), 9.06 (d, *J* = 2.4 Hz, 1H), 8.94 (d, *J* = 2.3 Hz, 1H), 8.60 (dd, *J* = 4.8, 1.5 Hz, 1H), 8.47 (d, *J* = 1.1 Hz, 1H), 8.34-8.33 (m, 1H), 8.31-8.29 (m, 1H), 8.16-8.14 (m, 1H), 8.04 (d, *J* = 8.8 Hz, 1H), 7.90 (dd, *J* = 8.8, 1.8 Hz, 1H), 7.54-7.52 (m, 1H), 7.43-7.41 (m, 1H), 7.43-7.41 (m, 1H), 6.08-6.06 (m, 1H), 4.01-3.99 (m, 1H), 3.87-3.82 (m, 1H), 2.64-2.57 (m, 1H), 2.11-2.06 (m, 2H), 1.84-1.80 (m, 1H), 1.69-1.65 (m, 2H); ESIMS found for C₂₃H₂₁N₅O₂ *m/z* 400 (M+H).

Step 4

[0413] TFA (5.0 mL) was added to a solution of N,5-di(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxamide (**CXXXIV**) (0.36 g, 0.90 mmol) and triethylsilane (0.29 mL, 1.81 mmol) in DCM (5.0 mL). The solution was stirred overnight at room temperature. An additional 5.0 mL of TFA was added, and the solution was again stirred overnight. The solvents were removed, and the residue was treated with 7 N ammonia in MeOH. The solvents were again removed, and the product was purified by flash


chromatography using a 12 g Thomson normal phase silica gel cartridge (100% CHCl₃ → 5:95 MeOH[7N NH₃]:CHCl₃) to afford N,5-di(pyridin-3-yl)-1H-indazole-3-carboxamide (**4**) (0.23 g, 0.73 mmol, 82% yield) as a white solid. ¹H NMR (DMSO-d₆) δ ppm 14.00 (s, 1H), 10.69 (s, 1H), 9.08 (d, *J* = 2.0 Hz, 1H), 8.93 (d, *J* = 2.0 Hz, 1H), 8.60 (dd, *J* = 4.8, 1.3 Hz, 1H), 8.48-8.47 (m, 1H), 8.33-8.31 (m, 2H), 8.15-8.12 (m, 1H), 7.85-7.81 (m, 2H), 7.54-7.51 (m, 1H), 7.41-7.39 (m, 1H); ESIMS found for C₁₈H₁₃N₅O *m/z* 316 (M+H).

[0414] The following compounds were prepared in accordance with the procedure described in the above Example 3.




[0415] N-(3'-Fluorobiphenyl-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide **5**.

[0416] White solid (77 mg, 0.19 mmol, 69% yield). ¹H NMR (DMSO-d₆) δ ppm 13.95 (s, 1H), 10.50 (s, 1H), 8.94 (d, *J* = 2.3 Hz, 1H), 8.59 (dd, *J* = 4.6, 1.5 Hz, 1H), 8.51 (d, *J* = 1.0 Hz, 1H), 8.31-8.30 (m, 1H), 8.15-8.13 (m, 1H), 7.99-7.97 (m, 1H), 7.83-7.82 (m, 2H), 7.55-7.45 (m, 6H), 7.24-7.22 (m, 1H); ESIMS found for C₂₅H₁₇FN₄O *m/z* 409 (M+H).




[0417] 5-(Pyridin-3-yl)-N-(pyridin-4-yl)-1H-indazole-3-carboxamide **6**.

[0418] Off-white solid (52 mg, 0.16 mmol, 77% yield). ¹H NMR (DMSO-d₆) δ ppm 14.05 (br, 1H), 10.83 (s, 1H), 8.94 (d, *J* = 2.0 Hz, 1H), 8.60 (dd, *J* = 4.6, 1.2 Hz, 1H), 8.48-8.47 (m, 3H), 8.15-8.13 (m, 1H), 7.94 (dd, *J* = 5.0, 1.4 Hz, 2H), 7.86-7.82 (m, 2H), 7.54-7.52 (m, 1H); ESIMS found for C₁₈H₁₃N₅O *m/z* 316 (M+H).




[0419] N-(5-((Dimethylamino)methyl)pyridin-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide **7**.

[0420] Off-white solid (37 mg, 0.10 mmol, 47% yield). ^1H NMR (DMSO- d_6) δ ppm 14.00 (s, 1H), 10.68 (s, 1H), 8.94 (d, $J = 2.0$ Hz, 1H), 8.91 (d, $J = 2.3$ Hz, 1H), 8.60 (dd, $J = 4.7, 1.2$ Hz, 1H), 8.49-8.48 (m, 1H), 8.38-8.37 (m, 1H), 8.21 (d, $J = 2.2$ Hz, 1H), 8.16-8.13 (m, 1H), 7.85-7.81 (m, 2H), 7.52 (dd, $J = 7.9, 4.9$ Hz, 1H), 3.44 (s, 2H), 2.19 (s, 6H); ESIMS found for $\text{C}_{21}\text{H}_{20}\text{N}_6\text{O}$ m/z 373 (M+H).



[0421] 5-(Pyridin-3-yl)-N-(6-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **8**.


[0422] Off-white solid (38 mg, 0.10 mmol, 77% yield). ^1H NMR (DMSO- d_6) δ ppm 13.99 (br, 1H), 10.64 (s, 1H), 8.96 (d, $J = 2.5$ Hz, 1H), 8.93 (d, $J = 2.4$ Hz, 1H), 8.59 (dd, $J = 4.8, 1.5$ Hz, 1H), 8.48 (d, $J = 1.2$ Hz, 1H), 8.27 (dd, $J = 8.5, 2.5$ Hz, 1H), 8.16-8.12 (m, 1H), 7.84-7.80 (m, 2H), 7.54-7.51 (m, 1H), 7.41 (d, $J = 8.5$ Hz, 1H), 2.37 (s, 2H), 2.50-2.47 (m, 4H), 1.72-1.70 (m, 4H); ESIMS found for $\text{C}_{23}\text{H}_{22}\text{N}_6\text{O}$ m/z 399 (M+H).



9

[0423] N-(5-(3-Fluorophenyl)pyridin-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide 9.


[0424] White solid (35 mg, 0.09 mmol, 47% yield). ¹H NMR (DMSO-d₆) δ ppm 14.05 (br s, 1H), 10.79 (s, 1H), 9.13 (d, *J* = 2.0 Hz, 1H), 8.94 (d, *J* = 1.9 Hz, 1H), 8.68-8.65 (m, 2H), 8.60 (dd, *J* = 4.83, 4.83 Hz, 1H), 8.52-8.49 (m, 1H), 8.16-8.12 (m, 1H), 7.85-7.81 (m, 2H), 7.62-7.56 (m, 3H), 7.54-7.50 (m, 1H), 7.31-7.26 (m, 1H). ESIMS found for C₂₄H₁₆FN₅O *m/z* 410.5 (M+H).



11

[0425] N-(2-(4-Methylpiperazin-1-yl)pyridin-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide 11.


[0426] White solid (11 mg, 0.03 mmol, 65% yield). ¹H NMR (DMSO-d₆) δ ppm 14.10 (s, 1H), 9.63 (s, 1H), 8.93 (d, *J* = 2.1 Hz, 1H), 8.65-8.59 (m, 2H), 8.48 (s, 1H), 8.16-8.12 (m, 1H), 8.11-8.09 (m, 1H), 7.87-7.80 (m, 2H), 7.55-7.51 (m, 1H), 7.20-7.17 (m, 1H), 3.10-3.06 (m, 4H), 2.80-2.40 (m, 4H), 2.30 (s, 3H). ESIMS found for C₂₃H₂₃N₇O *m/z* 414.0 (M+H).



12

[0427] N-(6-(4-Methylpiperazin-1-yl)pyridin-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide 12.


[0428] White solid (31 mg, 0.07 mmol, 39% yield). ¹H NMR (DMSO-d₆) δ ppm 13.86 (br s, 1H), 10.33 (s, 1H), 8.92 (d, *J* = 2.1 Hz, 1H), 8.60-8.58 (m, 2H), 8.46 (s, 1H), 8.14-8.11 (m, 1H), 8.10-8.02 (m, 1H), 7.83-7.78 (m, 2H), 7.54-7.50 (m, 1H), 6.86 (d, *J* = 9.1 Hz, 1H), 3.45-3.42 (m, 4H), 2.42-2.39 (m, 4H), 2.21 (s, 3H). ESIMS found for C₂₃H₂₃N₇O *m/z* 414.3 (M+H).



14

[0429] N-(Pyridazin-4-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide **14**.

[0430] Off-white solid (50 mg, 0.16 mmol, 99% yield). ¹H NMR (DMSO-d₆) δ ppm 14.20-13.90 (br, 1H), 11.15 (s, 1H), 9.71-9.70 (m, 1H), 9.09-9.08 (m, 1H), 8.94 (d, *J* = 2.0 Hz, 1H), 8.61-8.60 (m, 1H), 8.47-8.46 (m, 1H), 8.25 (dd, *J* = 5.9, 2.8 Hz, 1H), 8.16-8.13 (m, 1H), 7.86-7.85 (m, 2H), 7.53 (dd, *J* = 7.8, 5.0 Hz, 1H); ESIMS found for C₁₇H₁₂N₆O *m/z* 317 (M+H).




15

[0431] N-(6-((4-Methylpiperazin-1-yl)methyl)pyridin-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide **15**.

[0432] White solid (42 mg, 0.10 mmol, 81% yield). ¹H NMR (DMSO-d₆) δ ppm 13.97 (br, 1H), 10.65 (s, 1H), 8.97 (d, *J* = 2.4 Hz, 1H), 8.93 (d, *J* = 2.1 Hz, 1H), 8.59 (dd, *J* = 4.7, 1.5 Hz, 1H), 8.48-8.47 (m, 1H), 8.28 (dd, *J* = 8.5, 2.5 Hz, 1H), 8.15-8.12 (m, 1H), 7.85-7.81 (m, 2H), 7.54-7.51 (m, 1H), 7.40 (d, *J* = 8.5 Hz, 1H), 3.55 (s, 2H), 2.42-2.28 (m, 8H), 2.15 (s, 3); ESIMS found for C₂₄H₂₅N₇O *m/z* 428 (M+H).

Example 4

[0433] Preparation of 5-(5-fluoropyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide (**13**) is depicted below in Scheme 30.



Scheme 30

Step 1


[0434] To a stirring solution of 3-aminopyridine (CXXV) (0.195 g, 0.2.07 mmol) in DMF (10 mL) was added 5-bromo-1*H*-indazole-3-carboxylic acid (CXV) (0.500 g, 0.2.07 mmol) and *N,N*-diisopropylethylamine (0.723 mL, 4.15 mmol). The reaction mixture was cooled to 0°C and added with HATU (0.787 g, 2.07 mmol). The reaction mixture was allowed to warm to room temperature and stirred for an additional 2 h. The solution was concentrated under vacuum. The residue was purified by column chromatography (1:99 MeOH[7N NH₃]:CHCl₃ → 4:96 MeOH[7N NH₃]:CHCl₃) to afford 5-bromo-*N*-(pyridin-3-yl)-1*H*-indazole-3-carboxamide (CXXXV) (0.200 g, 0.63 mmol, 30% yield) as a white solid. ESIMS found for C₁₃H₉BrN₄O *m/z* 318.0 (M+H).

Step 2

[0435] To a microwave vial was added 5-bromo-*N*-(pyridin-3-yl)-1*H*-indazole-3-carboxamide (CXXXV) (0.200 g, 0.63 mmol), 5-fluoropyridine-3-boronic acid (CXXIX) (0.098 g, 0.694 mmol), tetrakis(triphenylphosphine)palladium(0) (0.036 g, 0.032 mmol), potassium phosphate (0.201 g, 0.947 mmol), water (1 mL), and DMF (5 mL). The reaction vial was capped, purged with argon and heated under microwave irradiation for 1 h at 180°C. The solution was filtered through a pad of Celite and concentrated under vacuum. The crude product was purified by column chromatography (100% CHCl₃ → 2:98 MeOH[7N NH₃]: CHCl₃) to afford 5-(5-fluoropyridin-3-yl)-*N*-(pyridin-3-yl)-1*H*-indazole-3-carboxamide (13) (4 mg, 0.01 mmol, 2% yield) as a white solid. ¹H NMR (DMSO-*d*₆) δ ppm 14.02 (br s, 1H), 10.70 (s, 1H), 9.08 (d, *J* = 2.5 Hz, 1H), 8.83 (t, *J* = 1.8 Hz, 1H), 8.60 (d, *J* = 2.7 Hz, 1H), 8.53-8.52 (m, 1H), 8.34-8.29 (m, 2H), 8.14-8.09 (m, 1H), 7.89-7.81 (m, 2H), 7.42-7.38 (m, 1H). ESIMS found for C₁₈H₁₂FN₅O *m/z* 334.0 (M+H).

Example 5

[0436] Preparation of *N*-(pyridin-3-yl)-5-(5-(trifluoromethyl)pyridin-3-yl)-1*H*-indazole-3-carboxamide (16) is depicted below in Scheme 31.



Scheme 31

Step 1

[0437] Preparation of intermediate 5-bromo-N-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxamide (**CXXXV**) was performed following the procedure listed in Scheme 19, Step 4. Light yellow solid (5.5 g, 13.7 mmol, 88% yield). ESIMS found for $C_{18}H_{17}BrN_4O_2$ m/z 401.1 ($M^{79Br}+H$) and 403.1 ($M^{81Br}+H$).


Steps 2-3

[0438] Preparation of intermediate N-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-5-(5-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide (**CXXXVIII**) was performed following the procedure listed in Scheme 26, Steps 1-2. Tan solid (295 mg, 0.63 mmol, 84% yield). ESIMS found for $C_{24}H_{20}F_3N_5O_2$ m/z 468.1 ($M+H$).

Step 4

[0439] Preparation of N-(pyridin-3-yl)-5-(5-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide (**16**) was performed following the procedure listed in Scheme 28, Step 4. White solid (95 mg, 0.25 mmol, 39.3% yield). ^1H NMR (DMSO- d_6) δ ppm 7.40 (dd, $J=2.2Hz$, $J=2Hz$, 1H), 7.84 (d, $J=6.7Hz$, 1H), 7.93 (dd, $J=1.5Hz$, $J=7Hz$, 1H), 8.29-8.34 (m, 2H), 8.50 (s, 1H), 8.57 (s, 1H), 8.99 (s, 1H), 9.09 (d, $J=2Hz$, 1H), 9.25 (d, $J=1.6Hz$, 1H), 10.72 (brs, 1H); ESIMS found for $C_{19}H_{12}F_3N_5O$ m/z 383.9 ($M+H$).


[0440] The following compounds were prepared in accordance with the procedure described in the above Example 5.



26

[0441] 5-(5-((Dimethylamino)methyl)pyridin-3-yl)-N-(6-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **26**.


[0442] White solid (93 mg, 0.21 mmol, 78% yield). ¹H NMR (DMSO-d₆) δ ppm 2.24 (s, 6H), 3.57 (s, 2H), 7.86 (Abq, *J*=8Hz, 2H), 7.93 (d, *J*=9Hz, 1H), 8.04 (brs, 1H), 8.50 (d, *J*=7Hz, 1H), 8.63 (dd, *J*=9Hz, *J*=2Hz, 1H), 8.85 (d, *J*=2Hz, 1H), 9.27 (d, *J*=2Hz, 1H), 11.11 (s, 1H), 14.11 (s, 1H); ESIMS found for C₂₂H₁₉F₃N₆O *m/z* 441.0 (M+H)



32

[0443] N-(5-(3-(Pyridin-3-ylcarbamoyl)-1H-indazol-5-yl)pyridin-3-yl)morpholine-4-carboxamide **32**.


[0444] White solid (132 mg, 0.30 mmol, 56% yield). ¹H NMR (DMSO-d₆) δ ppm 3.49 (t, *J*=5Hz, 4H), 3.64 (t, *J*=5Hz, 4H), 7.40 (dd, *J*=8Hz, *J*=5Hz, 1H), 7.82 (d, *J*=1Hz, 1H), 8.26 (t, *J*=2Hz, 1H), 8.30-8.34 (m, 2H), 8.47 (s, 1H), 8.54 (d, *J*=2Hz, 1H), 8.72 (d, *J*=2Hz, 1H), 8.87 (s, 1H), 9.09 (d, 2Hz, 1H), 10.71 (s, 1H), 14.01 (s, 1H); ESIMS found for C₂₃H₂₁N₇O₃ *m/z* 444.3 (M+H).



36

[0445] 5-(5-((Dimethylamino)methyl)pyridin-3-yl)-N-(6-(2-fluorophenoxy)pyridin-3-yl)-1H-indazole-3-carboxamide **36**.


[0446] White solid (137 mg, 0.28 mmol, 53% yield). ¹H NMR (DMSO-d₆) δ ppm 2.20 (s, 6H), 3.53 (s, 2H), 7.16 (d, *J*=9Hz, 1H), 7.22-7.40 (m, 4H), 7.82 (d/Abq, *J*=9Hz, *J*=1Hz, 2H), 8.00 (t, *J*=2Hz, 1H), 8.38 (dd, *J*=9Hz, *J*=3Hz, 1H), 8.47 (s, 1H), 8.49 (d, *J*=2Hz, 1H), 8.55 (d, *J*=3Hz, 1H), 8.83 (d, *J*=2Hz, 1H), 10.67 (s, 1H), 13.97 (brs, 1H); ESIMS found for C₂₇H₂₃FN₆O₂ *m/z* 383.1 (M+H).



38

[0447] 5-(5-(Cyclopropanecarboxamido)pyridin-3-yl)-N-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide **38**.


[0448] White solid (39 mg, 0.08 mmol, 61% yield). ¹H NMR (DMSO-d₆) δ ppm 0.83-0.90 (m, 4H), 1.80-1.86 (m, 1H), 2.25 (brs, 3H), 2.45 (brs, 4H), 3.45 (brs, 4H), 6.86 (d, *J*=9Hz, 1H), 7.79 (d, *J*=1Hz, 1H), 8.04 (dd, *J*=9Hz, *J*=3Hz, 1H), 8.42 (t, *J*=2Hz, 1H), 8.46 (s, 1H), 8.60 (dd, *J*=10Hz, *J*=3Hz, 2H), 8.76 (d, *J*=2Hz, 1H), 10.34 (s, 1H), 10.56 (s, 1H), 13.90 (s, 1H); ESIMS found for C₂₇H₂₇N₈O₂ *m/z* 497.4 (M+H).



39

[0449] 5-(5-(Cyclopropanecarboxamido)pyridin-3-yl)-N-(6-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **39**.


[0450] White solid (128 mg, 0.27 mmol, 45% yield). ¹H NMR (DMSO-d₆) δ ppm 0.82-0.90 (m, 4H), 1.80-1.86 (m, 1H), 7.84 (s, 2H), 7.92 (d, *J*=9Hz, 1H), 8.43 (d, *J*=2Hz, 1H), 8.48 (s, 1H), 8.61-8.65 (m, 2H), 8.77 (d, *J*=2Hz, 1H), 9.27 (d, *J*=2Hz, 1H), 10.57 (s, 1H), 11.11 (s, 1H), 14.11 (s, 1H); ESIMS found for C₂₃H₁₇F₃N₆O₂ *m/z* 467.1 (M+H).



40

[0451] 5-(5-((Dimethylamino)methyl)pyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide **40**.


[0452] White solid (312 mg, 0.84 mmol, 77% yield). ^1H NMR (DMSO- d_6) δ ppm 2.21 (s, 6H), 3.53 (s, 2H), 7.40 (dd, $J=8\text{Hz}$, $J=5\text{Hz}$, 1H), 7.83 (d/Abq, $J=9\text{Hz}$, $J=2\text{Hz}$, 2H), 8.01 (t, $J=2\text{Hz}$, 1H), 8.29-8.34 (m, 2H), 8.48 (dd, $J=4\text{Hz}$, $J=1\text{Hz}$, 1H), 8.83 (d, $J=2\text{Hz}$, 1H), 9.08 (d, $J=3\text{Hz}$, 1H), 10.70 (s, 1H), 13.99 (brs, 1H); ESIMS found for $\text{C}_{21}\text{H}_{20}\text{N}_6\text{O}$ m/z 373.0 (M+H).



41

[0453] 5-(5-(Cyclopropanecarboxamido)pyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide **41**.

[0454] White solid (148 mg, 0.37 mmol, 71% yield). ^1H NMR (DMSO- d_6) δ ppm 0.83-0.90 (m, 4H), 1.80-1.87 (m, 1H), 7.40 (dd, $J=8\text{Hz}$, $J=5\text{Hz}$, 1H), 7.82 (d, $J=1\text{Hz}$, 1H), 8.29-8.34 (m, 2H), 8.43 (t, $J=2\text{Hz}$, 1H), 8.47 (s, 1H), 8.62 (d, $J=2\text{Hz}$, 1H), 8.76 (d, $J=2\text{Hz}$, 1H), 9.08 (d, $J=2\text{Hz}$, 1H), 10.57 (s, 1H), 10.70 (s, 1H), 14.01 (s, 1H); ESIMS found for $\text{C}_{22}\text{H}_{18}\text{N}_6\text{O}_2$ m/z 399.0 (M+H).




43

[0455] N-(Pyridin-3-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **43**.

[0456] White solid (157 mg, 0.39 mmol, 76% yield). ^1H NMR (DMSO- d_6) δ ppm 1.70-1.74 (m, 4H), 2.46-2.52 (m, 4H), 3.71 (s, 2H), 7.40 (dd, $J=8\text{Hz}$, $J=5\text{Hz}$, 1H), 7.83 (d/Abq, $J=9\text{Hz}$, $J=2\text{Hz}$, 2H), 8.02 (t, $J=2\text{Hz}$, 1H), 8.29-8.34 (m, 2H), 8.48 (s, 1H), 8.51 (d, $J=2\text{Hz}$, 1H),


8.82 (d, $J=2$ Hz, 1H), 9.08 (d, $J=2$ Hz, 1H), 10.70 (s, 1H), 14.00 (s, 1H); ESIMS found for $C_{23}H_{22}N_6O$ m/z 399.0 (M+H).



44

[0457] N-(6-Ethoxypyridin-3-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **44**.


[0458] White solid (62 mg, 0.14 mmol, 39% yield). ^1H NMR (DMSO- d_6) δ ppm 1.32 (t, $J=7$ Hz, 3H), 1.70-1.74 (m, 4H), 2.47-2.52 (m, 4H), 3.71 (s, 2H), 4.29 (q, $J=7$ Hz, 2H), 6.81 (d, $J=9$ Hz, 1H), 7.82 (d/Abq, $J=9$ Hz, $J=2$ Hz, 2H), 8.01 (t, $J=2$ Hz, 1H), 8.16 (dd, $J=9$ Hz, $J=3$ Hz, 1H), 8.46 (s, 1H), 8.51 (d, $J=2$ Hz, 1H), 8.63 (d, $J=2$ Hz, 1H), 8.81 (d, $J=2$ Hz, 1H), 10.51 (s, 1H), 13.94 (brs, 1H); ESIMS found for $C_{25}H_{26}N_6O_2$ m/z 443.4 (M+H).



45

[0459] N-(6-Ethoxypyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **45**.


[0460] White solid (98 mg, 0.21 mmol, 44% yield). ^1H NMR (DMSO- d_6) δ ppm 1.32 (t, $J=7$ Hz, 3H), 1.34-1.42 (m, 2H), 1.47-1.53 (m, 4H), 2.38 (brs, 4H), , 3.56 (s, 2H), 4.29 (q, $J=7$ Hz, 2H), 6.81 (d, $J=9$ Hz, 1H), 7.81 (d/Abq, $J=9$ Hz, $J=2$ Hz, 2H), 7.99 (t, $J=2$ Hz, 1H), 8.16 (dd, $J=9$ Hz, $J=3$ Hz, 1H), 8.46 (d, $J=1$ Hz, 1H), 8.49 (d, $J=2$ Hz, 1H), 8.63 (d, $J=2$ Hz, 1H), 8.81 (d, $J=2$ Hz, 1H), 10.51 (s, 1H), 13.92 (brs, 1H); ESIMS found for $C_{26}H_{28}N_6O_2$ m/z 457.3 (M+H).



46

[0461] 5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide **46**.


[0462] White solid (126 mg, 0.31 mmol, 52% yield). ¹H NMR (DMSO-d₆) δ ppm 1.36-1.42 (m, 2H), 1.48-1.55 (m, 4H), 2.39 (brs, 4H), 3.57 (s, 2H), 7.40 (dd, *J*=8Hz, *J*=5Hz, 1H), 7.83 (d/Abq, *J*=9Hz, *J*=2Hz, 2H), 7.99 (t, *J*=2Hz, 1H), 8.30-8.34 (m, 2H), 8.48 (d, *J*=1Hz, 1H), 8.49 (d, *J*=2Hz, 1H), 8.82 (d, *J*=2Hz, 1H), 9.08 (d, *J*=2Hz, 1H), 10.70 (s, 1H), 14.00 (brs, 1H); ESIMS found for C₂₄H₂₄N₆O *m/z* 413.0 (M+H).



47

[0463] 5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-N-(4-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **47**.


[0464] White solid (150 mg, 0.31 mmol, 71% yield). ¹H NMR (DMSO-d₆) δ ppm 1.34-1.42 (m, 2H), 1.46-1.53 (m, 4H), 2.37 (brs, 4H), 3.55 (s, 2H), 7.81-7.87 (m, 3H), 7.98 (s, 1H), 8.41 (s, 1H), 8.48 (d, *J*=2Hz, 1H), 8.75 (d, *J*=5Hz, 1H), 8.80 (d, *J*=2Hz, 1H), 9.07 (s, 1H), 10.22 (s, 1H), 14.06 (brs, 1H); ESIMS found for C₂₅H₂₃F₃N₆O *m/z* 481.0 (M+H).



49


[0465] N-(Pyridin-3-yl)-5-(3-(pyrrolidin-1-ylmethyl)phenyl)-1H-indazole-3-carboxamide **49**.

[0466] Tan amorphous solid (53.4 mg, 0.13 mmol, 72% yield). ¹H NMR (DMSO-d₆) δ ppm 1.70-1.71 (m, 4H), 2.47-2.49 (m, 4H), 3.67 (s, 2H), 7.31 (d, *J*=8Hz, 1H), 7.40 (dd, *J*=8Hz, *J*=5Hz, 1H), 7.44 (t, *J*=8Hz, 1H), 7.58-7.60 (m, 1H), 7.63-7.64 (m, 1H), 7.76-7.78 (m, 2H), 8.30-8.34 (m, 2H), 8.44 (s, 1H), 9.08 (d, *J*=2Hz, 1H), 10.68 (s, 1H), 13.93 (s, 1H); ESIMS found for C₂₄H₂₃N₅O *m/z* 398 (M+H).

**50**


[0467] N-(6-Phenylpyridin-3-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **50**.

[0468] Tan flaky solid (61.3 mg, 0.13 mmol, 74% yield). ¹H NMR (DMSO-d₆) δ ppm 1.71-1.72 (m, 4H), 3.72 (s, 2H), 7.39-7.42 (m, 1H), 7.47-7.50 (m, 2H), 7.81-7.86 (m, 2H), 8.00 (d, *J*=9Hz, 1H), 8.02-8.03 (m, 1H), 8.08-8.10 (m, 2H), 8.45 (dd, *J*=9Hz, *J*=3Hz, 1H), 8.49-8.50 (m, 1H), 8.51 (d, *J*=2Hz, 1H), 8.83 (d, *J*=2Hz, 1H), 9.18 (d, *J*=3Hz, 1H), 10.81 (s, 1H), 14.03 (s, 1H); ESIMS found for C₂₉H₂₆N₆O *m/z* 475 (M+H).

**51**


[0469] N-(Pyridin-3-yl)-5-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide **51**.

[0470] Yellow solid (32 mg, 0.08 mmol, 37.8% yield). ¹H NMR (DMSO-d₆) δ ppm 1.94-2.01 (m, 4H), 3.42-3.48 (m, 4H), 6.57 (d, *J*=9Hz, 1H), 7.40 (dd, *J*=8Hz, *J*=5Hz, 1H), 7.72 (d, *J*=1Hz, 2H), 7.85 (dd, *J*=9Hz, *J*=3Hz, 1H), 8.29-8.34 (m, 3H), 8.43 (d, *J*=2Hz, 1H), 9.08 (d, *J*=2Hz, 1H), 10.63 (s, 1H), 13.87 (s, 1H); ESIMS found for C₂₂H₂₀N₆O *m/z* 385.0 (M+H).

**52**

[0471] N-(6-Cyanopyridin-3-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **52**.


[0472] Beige solid (52 mg, 0.12 mmol, 49.1% yield). ^1H NMR (DMSO- d_6) δ ppm 1.70-1.75 (m, 4H), 3.31-3.36 (m, 4H), 7.85 (dq, $J=9\text{Hz}$, $J=2\text{Hz}$, 2H), 8.02 (s, 1H), 8.05 (d, $J=9\text{Hz}$, 1H), 8.47 (s, 1H), 8.52 (d, $J=2\text{Hz}$, 1H), 8.58 (dd, $J=9\text{Hz}$, $J=3\text{Hz}$, 1H), 8.82 (d, $J=2\text{Hz}$, 1H), 9.28 (d, $J=2\text{Hz}$, 1H), 11.18 (s, 1H), 14.13 (brs, 1H); ESIMS found for $\text{C}_{24}\text{H}_{21}\text{N}_7\text{O}$ m/z 424.3 (M+H).



54

[0473] 5-(6-Methoxypyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide 54.


[0474] White solid (79.7 mg, 0.23 mmol, 44.2% yield). ^1H NMR (DMSO- d_6) δ ppm 3.91 (s, 3H), 6.95 (d, $J=9\text{Hz}$, 1H), 7.40 (dd, $J=9\text{Hz}$, $J=5\text{Hz}$, 1H), 7.78 (dd, $J=11\text{Hz}$, $J=2\text{Hz}$, 2H), 8.06 (dd, $J=9\text{Hz}$, $J=3\text{Hz}$, 1H), 8.29-8.34 (m, 2H), 8.39 (s, 1H), 8.51 (d, $J=2\text{Hz}$, 1H), 9.08 (d, $J=3\text{Hz}$, 1H), 10.67 (s, 1H), 13.91 (brs, 1H); ESIMS found for $\text{C}_{19}\text{H}_{15}\text{N}_5\text{O}_2$ m/z 346.0 (M+H).



55

[0475] 5-(5-Benzylpyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide 55.


[0476] Yellow solid (101.9 mg, 0.25 mmol, 76% yield). ^1H NMR (DMSO- d_6) δ ppm 4.09 (s, 2H), 7.19-7.23 (m, 1H), 7.30-7.35 (m, 4H), 7.39-7.41 (m, 1H), 7.78-7.82 (m, 2H), 7.99 (t, $J=2\text{Hz}$, 1H), 8.31-8.33 (m, 2H), 8.45 (s, 1H), 8.51 (d, $J=2\text{Hz}$, 1H), 8.76 (d, $J=2\text{Hz}$, 1H), 9.08 (d, $J=2\text{Hz}$, 1H), 10.69 (s, 1H), 14.00 (s, 1H); ESIMS found for $\text{C}_{25}\text{H}_{19}\text{N}_5\text{O}$ m/z 406 (M+H).



56

[0477] 5-(5-Phenoxypyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide 56.


[0478] White solid (73.6 mg, 0.18 mmol, 75% yield). ¹H NMR (DMSO-d₆) δ ppm 7.17-7.18 (m, 2H), 7.22-7.23 (m, 1H), 7.38-7.41 (m, 1H), 7.44-7.47 (m, 2H), 7.72-7.73 (m, 1H), 7.80-7.81 (m, 2H), 8.29-8.31 (m, 2H), 8.37-8.38 (m, 1H), 8.44-8.45 (m, 1H), 8.74 (d, *J*=2Hz, 1H), 9.06 (d, *J*=2Hz, 1H), 10.69 (s, 1H), 14.00 (s, 1H); ESIMS found for C₂₄H₁₇N₅O₂ *m/z* 408 (M+H).



57

[0479] 5-(5-(Pyrrolidin-1-ylmethyl)pyridin-3-yl)-N-(4-(trifluoromethyl) pyridin-3-yl)-1H-indazole-3-carboxamide 57.


[0480] White solid (64 mg, 0.14 mmol, 35.2% yield). ¹H NMR (DMSO-d₆) δ ppm 1.67-1.74 (m, 4H), 2.44-2.52 (m, 4H), 3.70 (s, 2H), 7.81-7.88 (m, 3H), 8.00 (d, *J*=2Hz, 1H), 8.41 (s, 1H), 8.50 (d, *J*=2Hz, 1H), 8.75 (d, *J*=5Hz, 1H), 8.81 (d, *J*=2Hz, 1H), 9.07 (s, 1H), 10.22 (s, 1H), 14.01 (brs, 1H); ESIMS found for C₂₄H₂₁F₃N₆O *m/z* 467.3 (M+H).



59

[0481] 5-(5-(Cyclohexylcarbamoyl)pyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide 59.


[0482] Light brown solid (117 mg, 0.27 mmol, 49.7% yield). ¹H NMR (DMSO-d₆) δ ppm 1.10-1.21 (m, 1H), 1.28-1.39 (m, 4H), 1.63 (d, *J*=12Hz, 1H), 1.72-1.78 (m, 2H), 1.86-1.91 (m, 2H), 3.77-3.87 (m, 1H), 7.41 (dd, *J*=8Hz, *J*=5Hz, 1H), 7.84 (d, *J*=8Hz, 1H), 7.91 (d, *J*=9Hz, 1H), 8.30-8.36 (m, 2H), 8.48 (t, *J*=2Hz, 1H), 8.55 (s, 1H), 8.59 (d, *J*=8Hz, 1H), 8.99 (d, *J*=2Hz, 1H), 9.04 (d, *J*=2Hz, 1H), 9.09 (d, *J*=2Hz, 1H), 10.72 (s, 1H), 14.04 (s, 1H); ESIMS found for C₂₅H₂₄N₆O₂ *m/z* 441.0 (M+H).



60

[0483] 5-(3-Fluoro-5-((4-methylpiperazin-1-yl)methyl)phenyl)-N-(4-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **60**.


[0484] White solid (43 mg, 0.08 mmol, 76.3% yield). ¹H NMR (DMSO-d₆) δ ppm 1.23 (s, 3H), 2.22-2.50 (m, 8H), 3.56 (s, 2H), 7.12 (d, *J*=9Hz, 1H), 7.42 (dd, *J*=8Hz, *J*=2Hz, 1H), 7.47 (s, 1H), 7.80 (d, *J*=1Hz, 2H), 7.85 (d, *J*=5Hz, 1H), 8.39 (s, 1H), 8.75 (d, *J*=5Hz, 1H), 9.08 (s, 1H), 10.22 (s, 1H), 14.02 (brs, 1H); ESIMS found for C₂₆H₂₄F₄N₆O *m/z* 513.3 (M+H).



61

[0485] 5-(5-((4-Methylpiperazin-1-yl)methyl)pyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide **61**.

[0486] White solid (81.6 mg, 0.19 mmol, 55% yield). ¹H NMR (DMSO-d₆) δ ppm 2.14 (s, 3H), 2.33-2.42 (m, 8H), 3.60 (s, 2H), 7.39-7.41 (m, 1H), 7.81-7.85 (m, 2H), 8.00-8.01 (m, 1H), 8.31-8.33 (m, 2H), 8.47-8.48 (m, 1H), 8.49 (d, *J*=2Hz, 1H), 8.82 (d, *J*=2Hz, 1H), 9.08 (d, *J*=3Hz, 1H), 10.74 (s, 1H), 14.00 (s, 1H); ESIMS found for C₂₄H₂₅N₇O *m/z* 427.8 (M+H).




62

[0487] N-(6-Cyanopyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **62**.

[0488] Off-white solid (42 mg, 0.10 mmol, 36.9% yield). ¹H NMR (DMSO-d₆) δ ppm 1.36-1.42 (m, 2H), 1.47-1.54 (m, 4H), 2.38 (brs, 4H), 3.57 (s, 2H), 7.85 (d, *J*=1Hz, 2H), 8.00 (t, *J*=2Hz, 1H), 8.05 (d, *J*=9Hz, 1H), 8.47 (d, *J*=1Hz, 1H), 8.50 (d, *J*=2Hz, 1H), 8.58 (dd,


$J=9\text{Hz}$, $J=3\text{Hz}$, 1H), 8.82 (d, $J=2\text{Hz}$, 1H), 9.28 (d, $J=2\text{Hz}$, 1H), 11.18 (s, 1H), 14.12 (brs, 1H); ESIMS found for $\text{C}_{25}\text{H}_{23}\text{N}_7\text{O}$ m/z 438.1 (M+H).



63

[0489] 5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-N-(6-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **63**.


[0490] White solid (78 mg, 0.16 mmol, 49% yield). ^1H NMR (DMSO- d_6) δ ppm 1.35-1.44 (m, 2H), 1.46-1.57 (m, 4H), 2.40 (brs, 4H), 3.59 (brs, 2H), 7.85 (s, 2H), 7.93 (d, $J=9\text{Hz}$, 1H), 8.01 (s, 1H), 8.48 (s, 1H), 8.50 (s, 1H), 8.63 (d, $J=8\text{Hz}$, 1H), 8.83 (s, 1H), 9.27 (s, 1H), 11.11 (s, 1H), 14.11 (brs, 1H); ESIMS found for $\text{C}_{25}\text{H}_{23}\text{F}_3\text{N}_6\text{O}$ m/z 481.1 (M+H).



64

[0491] 5-(5-(Morpholinomethyl)pyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide **64**.


[0492] White solid (77 mg, 0.19 mmol, 66% yield). ^1H NMR (DMSO- d_6) δ ppm 2.41-2.43 (m, 4H), 3.58-3.60 (m, 4H), 3.61 (s, 2H), 7.39-7.41 (m, 1H), 7.81-7.85 (m, 2H), 8.02-8.03 (m, 1H), 8.31-8.33 (m, 2H), 8.47-8.48 (m, 1H), 8.51 (d, $J=2\text{Hz}$, 1H), 8.83 (d, $J=2\text{Hz}$, 1H), 9.08 (d, $J=2\text{Hz}$, 1H), 10.70 (s, 1H), 14.00 (s, 1H); ESIMS found for $\text{C}_{23}\text{H}_{22}\text{N}_6\text{O}_2$ m/z 415 (M+H).



65


[0493] N-(6-Phenylpyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **65**.

[0494] White solid (61.5 mg, 0.13 mmol, 68% yield). ¹H NMR (DMSO-d₆) δ ppm 1.39-1.40 (m, 2H), 1.49-1.53 (m, 4H), 2.38-2.39 (m, 4H), 3.57 (s, 2H), 7.39-7.43 (m, 1H), 7.47-7.50 (m, 2H), 7.82-7.86 (m, 2H), 7.99-8.01 (m, 2H), 8.08-8.10 (m, 2H), 8.44 (dd, *J*=9Hz, *J*=3Hz, 1H), 8.50-8.51 (m, 2H), 8.83 (d, *J*=2Hz, 1H), 9.18 (d, *J*=3Hz, 1H), 10.81 (s, 1H), 14.02 (s, 1H); ESIMS found for C₃₀H₂₈N₆O *m/z* 489 (M+H).

**66**


[0495] 5-(5-Cyanopyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide **66**.

[0496] Beige solid (107 mg, 0.31 mmol, 66.7% yield). ¹H NMR (DMSO-d₆) δ ppm 7.40 (dd, *J*=8Hz, *J*=4Hz, 1H), 7.84 (d, *J*=8Hz, 1H), 7.91 (dd, *J*=9Hz, *J*=2Hz, 1H), 8.30-8.34 (m, 2H), 8.57 (s, 1H), 8.72 (t, *J*=2Hz, 1H), 9.03 (d, *J*=2Hz, 1H), 9.09 (d, *J*=2Hz, 1H), 9.23 (d, *J*=2Hz, 1H), 10.72 (s, 1H), 14.06 (s, 1H); ESIMS found for C₁₉H₁₂N₆O *m/z* 340.8 (M+H).

**67**

[0497] 5-(3-Fluoro-5-(piperidin-1-ylmethyl)phenyl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide **67**.


[0498] Yellow solid (84 mg, 0.20 mmol, 66% yield). ¹H NMR (DMSO-d₆) δ ppm 1.37-1.39 (m, 2H), 1.49-1.54 (m, 4H), 2.37-2.38 (m, 4H), 3.54 (s, 2H), 7.12-7.13 (m, 1H), 7.39-7.43 (m, 2H), 7.47-7.48 (m, 1H), 7.77-7.81 (m, 2H), 8.31-8.33 (m, 2H), 8.44-8.45 (m, 1H), 9.08 (d, *J*=2Hz, 1H), 10.69 (s, 1H), 13.97 (s, 1H); ESIMS found for C₂₅H₂₄FN₅O *m/z* 430 (M+H).



68

[0499] 5-(5-(Morpholinomethyl)pyridin-3-yl)-N-(6-(trifluoromethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **68**.


[0500] White solid (72 mg, 0.15 mmol, 30.5% yield). ¹H NMR (DMSO-d₆) δ ppm 2.43 (brs, 4H), 3.56-3.63 (m, 4H), 3.62 (s, 2H), 7.85 (Abq, *J*=9Hz, 2H), 7.93 (d, *J*=9Hz, 1H), 8.04 (s, 1H), 8.49 (s, 1H), 8.52 (d, *J*=1Hz, 1H), 8.63 (dd, *J*=9Hz, *J*=3Hz, 1H), 8.84 (d, *J*=2Hz, 1H), 9.27 (d, *J*=2Hz, 1H), 11.11 (s, 1H), 14.11 (brs, 1H); ESIMS found for C₂₄H₂₁F₃N₆O₂ *m/z* 483.3 (M+H).



69

[0501] N-(6-Morpholinopyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **69**.


[0502] Light yellow solid (58 mg, 0.12 mmol, 36.4% yield). ¹H NMR (DMSO-d₆) δ ppm 1.37-1.44 (m, 2H), 1.51 (quin, *J*=5Hz, 4H), 2.33-2.40 (m, 4H), 3.40 (t, *J*=5Hz, 4H), 3.56 (s, 2H), 3.71 (t, 5Hz, 4H), 6.89 (d, *J*=9Hz, 1H), 7.78 (d, *J*=8Hz, 1H), 7.81 (d, *J*=9Hz, 1H), 7.97 (t, *J*=2Hz, 1H), 8.06 (dd, *J*=9Hz, *J*=2Hz, 1H), 8.46 (d, *J*=10Hz, 1H), 8.60 (d, *J*=2Hz, 1H), 8.79 (d, *J*=2Hz, 1H), 10.35 (s, 1H), 13.90 (brs, 1H); ESIMS found for C₂₈H₃₁N₇O₂ *m/z* 498.0 (M+H).



70

[0503] N-(6-(4-Methylpiperazin-1-yl)pyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **70**.


[0504] Light yellow solid (37 mg, 0.07 mmol, 39.2% yield). ^1H NMR (DMSO- d_6) δ ppm 1.37-1.44 (m, 2H), 1.51 (quin, $J=5\text{Hz}$, 4H), 2.22 (s, 3H), 2.35-2.42 (m, 8H), 3.44 (t, $J=5\text{Hz}$, 4H), 3.56 (s, 2H), 6.86 (d, $J=9\text{Hz}$, 1H), 7.79 (d, $J=9\text{Hz}$, 1H), 7.82 (d, $J=10\text{Hz}$, 1H), 7.98 (d, $J=2\text{Hz}$, 1H), 8.03 (dd, $J=9\text{Hz}$, $J=3\text{Hz}$, 1H), 8.48 (d, $J=11\text{Hz}$, 1H), 8.58 (d, $J=3\text{Hz}$, 1H), 8.81 (d, $J=3\text{Hz}$, 1H), 10.34 (s, 1H), 13.89 (brs, 1H); ESIMS found for $\text{C}_{29}\text{H}_{34}\text{N}_8\text{O}$ m/z 511.5 ($\text{M}+\text{H}$).



71

[0505] 5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-N-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide **71**.


[0506] Tan solid (53.9 mg, 0.11 mmol, 53% yield). ^1H NMR (DMSO- d_6) δ ppm 1.38-1.39 (m, 2H), 1.51-1.52 (m, 4H), 1.93-1.96 (m, 4H), 2.36-2.38 (m, 4H), 3.36-3.39 (m, 4H), 3.56 (s, 2H), 6.46 (d, $J=9\text{Hz}$, 1H), 7.78-7.83 (m, 2H), 7.96 (dd, $J=9\text{Hz}$, $J=3\text{Hz}$, 1H), 7.98-7.99 (m, 1H), 8.46-8.47 (m, 2H), 8.49 (d, $J=3\text{Hz}$, 1H), 8.80-8.81 (m, 1H), 10.23 (s, 1H), 13.87 (s, 1H); ESIMS found for $\text{C}_{28}\text{H}_{31}\text{N}_7\text{O}$ m/z 482 ($\text{M}+\text{H}$).



72

[0507] N-(6-(3-Fluorophenyl)pyridin-3-yl)-5-(5-(piperidin-1-ylmethyl) pyridin-3-yl)-1H-indazole-3-carboxamide **72**.


[0508] White solid (54.8 mg, 0.11 mmol, 64% yield). ¹H NMR (DMSO-d₆) δ ppm 1.39-1.40 (m, 2H), 1.50-1.54 (m, 4H), 2.38-2.39 (m, 4H), 3.57 (s, 2H), 7.22-7.26 (m, 1H), 7.51-7.55 (m, 1H), 7.82-7.86 (m, 2H), 7.88-7.91 (m, 1H), 7.94-7.96 (m, 1H), 8.00-8.01 (m, 1H), 8.06 (d, *J*=9Hz, 1H), 8.46 (dd, *J*=9Hz, *J*=3Hz, 1H), 8.50 (s, 2H), 8.82 (d, *J*=2Hz, 1H), 9.20 (d, *J*=2Hz, 1H), 10.86 (s, 1H), 14.03 (s, 1H); ESIMS found for C₃₀H₂₇FN₆O *m/z* 507 (M+H).



73

[0509] N-(6-(4-Fluorophenyl)pyridin-3-yl)-5-(5-(piperidin-1-ylmethyl) pyridin-3-yl)-1H-indazole-3-carboxamide **73**.


[0510] White solid (50.8 mg, 0.10 mmol, 55% yield). ¹H NMR (DMSO-d₆) δ ppm 1.39-1.40 (m, 2H), 1.49-1.53 (m, 4H), 2.36-2.39 (m, 4H), 3.57 (s, 2H), 7.29-7.32 (m, 2H), 7.82-7.86 (m, 2H), 7.98-8.01 (m, 2H), 8.12-8.15 (m, 2H), 8.43 (dd, *J*=9Hz, *J*=3Hz, 1H), 8.49 (s, 2H), 8.82 (d, *J*=2Hz, 1H), 9.17 (d, *J*=3Hz, 1H), 10.81 (s, 1H), 14.02 (s, 1H); ESIMS found for C₃₀H₂₇FN₆O *m/z* 507 (M+H).



74

[0511] N-(6-((2-(Dimethylamino)ethyl)(methyl)amino)pyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **74**.


[0512] Light yellow solid (88.5 mg, 0.17 mmol, 61.7% yield). ^1H NMR (DMSO- d_6) δ ppm 1.38-1.42 (m, 2H), 1.51 (quin, $J=5\text{Hz}$, 4H), 2.18 (s, 6H), 2.34-2.40 (m, 6H), 2.99 (s, 3H), 3.56 (s, 2H), 3.61 (t, $J=7\text{Hz}$, 2H), 6.61 (d, $J=9\text{Hz}$, 1H), 7.79 (d, $J=9\text{Hz}$, 1H), 7.81 (d, $J=9\text{Hz}$, 1H), 7.95 (dd, $J=9\text{Hz}$, $J=3\text{Hz}$, 1H), 7.98 (t, $J=2\text{Hz}$, 1H), 8.46 (s, 1H), 8.48 (d, $J=2\text{Hz}$, 2H), 8.81 (d, $J=2\text{Hz}$, 1H), 10.24 (s, 1H), 13.84 (brs, 1H); ESIMS found for $\text{C}_{29}\text{H}_{36}\text{N}_8\text{O}$ m/z 513.5 (M+H).



75

[0513] 5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-N-(pyridazin-4-yl)-1H-indazole-3-carboxamide **75**.


[0514] White solid (53 mg, 0.13 mmol, 33.7% yield). ^1H NMR (DMSO- d_6) δ ppm 1.36-1.43 (m, 2H), 1.47-1.54 (m, 4H), 2.33-2.42 (m, 4H), 3.57 (s, 2H), 7.85 (s, 2H), 8.00 (t, $J=2\text{Hz}$, 1H), 8.25 (dd, $J=6\text{Hz}$, $J=3\text{Hz}$, 1H), 8.47 (t, $J=1\text{Hz}$, 1H), 8.50 (d, $J=2\text{Hz}$, 1H), 8.82 (d, $J=2\text{Hz}$, 1H), 9.09 (d, $J=6\text{Hz}$, 1H), 9.71 (dd, $J=3\text{Hz}$, $J=1\text{Hz}$, 1H), 11.16 (s, 1H), 14.16 (brs, 1H); ESIMS found for $\text{C}_{23}\text{H}_{23}\text{N}_7\text{O}$ m/z 414.1 (M+H).



76


[0515] 5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-N-(pyridin-3-ylmethyl)-1H-indazole-3-carboxamide **76**.

[0516] White solid (26.8 mg, 0.06 mmol, 27% yield). ¹H NMR (DMSO-d₆) δ ppm 1.38-1.39 (m, 2H), 1.49-1.51 (m, 4H), 2.36-2.37 (m, 4H), 3.55 (s, 2H), 4.53 (d, *J*=6Hz, 2H), 7.35 (dd, *J*=8Hz, *J*=5Hz, 1H), 7.74-7.80 (m, 3H), 7.95-7.96 (m, 1H), 8.41-8.42 (m, 1H), 8.45-8.46 (m, 1H), 8.48-8.49 (m, 1H), 8.58-8.59 (m, 1H), 8.78 (d, *J*=2Hz, 1H), 9.17 (t, *J*=6Hz, 1H), 13.77 (s, 1H); ESIMS found for C₂₅H₂₆N₆O *m/z* 427 (M+H).

**77**


[0517] N-Cyclohexyl-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **77**.

[0518] White solid (50.4 mg, 0.12 mmol, 72.5% yield). ¹H NMR (DMSO-d₆) δ ppm 1.12-1.47 (m, 7H), 1.50-1.53 (m, 4H), 1.60-1.63 (m, 1H), 1.73-1.75 (m, 2H), 1.83-1.84 (m, 2H), 2.37-2.38 (m, 4H), 3.55 (s, 2H), 3.81-3.87 (m, 1H), 7.73-7.78 (m, 2H), 7.95-7.96 (m, 1H), 8.14 (d, *J*=8Hz, 1H), 8.41-8.42 (m, 1H), 8.47 (d, *J*=2Hz, 1H), 8.78 (d, *J*=2Hz, 1H), 13.67 (s, 1H); ESIMS found for C₂₅H₃₁N₅O *m/z* 418 (M+H).

**78**

[0519] N-(Benzo[d][1,3]dioxol-5-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **78**.


[0520] White solid (48.6 mg, 0.11 mmol, 22.1% yield). ¹H NMR (DMSO-d₆) δ ppm 1.37-1.43 (m, 2H), 1.51 (quin, *J*=5Hz, 4H), 2.36-2.42 (m, 4H), 3.56 (s, 2H), 6.01 (s, 2H), 6.90 (d, *J*=9Hz, 1H), 7.37 (dd, *J*=9Hz, *J*=2Hz, 1H), 7.57 (d, *J*=2Hz, 1H), 7.91 (dd, *J*=9Hz, *J*=Hz, 1H), 7.82 (dd, *J*=9Hz, *J*=1Hz, 1H), 7.99 (t, *J*=2Hz, 1H), 8.47 (dd, *J*=12Hz, *J*=2Hz, 1H), 8.81 (d, *J*=2Hz, 1H), 10.34 (s, 1H), 13.89 (s, 1H); ESIMS found for C₂₆H₂₅N₅O₃ *m/z* 456.0 (M+H).



79

[0521] N-(2,3-Dihydrobenzo[*b*][1,4]dioxin-6-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **79**.


[0522] White solid (98.4 mg, 0.21 mmol, 38.7% yield). ¹H NMR (DMSO-*d*₆) δ ppm 1.36-1.42 (m, 2H), 1.51 (quin, *J*=5Hz, 4H), 2.34-2.41 (m, 4H), 3.56 (s, 2H), 4.20-4.27 (m, 4H), 6.82 (d, *J*=9Hz, 1H), 7.35 (dd, *J*=9Hz, *J*=3Hz, 1H), 7.51 (d, *J*=3Hz, 1H), 7.78 (dd, *J*=9Hz, *J*=1Hz, 1H), 7.81 (dd, *J*=9Hz, *J*=1Hz, 1H), 7.98 (t, *J*=2Hz, 1H), 8.47 (dd, *J*=12Hz, *J*=2Hz, 1H), 8.81 (d, *J*=2Hz, 1H), 10.26 (s, 1H), 13.87 (brs, 1H); ESIMS found for C₂₇H₂₇N₅O₃ *m/z* 470.4 (M+H).



80

[0523] N-(5-Benzylpyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **80**.


[0524] White solid (81.9 mg, 0.16 mmol, 59% yield). ¹H NMR (DMSO-*d*₆) δ ppm 1.39-1.41 (m, 2H), 1.49-1.53 (m, 4H), 2.37-2.39 (m, 4H), 3.56 (s, 2H), 4.00 (s, 2H), 7.20-7.23 (m, 1H), 7.28-7.34 (m, 4H), 7.79-7.84 (m, 2H), 7.98-7.99 (m, 1H), 8.23-8.24 (m, 1H), 8.25 (d, *J*=2Hz, 1H), 8.45-8.46 (m, 1H), 8.49 (d, *J*=2Hz, 1H), 8.81 (d, *J*=2Hz, 1H), 8.89 (d, *J*=2Hz, 1H), 10.65 (s, 1H), 13.97 (s, 1H); ESIMS found for C₃₁H₃₀N₆O *m/z* 503 (M+H).



81


[0525] 5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-N-(pyrazin-2-yl)-1H-indazole-3-carboxamide **81**.

[0526] White solid (104 mg, 0.25 mmol, 41.7% yield). ¹H NMR (DMSO-d₆) δ ppm 1.35-1.42 (m, 2H), 1.51 (quin, *J*=5Hz, 4H), 2.33-2.42 (m, 4H), 3.57 (s, 2H), 7.83 (d, *J*=9Hz, 1H), 7.85 (d, *J*=9Hz, 1H), 8.00 (s, 1H), 8.45 (d, *J*=2Hz, 1H), 8.46 (s, 1H), 8.50 (s, 1H), 8.83 (d, *J*=2Hz, 1H), 9.50 (s, 1H), 10.36 (s, 1H), 14.11 (brs, 1H); ESIMS found for C₂₃H₂₃N₇O *m/z* 413.9 (M+H).

**82**


[0527] N-Phenyl-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **82**.

[0528] White solid (97.8 mg, 0.24 mmol, 81% yield). ¹H NMR (DMSO-d₆) δ ppm 1.39-1.40 (m, 2H), 1.49-1.53 (m, 4H), 2.37-2.39 (m, 4H), 3.57 (s, 2H), 7.09-7.12 (m, 1H), 7.34-7.37 (m, 2H), 7.80 (d, *J*=9Hz, 1H), 7.83 (dd, *J*=9Hz, 2Hz, 1H), 7.90-7.92 (m, 2H), 7.99-8.00 (m, 1H), 8.47-8.48 (m, 1H), 8.49 (d, *J*=2Hz, 1H), 8.81 (d, *J*=2Hz, 1H), 10.40 (s, 1H), 13.92 (s, 1H); ESIMS found for C₂₅H₂₅N₅O *m/z* 412 (M+H).

**83**

[0529] (4-Methylpiperazin-1-yl)(5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazol-3-yl)methanone **83**.


[0530] Light yellow amorphous solid (74.6 mg, 0.18 mmol, 93% yield). ¹H NMR (DMSO-d₆) δ ppm 1.38-1.39 (m, 2H), 1.48-1.53 (m, 4H), 2.22 (s, 3H), 2.36-2.41 (m, 8H), 3.55 (s, 2H), 3.72-3.73 (m, 2H), 4.01-4.02 (m, 2H), 7.73 (d, *J*=9Hz, 1H), 7.79 (dd, *J*=9Hz, *J*=2Hz, 1H), 7.95-7.96 (m, 1H), 8.22 (d, *J*=1Hz, 1H), 8.46 (d, *J*=2Hz, 1H), 8.78 (d, *J*=2Hz, 1H), 13.64 (s, 1H); ESIMS found for C₂₄H₃₀N₆O *m/z* 419 (M+H).



84

[0531] 5-(5-(((2R,6S)-2,6-Dimethylpiperidin-1-yl)methyl)pyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide **84**.


[0532] Beige solid (76.5 mg, 0.17 mmol, 75.5% yield). ^1H NMR (DMSO- d_6) δ ppm 1.00 (d, $J=6\text{Hz}$, 6H), 1.21-1.35 (m, 3H), 1.55 (d, $J=11\text{Hz}$, 2H), 1.60-1.65 (m, 1H), 2.45-2.53 (m, 2H), 3.84 (s, 1H), 7.40 (dd, $J=7\text{Hz}$, 3Hz, 1H), 7.79 (dd, $J=9\text{Hz}$, $J=2\text{Hz}$, 1H), 7.83 (dd, $J=9\text{Hz}$, $J=1\text{Hz}$, 1H), 8.04 (s, 1H), 8.29-8.35 (m, 2H), 8.46 (s, 1H), 8.60 (d, $J=2\text{Hz}$, 1H), 8.73 (d, $J=2\text{Hz}$, 1H), 9.08 (d, $J=3\text{Hz}$, 1H), 10.70 (s, 1H), 14.00 (brs, 1H); ESIMS found for $\text{C}_{26}\text{H}_{28}\text{N}_6\text{O}$ m/z 441.3 (M+H).



86

[0533] N-(5-((Dimethylamino)methyl)pyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **86**.


[0534] White solid (41.5 mg, 0.09 mmol, 72% yield). ^1H NMR (DMSO- d_6) δ ppm 1.39-1.40 (m, 2H), 1.49-1.54 (m, 4H), 2.19 (s, 6H), 2.36-2.39 (m, 4H), 3.44 (s, 2H), 3.58 (s, 2H), 7.81 (d, $J=9\text{Hz}$, 1H), 7.85 (dd, $J=9\text{Hz}$, $J=2\text{Hz}$, 1H), 8.00-8.01 (m, 1H), 8.21 (d, $J=2\text{Hz}$, 1H), 8.37-8.38 (m, 1H), 8.49-8.50 (m, 2H), 8.83 (d, $J=2\text{Hz}$, 1H), 8.91 (d, $J=2\text{Hz}$, 1H), 10.69 (s, 1H), 14.01 (brs, 1H); ESIMS found for $\text{C}_{27}\text{H}_{31}\text{N}_7\text{O}$ m/z 470 (M+H).



87

[0535] N-(1-Methylpiperidin-4-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **87**.


[0536] White amorphous solid (18.2 mg, 0.04 mmol, 59.8% yield). ¹H NMR (DMSO-d₆) δ ppm 1.39-1.40 (m, 2H), 1.49-1.53 (m, 4H), 1.66-1.75 (m, 4H), 1.95-2.00 (m, 2H), 2.18 (s, 3H), 2.37-2.38 (m, 4H), 2.77 (d, *J*=11Hz, 2H), 3.55 (s, 2H), 3.81-3.83 (m, 1H), 7.73-7.75 (m, 1H), 7.77-7.79 (m, 1H), 7.95-7.96 (m, 1H), 8.25 (d, *J*=8Hz, 1H), 8.41-8.42 (m, 1H), 8.47 (d, *J*=2Hz, 1H), 8.78 (d, *J*=2Hz, 1H), 13.70 (s, 1H); ESIMS found for C₂₅H₃₂N₆O *m/z* 433 (M+H).



106


[0537] N-(5-((Dimethylamino)methyl)pyridin-3-yl)-5-(5-(pyrrolidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **106**.

[0538] White solid (39.4 mg, 0.09 mmol, 74% yield). ¹H NMR (DMSO-d₆) δ ppm 1.71-1.73 (m, 4H), 2.49-2.50 (m, 4H), 2.18 (s, 6H), 3.43 (s, 2H), 3.71 (s, 2H), 7.81 (d, *J*=9Hz, 1H), 7.84 (ABq, *J*=9Hz, 1H), 8.02-8.03 (m, 1H), 8.21 (d, *J*=2Hz, 1H), 8.37-8.38 (m, 1H), 8.48-8.49 (m, 1H), 8.51 (d, *J*=2Hz, 1H), 8.83 (d, *J*=2Hz, 1H), 8.91 (d, *J*=2Hz, 1H), 10.68 (s, 1H), 13.98 (s, 1H); ESIMS found for C₂₆H₂₉N₇O *m/z* 456 (M+H).




124

[0539] N-(5-((4-Methylpiperazin-1-yl)methyl)pyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **124**.

**126**


[0540] N-(6-(Piperidin-1-yl)pyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **126**.

[0541] Grey solid (92.7 mg, 0.19 mmol, 29.0% yield). ¹H NMR (DMSO-d₆) δ ppm 1.48-1.64 (m, 12H), 2.32-2.43 (m, 4H), 3.48 (t, *J*=4.5Hz, 4H), 3.56 (s, 2H), 6.83 (d, *J*=9Hz, 1H), 7.80 (ABq, *J*=10Hz, 2H), 7.98 (s, 1H), 8.00 (d, *J*=2.4Hz, 1H), 8.47 (d, *J*=10Hz, 2H), 8.55 (d, *J*=2.5Hz, 1H), 8.81 (d, *J*=2Hz, 1H), 10.27 (s, 1H), 13.86 (s, 1H); ESIMS found for C₂₉H₃₃N₇O *m/z* 496.5 (M+H).

**162**


[0542] N-(3-Fluorophenyl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **162**.

[0543] White solid (176 mg, 0.41 mmol, 56.8% yield). ¹H NMR (DMSO-d₆) δ ppm 1.36-1.43 (m, 2H), 1.47-1.55 (m, 4H), 2.38 (brs, 4H), 3.56 (s, 2H), 6.93 (dt, *J*=9Hz, *J*=3Hz, 1H), 7.39 (q, *J*=8Hz, 1H), 7.75 (dd, *J*=8Hz, *J*=1Hz, 1H), 7.82 (d/Abq, *J*=9Hz, *J*=1Hz, 2H), 7.89 (td, *J*=12Hz, *J*=2Hz, 1H), 7.99 (t, *J*=2Hz, 1H), 8.47 (s, 1H), 8.49 (d, *J*=2Hz, 1H), 8.82 (d, *J*=2Hz, 1H), 10.66 (s, 1H), 13.97 (brs, 1H); ESIMS found for C₂₅H₂₄FN₅O *m/z* 430.0 (M+H).

**163**

[0544] 5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-N-(tetrahydro-2H-pyran-4-yl)-1H-indazole-3-carboxamide **163**.


[0545] Tan amorphous solid (88 mg, 0.21 mmol, 88% yield). ¹H NMR (DMSO-d₆) δ ppm 1.39-1.40 (m, 2H), 1.49-1.53 (m, 4H), 1.69-1.76 (m, 4H), 2.37-2.38 (m, 4H), 3.39-3.42 (m, 2H), 3.56 (s, 2H), 3.88-3.90 (m, 2H), 4.05-4.10 (m, 1H), 7.74 (d, *J*=9Hz, 1H), 7.77-7.79 (m, 1H), 7.95-7.96 (m, 1H), 8.37 (d, *J*=8Hz, 1H), 8.41-8.42 (m, 1H), 8.47 (d, *J*=2Hz, 1H), 8.79 (d, *J*=2Hz, 1H), 13.72 (s, 1H); ESIMS found for C₂₄H₂₉N₅O₂ *m/z* 420 (M+H).



168

[0546] N-(5-Fluoropyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **168**.


[0547] White solid (286 mg, 0.66 mmol, 56% yield). ¹H NMR (DMSO-d₆) δ ppm 1.39 (m, 2H), 1.49-1.53 (m, 4H), 2.38 (brs, 4H), 3.56 (s, 2H), 7.81-7.86 (m, 2H), 7.99 (s, 1H), 8.31-8.34 (m, 2H), 8.47 (s, 1H), 8.49 (d, *J*=1.3 Hz, 1H), 8.82 (d, *J*=1.7Hz, 1H), 8.99 (s, 1H), 10.97 (s, 1H), 14.07 (brs, 1H); ESIMS found for C₂₄H₂₃FN₆O *m/z* 431.4 (M+H).



169

[0548] N-(6-(4-Hydroxypiperidin-1-yl)pyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **169**.


[0549] Off-white solid (33 mg, 0.06 mmol, 53.8% yield). ¹H NMR (DMSO-d₆) δ ppm 1.32-1.43 (m, 4H), 1.45-1.57 (m, 4H), 1.74-1.83 (m, 2H), 2.33-2.44 (m, 4H), 3.04 (t, *J*=10Hz, 2H), 3.56 (s, 2H), 3.63-3.73 (m, 1H), 3.93-4.02 (m, 2H), 4.72 (s, 1H), 6.85 (d, *J*=9Hz, 1H), 7.80 (ABq, *J*=10Hz, 2H), 7.99 (d, *J*=7Hz, 2H), 8.47 (d, *J*=10Hz, 2H), 8.54 (s, 1H), 8.81 (s, 1H), 10.28 (s, 1H), 13.87 (s, 1H); ESIMS found for C₂₉H₃₃N₇O₂ *m/z* 512.3 (M+H).



170

[0550] 5-(5-((4-Hydroxypiperidin-1-yl)methyl)pyridin-3-yl)-N-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide **170**.


[0551] Off-white solid (125.4 mg, 0.25 mmol, 73.2% yield). ^1H NMR (DMSO- d_6) δ ppm 1.93-1.96 (m, 4H), 2.09-2.12 (m, 2H), 2.70-2.72 (m, 2H), 3.37-3.39 (m, 4H), 3.46-3.47 (m, 1H), 3.58 (s, 1H), 4.52 (d, $J=4\text{Hz}$, 1H), 6.46 d, $J=9\text{Hz}$, 1H), 7.77-7.82 (m, 2H), 7.95-7.98 (m, 2H), 8.44-8.48 (m, 2H), 8.49 (d, $J=2.5\text{Hz}$, 1H), 8.80 (d, $J=2.1\text{Hz}$, 1H), 10.20 (s, 1H), 13.85 (s, 1H); ESIMS found for $\text{C}_{28}\text{H}_{31}\text{N}_7\text{O}_2$ m/z 498 ($\text{M}+\text{H}$).



172

[0552] N-(5-Methyl-6-(pyrrolidin-1-yl)pyridin-3-yl)-5-(5-(piperidin-1-yl)methyl)pyridin-3-yl)-1H-indazole-3-carboxamide **172**.


[0553] Off-white solid (186 mg, 0.38 mmol, 72.2% yield). ^1H NMR (DMSO- d_6) δ ppm 1.34-1.43 (m, 2H), 1.47-1.55 (m, 4H), 1.82-1.89 (m, 4H), 2.30 s, 3H), 2.33-2.42 (m, 4H), 3.43 (t, $J=6.6\text{Hz}$, 4H), 3.56 (s, 2H), 7.81 (ABq, $J=10\text{Hz}$, 2H), 7.89 (d, $J=2\text{Hz}$, 1H), 7.98 (s, 1H), 8.38 (d, $J=2\text{Hz}$, 1H), 8.47 (d, $J=8\text{Hz}$, 2H), 8.81 (d, $J=2\text{Hz}$, 1H), 10.24 (s, 1H), 13.86 (s, 1H); ESIMS found for $\text{C}_{29}\text{H}_{33}\text{N}_7\text{O}$ m/z 496.4 ($\text{M}+\text{H}$).



173

[0554] N-(6-(Azetidin-1-yl)-5-methylpyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **173**.


[0555] Off-white solid (184 mg, 0.38 mmol, 62.6% yield). ¹H NMR (DMSO-d₆) δ ppm 1.35-1.43 (m, 2H), 1.47-1.54 (m, 4H), 2.16 (s, 3H), 2.22 (quin, *J*=7Hz, 2H), 2.34-2.42 (m, 4H), 3.56 (s, 2H), 4.00 (t, *J*=7Hz, 4H), 7.81 (ABq, *J*=10Hz, 2H), 7.85 (d, *J*=2Hz, 1H), 8.39 (d, *J*=2Hz, 1H), 8.47 (d, *J*=10Hz, 2H), 8.81 (d, *J*=2Hz, 1H), 10.24 (s, 1H), 13.87 (s, 1H); ESIMS found for C₂₈H₃₁N₇O *m/z* 482.0 (M+H).



174

[0556] N-(6-(Azetidin-1-yl)pyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **174**.


[0557] White solid (14.9 mg, 0.03 mmol, 11.0% yield). ¹H NMR (DMSO-d₆) δ ppm 1.36-1.43 (m, 2H), 1.47-1.54 (m, 4H), 2.32 (quin, *J*=7Hz, 2H), 2.35-2.42 (m, 4H), 3.56 (s, 2H), 3.92 (t, *J*=7Hz, 4H), 6.39 (d, *J*=9Hz, 1H), 7.77-7.83 (m, 2H), 7.98 (dd, *J*=9Hz, *J*=2Hz, 2H), 8.42-8.53 (m, 3H), 8.78-8.84 (m, 1H), 10.27 (s, 1H), 13.87 (s, 1H); ESIMS found for C₂₇H₂₉N₇O *m/z* 468.0 (M+H).



175

[0558] N-(6-Methoxypyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **175**.


[0559] White solid (31.2 mg, 0.07 mmol, 25.8% yield). ¹H NMR (DMSO-d₆) δ ppm 1.36-1.43 (m, 2H), 1.47-1.55 (m, 4H), 2.33-2.42 (m, 4H), 3.56 (s, 2H), 3.85 (s, 3H), 6.84 (d, *J*=9Hz, 1H), 7.81 (ABq, *J*=12Hz, 2H), 7.98 (s, 1H), 8.18 (dd, *J*=9Hz, *J*=2.7Hz, 1H), 8.47 (dd, *J*=10Hz, *J*=1Hz, 2H), 8.65 (d, *J*=2.6Hz, 1H), 8.81 (d, *J*=2Hz, 1H), 10.50 (s, 1H), 13.91 (brs, 1H); ESIMS found for C₂₅H₂₆N₆O₂ *m/z* 443.4 (M+H).



176

[0560] N-(2-Aminopyrimidin-5-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **176**.


[0561] Yellow solid (412 mg, 0.96 mmol, 52.5% yield). ^1H NMR (DMSO- d_6) δ ppm 1.37-1.43 (m, 2H), 1.47-1.54 (m, 4H), 2.35-2.41 (m, 4H), 3.56 (s, 2H), 6.49 (s, 2H), 7.81 (ABq, $J=10\text{Hz}$, 2H), 7.98 (s, 1H), 8.47 (dd, $J=12\text{Hz}$, $J=2\text{Hz}$, 2H), 8.63 (s, 1H), 8.81 (d, $J=2\text{Hz}$, 1H), 10.32 (s, 1H), 13.91 (s, 1H); ESIMS found for $\text{C}_{23}\text{H}_{24}\text{N}_8\text{O}$ m/z 429.3 (M+H).



177

[0562] N-(6-(Piperazin-1-yl)pyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **177**.


[0563] Tan solid (160 mg, 0.32 mmol, 28.5% yield). ^1H NMR (DMSO- d_6) δ ppm 1.37-1.43 (m, 2H), 1.48-1.54 (m, 4H), 2.34-2.41 (m, 4H), 2.79 (t, $J=5\text{Hz}$, 4H), 3.36 (t, $J=5\text{Hz}$, 4H), 3.56 (s, 2H), 6.82 (d, $J=9\text{Hz}$, 1H), 7.81 (ABq, $J=10\text{Hz}$, 2H), 7.98 (s, 1H), 8.02 (dd, $J=9\text{Hz}$, $J=2.7\text{Hz}$, 1H), 8.47 (dd, $J=9\text{Hz}$, $J=2\text{Hz}$, 2H), 8.57 (d, $J=2.5\text{Hz}$, 1H), 8.81 (d, $J=2\text{Hz}$, 1H), 10.29 (s, 1H); ESIMS found for $\text{C}_{28}\text{H}_{32}\text{N}_8\text{O}$ m/z 497.1 (M+H).



178

[0564] N-(6-Hydroxypyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **178**.


[0565] Off-white solid (78.3 mg, 0.18 mmol, 52.4% yield). ^1H NMR (DMSO- d_6) δ ppm 1.36-1.43 (m, 2H), 1.48-1.54 (m, 4H), 2.35-2.42 (m, 4H), 3.56 (s, 2H), 6.38 (d, $J=10\text{Hz}$, 1H), 7.80 (ABq, $J=11\text{Hz}$, 2H), 7.83 (dd, $J=10\text{Hz}$, $J=3\text{Hz}$, 1H), 7.97 (s, 1H), 8.04 (d, $J=2.5\text{Hz}$, 1H), 8.44 (s, 1H), 8.48 (d, $J=2\text{Hz}$, 1H), 8.80 (d, $J=2\text{Hz}$, 1H), 10.27 (s, 1H), 11.42 (brs, 1H), 13.87 (brs, 1H); ESIMS found for $\text{C}_{24}\text{H}_{24}\text{N}_6\text{O}_2$ m/z 429.1 (M+H).



179

[0566] 5-(5-(Piperidin-1-ylmethyl)pyridin-3-yl)-N-(6-(pyrrolidine-1-carbonyl)pyridin-3-yl)-1H-indazole-3-carboxamide 179.


[0567] Light yellow solid (61 mg, 0.12 mmol, 37.8% yield). ^1H NMR (DMSO- d_6) δ ppm 1.37-1.43 (m, 2H), 1.48-1.55 (m, 4H), 1.82-1.90 (m, 4H), 2.38 (brs, 4H), 3.17 (d, $J=5\text{Hz}$, 2H), 3.51 (t, $J=7\text{Hz}$, 2H), 3.57 (s, 2H), 3.70 (t, $J=7\text{Hz}$, 2H), 7.79 (d, $J=9\text{Hz}$, 1H), 7.84 (Abq, $J=11\text{Hz}$, 2H), 8.00 (s, 1H), 8.46 (dd, $J=9\text{Hz}$, $J=2.5\text{Hz}$, 1H), 8.48 (dd, $J=9\text{Hz}$, $J=2\text{Hz}$, 2H), 8.82 (d, $J=2\text{Hz}$, 1H), 9.10 (d, $J=2\text{Hz}$, 1H), 10.91 (s, 1H), 14.05 (brs, 1H); ESIMS found for $\text{C}_{29}\text{H}_{31}\text{N}_7\text{O}_2$ m/z 510.6 (M+H).



181


[0568] N-(6-(Cyclopentylcarbamoyl)pyridin-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide 181.

[0569] Light yellow solid (18 mg, 0.04 mmol, 16.6% yield). ^1H NMR (DMSO- d_6) δ ppm 1.50-1.64 (m, 4H), 1.67-1.76 (m, 2H), 1.85-1.94 (m, 4H), 4.24 (quin, $J=8\text{Hz}$, 1H), 7.53 (dd, $J=8\text{Hz}$, $J=5\text{Hz}$, 1H), 7.84 (ABq, 2H), 8.03 (d, $J=9\text{Hz}$, 1H), 8.14 (d, $J=8\text{Hz}$, 1H), 8.45 (d, $J=8\text{Hz}$, 1H), 8.48 (s, 1H), 8.54 (dd, $J=9\text{Hz}$, $J=2.5\text{Hz}$, 1H), 8.60 (d, $J=4\text{Hz}$, 1H), 8.94 (d, $J=2\text{Hz}$, 1H), 9.16 (d, $J=2\text{Hz}$, 1H), 10.97 (s, 1H), 14.08 (brs, 1H); ESIMS found for $\text{C}_{24}\text{H}_{22}\text{N}_6\text{O}_2$ m/z 427.1 (M+H).

**182**


[0570] 5-(5-Aminopyridin-3-yl)-N-(6-(piperidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide **182**.

[0571] Off-white solid (23.4 mg, 0.06 mmol, 19.4% yield). ¹H NMR (DMSO-d₆) δ ppm 1.51-1.63 (m, 6H), 3.47 (t, *J*=5Hz, 4H), 5.45 (s, 2H), 6.83 (d, *J*=10Hz, 1H), 7.24 (t, *J*=2Hz, 1H), 7.73 (dq, *J*=9Hz, *J*=2Hz, 2H), 7.94 (d, *J*=2.5Hz, 1H), 8.00 (dd, *J*=9Hz, *J*=2.5Hz, 1H), 8.08 (d, *J*=2Hz, 1H), 8.40 (s, 1H), 8.56 (d, *J*=2.5Hz, 1H), 10.27 (s, 1H), 13.84 (s, 1H); ESIMS found for C₂₃H₂₃N₇O *m/z* 414.3 (M+H).

**183**

[0572] 5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-N-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide **183**.


[0573] Off-white solid (307 mg, 0.61 mmol, 39.6% yield). ¹H NMR (DMSO-d₆) δ ppm 1.95 (t, *J*=6.5Hz, 4H), 2.28 (tt, *J*=13.5Hz, *J*=7Hz, 2H), 2.76 (t, *J*=7Hz, 2H), 2.94 (t, *J*=13.5Hz, 2H), 3.38 (t, *J*=6.5Hz, 4H), 3.77 (s, 2H), 6.46 (d, *J*=9Hz, 1H), 7.81 (dq, *J*=8.5Hz, *J*=1.5Hz, 2H), 7.97 (dd, *J*=9Hz, *J*=2.5Hz, 1H), 8.03 (s, 1H), 8.48 (s, 1H), 8.49 (d, *J*=2.5Hz, 1H), 8.52 (s, 1H), 8.84 (d, *J*=2Hz, 1H), 10.23 (s, 1H), 13.87 (s, 1H); ESIMS found for C₂₇H₂₇F₂N₇O *m/z* 504.0 (M+H).

**151**

184

[0574] N-(6-(Cyclopentylcarbamoyl)pyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **184**.


[0575] White solid (3.2 mg, 0.01 mmol, 18.5% yield). ¹H NMR (DMSO-d₆) δ ppm 1.36-1.43 (m, 2H), 1.43-1.64 (m, 8H), 1.64-1.76 (m, 2H), 1.82-1.93 (m, 2H), 2.38 (brs, 4H), 3.57 (s, 2H), 4.24 (quin, *J*=7Hz, 1H), 7.84 (ABq, *J*=10Hz, 2H), 8.00 (s, 1H), 8.03 (d, *J*=9Hz, 1H), 8.44 (d, *J*=8Hz, 1H), 8.48 (dd, *J*=8Hz, *J*=2Hz, 2H), 8.55 (dd, *J*=9Hz, *J*=2.5Hz, 1H), 8.82 (d, *J*=2.5Hz, 1H), 9.16 (d, *J*=2.5Hz, 1H), 10.98 (s, 1H), 14.06 (brs, 1H); ESIMS found for C₃₀H₃₃N₇O₂ *m/z* 524.5 (M+H).



185

[0576] N-(6-(Methylsulfonyl)pyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide **185**.


[0577] White solid (72 mg, 0.15 mmol, 56.4% yield). ¹H NMR (DMSO-d₆) δ ppm 1.36-1.43 (m, 2H), 1.48-1.55 (m, 4H), 2.39 (brs, 4H), 3.27 (s, 3H), 3.57 (s, 2H), 7.85 (s, 2H), 8.00 (s, 1H), 8.08 (d, *J*=8.5Hz, 1H), 8.49 (dd, *J*=10Hz, *J*=1.5Hz, 2H), 8.83 (d, *J*=2.5Hz, 1H), 9.26 (d, *J*=2.5Hz, 1H), 11.19 (s, 1H), 14.13 (brs, 1H); ESIMS found for C₂₅H₂₆N₆O₃S *m/z* 491.1 (M+H).



186


[0578] 5-(5-(4-Methylpiperazin-1-yl)pyridin-3-yl)-N-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide **186**.

[0579] Off-white solid (196 mg, 0.41 mmol, 47.8% yield). ¹H NMR (DMSO-d₆) δ ppm 1.89-1.98 (m, 4H), 2.27 (brs, 3H), 3.25-3.42 (m, 12H), 6.45 (d, *J*=9Hz, 1H), 7.53 (s, 1H), 7.77 (q, *J*=8.5Hz, 2H), 7.96 (d, *J*=6.5Hz, 1H), 8.31 (d, *J*=5.5Hz, 2H), 8.43 (s, 1H), 8.48 (s, 1H), 10.21 (s, 1H), 13.83 (s, 1H); ESIMS found for C₂₇H₃₀N₈O *m/z* 483.4 (M+H).

**187**


[0580] 5-(5-Morpholinopyridin-3-yl)-N-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide **187**.

[0581] White solid (92 mg, 0.20 mmol, 43.5% yield). ¹H NMR (DMSO-d₆) δ ppm 1.94 (t, *J*=6.5 Hz, 4H), 3.28 (t, *J*=4.5Hz, 4H), 3.38 (t, *J*=6.5Hz, 4H), 3.78 (t, *J*=4.5Hz, 4H), 6.45 (d, *J*=9Hz, 1H), 7.55 (s, 1H), 7.77 (dq, *J*=8.5Hz, *J*=1.5Hz, 2H), 7.96 (dd, *J*=9Hz, *J*=2.5Hz 1H), 8.33 (dd, *J*=6.5Hz, *J*=3Hz, 2H), 8.44 (s, 1H), 8.49 (d, *J*=2.5Hz, 1H), 10.21 (s, 1H), 13.83 (s, 1H); ESIMS found for C₂₆H₂₇N₇O₂ *m/z* 470.5 (M+H).

**188**


[0582] 5-(5-((3,3-Difluoropyrrolidin-1-yl)methyl)pyridin-3-yl)-N-(pyridin-3-yl)-1H-indazole-3-carboxamide **188**.

[0583] White solid (209 mg, 0.48 mmol, 56.6% yield). ¹H NMR (DMSO-d₆) δ ppm 2.23-2.32 (m, 2H), 2.76 (t, *J*=7Hz, 2H), 2.94 (t, *J*=13.5Hz, 2H), 3.77 (s, 2H), 7.40 (q, *J*=8Hz, 1H), 7.83 (dq, *J*=8Hz, *J*=2Hz, 2H), 8.04 (s, 1H), 8.31-8.34 (m, 2H), 8.49 (s, 1H), 8.53 (d, *J*=2Hz, 1H), 8.85 (d, *J*=2.5Hz, 1H), 9.08 (d, *J*=2Hz, 1H), 10.70 (s, 1H), 14.01 (brs, 1H); ESIMS found for C₂₃H₂₀F₂N₆O *m/z* 435.2 (M+H).

**189**

[0584] N-(Pyridin-3-yl)-5-(5-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide **189**.

[0585] White solid (30 mg, 0.08 mmol, 26.0% yield). ¹H NMR (DMSO-d₆) δ ppm 1.91-2.05 (m, 4H), 3.33-3.39 (m, 4H), 7.09 (s, 1H), 7.40 (q, *J*=8Hz, 1H), 7.79 (s, 2H), 7.96 (d, *J*=2.5Hz, 1H), 8.14 (s, 1H), 8.30-8.34 (m, 2H), 8.44 (s, 1H), 9.07 (d, *J*=2Hz, 1H), 10.68 (s, 1H), 13.97 (brs, 1H); ESIMS found for C₂₂H₂₀N₆O *m/z* 385.2 (M+H).




190

[0586] 5-(5-((Dimethylamino)methyl)pyridin-3-yl)-N-(6-(pyrrolidin-1-yl)pyridin-3-yl)-1H-indazole-3-carboxamide **190**.

[0587] White solid (142 mg, 0.32 mmol, 39.7% yield). ¹H NMR (DMSO-d₆) δ ppm 1.92-1.97 (m, 4H), 2.20 (s, 6H), 3.35-3.40 (m, 4H), 3.53 (s, 2H), 6.46 (d, *J*=9Hz, 1H), 7.80 (dq, *J*=9Hz, *J*=1.5Hz, 2H), 7.97 (dd, *J*=9Hz, *J*=3Hz, 1H), 8.00 (s, 1H), 8.46-8.50 (m, 3H), 8.82 (d, *J*=2.5Hz, 1H), 10.22 (s, 1H), 13.86 (brs, 1H); ESIMS found for C₂₅H₂₇N₇O *m/z* 442.4 (M+H).

Example 6

[0588] Preparation of N-(6-(2-fluorophenoxy)pyridin-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide (**18**) is depicted below in Scheme 32.



Scheme 32

Step 1

[0589] To a solution of methyl 5-bromo-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylate (**CXVII**) (7.0 g, 20.6 mmol) in DMF (80 mL) and water (16 mL) was added K_3PO_4 (6.56 g, 30.9 mmol), pyridin-3-ylboronic acid (**CXXXI**) (2.79 g, 22.7 mmol), $Pd(PPh_3)_4$ (1.19 g, 1.03 mmol) and. The solution was purged with argon and heated at 90°C for 3 h. The solution was cooled to room temperature and then concentrated under reduced pressure. The residue was dissolved in DCM and washed with water, dried over $MgSO_4$, filtered and then evaporated under vacuum. The residue was purified on a silica gel column (100% DCM $\rightarrow$ 1.5:98.5 MeOH:DCM) to give methyl 5-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylate (**CXXXIX**) as an orange oil which solidified at rt (6.28 g, 18.6 mmol, 90% yield). ESIMS found for $C_{19}H_{19}N_3O_3$ m/z 338.0 (M+H).

Step 2

[0590] Preparation of intermediate 5-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxylic acid (**CXL**) was performed following the procedure listed in Scheme 25, Step 4. White solid (900 mg, 2.78 mmol, 15% yield). ESIMS found for $C_{18}H_{17}N_3O_3$ m/z 324.1 (M+H).


Step 3

[0591] Preparation of intermediate N-(6-(2-fluorophenoxy)pyridin-3-yl)-5-(pyridin-3-yl)-1-(tetrahydro-2H-pyran-2-yl)-1H-indazole-3-carboxamide (CXLI) was performed following the procedure listed in Scheme 28, Step 3. Off-white solid (207 mg, 0.41 mmol, 66% yield). ¹H NMR (DMSO-d₆) δ ppm 1.60-1.69 (m, 2H), 1.76-1.87 (m, 1H), 2.03-2.13 (m, 2H), 2.56-2.65 (m, 1H), 3.84 (dt, *J*=11Hz, *J*=4Hz, 1H), 3.99 (t, *J*=11Hz, 1H), 6.07 (dd, *J*=10Hz, *J*=2Hz, 1H), 6.98 (dd, *J*=3Hz, *J*=2Hz, 1H), 7.03-7.08 (m, 2H), 7.14 (d, *J*=9Hz, 1H), 7.46 (t, *J*=7Hz, 1H), 7.61 (dd, *J*=8Hz, *J*=5Hz, 1H), 7.91 (dd, *J*=9Hz, *J*=2Hz, 1H), 8.05 (d, *J*=9Hz, 1H), 8.25 (d, *J*=8Hz, 1H), 8.37 (dd, *J*=9Hz, *J*=3Hz, 1H), 8.49 (s, 1H), 8.64 (dd, *J*=5Hz, *J*=2Hz, 1H), 8.66 (d, *J*=3Hz, 1H), 9.00 (d, *J*=2Hz, 1H), 10.59 (s, 1H); ESIMS found for C₂₉H₂₄FN₅O₃ *m/z* 509.2 (M+H).

Step 4


[0592] Preparation of N-(6-(2-fluorophenoxy)pyridin-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide (18) was performed following the procedure listed in Scheme 28, Step 4. White solid (128 mg, 0.30 mmol, 54.7% yield). ¹H NMR (DMSO-d₆) δ ppm 7.16 (d, *J*=9Hz, 1H), 7.23-7.39 (m, 4H), 7.52 (dd, *J*=8Hz, *J*=5Hz, 1H), 7.79-7.85 (m, 2H), 8.13 (td, *J*=8Hz, *J*=2Hz, 1H), 8.38 (dd, *J*=9Hz, *J*=3Hz, 1H), 8.46 (s, 1H), 8.56 (d, *J*=3Hz, 1H), 8.59 (dd, *J*=5Hz, *J*=1Hz, 1H), 8.93 (d, *J*=2Hz, 1H), 10.65 (s, 1H), 13.96 (brs, 1H); ESIMS found for C₂₄H₁₆FN₅O₂ *m/z* 426.0 (M+H).

[0593] The following compounds were prepared in accordance with the procedure described in the above Example 6.



[0594] N-(6-(3-Fluorophenoxy)pyridin-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide 19.

[0595] Off-white solid (148 mg, 0.35 mmol, 89.3% yield). ¹H NMR (DMSO-d₆) δ ppm 6.98 (dd, *J*=8Hz, *J*=2Hz, 1H), 7.01-7.06 (m, 2H), 7.13 (d, *J*=9Hz, 1H), 7.44 (q, *J*=7Hz, 1H), 7.53 (dd, *J*=8Hz, *J*=5Hz, 1H), 7.80-7.85 (m, 2H), 8.14 (td, *J*=6Hz, *J*=2Hz, 1H), 8.40 (dd, *J*=9Hz, *J*=3Hz, 1H), 8.47 (s, 1H), 8.60 (dd, *J*=5Hz, *J*=1Hz, 1H), 8.69 (d, *J*=3Hz, 1H), 8.93 (d, *J*=2Hz, 1H), 10.71 (s, 1H), 13.99 (s, 1H); ESIMS found for C₂₄H₁₆FN₅O₂ *m/z* 426.0 (M+H).




[0596] N-(6-(4-Fluorophenoxy)pyridin-3-yl)-5-(pyridin-3-yl)-1H-indazole-3-carboxamide **20**.

[0597] White solid (82 mg, 0.19 mmol, 91.8% yield). ¹H NMR (DMSO-d₆) δ ppm 7.08 (d, *J*=9Hz, 1H), 7.15-7.21 (m, 2H), 7.22-7.27 (m, 2H), 7.67 (dd, *J*=8Hz, *J*=5Hz, 1H), 7.81-7.88 (m, 2H), 8.31 (d, *J*=8Hz, 1H), 8.36 (dd, *J*=9Hz, *J*=3Hz, 1H), 8.51 (s, 1H), 8.63 (d, *J*=3Hz, 1H), 8.66 (dd, *J*=5Hz, *J*=1Hz, 1H), 9.02 (d, 2H, 1H), 10.67 (s, 1H), 14.00 (s, 1H); ESIMS found for C₂₄H₁₆FN₅O₂ *m/z* 426.0 (M+H).

Example 7

[0598] Preparation of N-(6-carbamoylpyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide (**180**) is depicted below in Scheme 33.



Scheme 33

Step 1

[0599] To a solution of N-(6-cyanopyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-carboxamide (**62**) (200 mg, 0.45 mmol) in glacial acetic acid (2 mL) heated at 85°C was carefully added dropwise sulfuric acid (2 mL). The reaction was heated at 85°C for another 20 minutes before pouring into ice. The solution was basified with cold 5N NH₄OH. The solids formed were filtered, washed with cold washed and dried under vacuum. The dry solid was suspended in DCM and a few drops of MeOH were added. The insoluble solids were filtered and discarded. The filtrate was concentrated and suspended again in DCM, boiled for 15 minutes and filtered. The solid was dried under vacuum to give N-(6-carbamoylpyridin-3-yl)-5-(5-(piperidin-1-ylmethyl)pyridin-3-yl)-1H-indazole-3-

carboxamide (**180**) as a white solid (192 mg, 0.42 mmol, 93.7% yield). ¹H NMR (DMSO-d₆) δ ppm 1.36-1.42 (m, 2H), 1.48-1.55 (m, 4H), 2.38 (brs, 4H), 3.56 (s, 2H), 7.49 (s, 1H), 7.65 (d, *J*=9Hz, 1H), 7.80 (d, *J*=9Hz, 1H), 7.97 (s, 1H), 8.03 (s, 2H), 8.41 (s, 1H), 8.45 (d, *J*=2Hz, 1H), 8.54 (dd, *J*=9Hz, *J*=2.5Hz, 1H), 8.80 (d, *J*=2Hz, 1H), 9.15 (d, *J*=2Hz, 1H), 10.83 (brs, 1H); ESIMS found for C₂₅H₂₅N₇O₂ *m/z* 456.4 (M+H).

Administration and Pharmaceutical Compositions

[0600] Some embodiments include administration of the compounds described herein as pharmaceutical compositions comprising: (a) a safe and therapeutically effective amount of the indazole-3-carboxamide, or its corresponding enantiomer, diastereoisomer or tautomer, or pharmaceutically acceptable salt; and (b) a pharmaceutically acceptable carrier.

[0601] In some embodiments, the methods described herein further include administering the compounds of this invention in combination (administered together or sequentially) with other known agents.

[0602] Administration of the compounds disclosed herein or the pharmaceutically acceptable salts thereof can be via any of the accepted modes of administration for agents that serve similar utilities including, but not limited to, orally, subcutaneously, intravenously, intranasally, topically, transdermally, intraperitoneally, intramuscularly, intrapulmonarily, vaginally, rectally, otopologically, neuro-otologically, intraocularly, subconjunctivally, via anterior eye chamber injection, intravitreally, intraperitoneally, intrathecally, intracystically, intrapleurally, via wound irrigation, intrabuccally, intra-abdominally, intra-articularly, intra-aurally, intrabronchially, intracapsularly, intrameningeally, via inhalation, via endotracheal or endobronchial instillation, via direct instillation into pulmonary cavities, intraspinally, intrasynovially, intrathoracically, via thoracostomy irrigation, epidurally, intratympanically, intracisternally, intravascularly, intraventricularly, intraosseously, via irrigation of infected bone, or via application as part of any admixture with a prosthetic devices. Oral and parenteral administrations are customary in treating the indications.

[0603] Compounds of the invention intended for pharmaceutical use may be administered as crystalline or amorphous products. Pharmaceutically acceptable compositions may include solid, semi-solid, liquid, solutions, colloidal, liposomes, emulsions, suspensions, complexes, coacervates and aerosols. Dosage forms, such as, *e.g.*, tablets, capsules, powders, liquids, suspensions, suppositories, aerosols, implants, controlled release or the like. They may be obtained, for example, as solid plugs, powders, or films by methods such as precipitation, crystallization, milling, grinding, supercritical fluid processing, coacervation, complex coacervation, encapsulation, emulsification, complexation, freeze drying, spray drying, or evaporative drying. Microwave or radio frequency drying may be used for this purpose. The compounds can also be administered in sustained or controlled release dosage forms, including

depot injections, osmotic pumps, pills (tablets and or capsules), transdermal (including electrotransport) patches, implants and the like, for prolonged and/or timed, pulsed administration at a predetermined rate.

[0604] The compounds can be administered either alone or more typically in combination with a conventional pharmaceutical carrier, excipient or the like. The term "excipient" is used herein to describe any ingredient other than the compound(s) of the invention. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d- α -tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tweens, poloxamers or other similar polymeric delivery matrices, serum proteins, such as human serum albumin, buffer substances such as phosphates, tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium-chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethyl cellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, and wool fat. Cyclodextrins such as α -, β , and γ -cyclodextrin, or chemically modified derivatives such as hydroxyalkylcyclodextrins, including 2- and 3-hydroxypropyl- β -cyclodextrins, or other solubilized derivatives can also be advantageously used to enhance delivery of compounds of the formulae described herein. Dosage forms or compositions containing a compound as described herein in the range of 0.005% to 100% with the balance made up from non-toxic carrier may be prepared. The contemplated compositions may contain 0.001%-100% active ingredient, in one embodiment 0.1-95%, in another embodiment 75-85%, in a further embodiment 20-80%, Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington: The Science and Practice of Pharmacy*, 21st Edition (Lippincott Williams & Wilkins. 2005).

[0605] In one preferred embodiment, the compositions will take the form of a unit dosage form such as a pill or tablet and thus the composition may contain, along with the active ingredient, a diluent such as lactose, sucrose, dicalcium phosphate, or the like; a lubricant such as magnesium stearate or the like; and a binder such as starch, gum acacia, polyvinylpyrrolidone, gelatin, cellulose, cellulose derivatives or the like. In another solid dosage form, a powder, granule, solution or suspension (*e.g.*, in propylene carbonate, vegetable oils, PEG's, poloxamer 124 or triglycerides) is encapsulated in a capsule (gelatin or cellulose base capsule). Unit dosage forms in which the two active ingredients are physically separated are also contemplated; *e.g.*, capsules with granules (or tablets in a capsule) of each drug; two-layer tablets; two-compartment gel caps, etc. Enteric coated or delayed release oral dosage forms are also contemplated.

[0606] Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound as defined above and optional pharmaceutical adjuvants in a carrier (*e.g.*, water, saline, aqueous dextrose, glycerol, glycols, ethanol or the like) to form a solution, colloid, liposome, emulsion, complexes, coacervate or suspension. If desired, the pharmaceutical composition can also contain minor amounts of nontoxic auxiliary substances such as wetting agents, emulsifying agents, co-solvents, solubilizing agents, pH buffering agents and the like (*e.g.*, sodium acetate, sodium citrate, cyclodextrin derivatives, sorbitan monolaurate, triethanolamine acetate, triethanolamine oleate, and the like).

[0607] In some embodiments, the unit dosage of compounds of Formula (I) is 0.25 mg/Kg to 50 mg/Kg in humans.

[0608] In some embodiments, the unit dosage of compounds of Formula (I) is 0.25 mg/Kg to 20 mg/Kg in humans.

[0609] In some embodiments, the unit dosage of compounds of Formula (I) is 0.50 mg/Kg to 19 mg/Kg in humans.

[0610] In some embodiments, the unit dosage of compounds of Formula (I) is 0.75 mg/Kg to 18 mg/Kg in humans.

[0611] In some embodiments, the unit dosage of compounds of Formula (I) is 1.0 mg/Kg to 17 mg/Kg in humans.

[0612] In some embodiments, the unit dosage of compounds of Formula (I) is 1.25 mg/Kg to 16 mg/Kg in humans.

[0613] In some embodiments, the unit dosage of compounds of Formula (I) is 1.50 mg/Kg to 15 mg/Kg in humans.

[0614] In some embodiments, the unit dosage of compounds of Formula (I) is 1.75 mg/Kg to 14 mg/Kg in humans.

[0615] In some embodiments, the unit dosage of compounds of Formula (I) is 2.0 mg/Kg to 13 mg/Kg in humans.

[0616] In some embodiments, the unit dosage of compounds of Formula (I) is 3.0 mg/Kg to 12 mg/Kg in humans.

[0617] In some embodiments, the unit dosage of compounds of Formula (I) is 4.0 mg/Kg to 11 mg/Kg in humans.

[0618] In some embodiments, the unit dosage of compounds of Formula (I) is 5.0 mg/Kg to 10 mg/Kg in humans.

[0619] In some embodiments, the compositions are provided in unit dosage forms suitable for single administration of a precise dose.

[0620] In some embodiments, the compositions are provided in unit dosage forms suitable for twice a day administration of a precise dose.

[0621] In some embodiments, the compositions are provided in unit dosage forms suitable for three times a day administration of a precise dose.

[0622] Injectables can be prepared in conventional forms, either as liquid solutions, colloid, liposomes, complexes, coacervate or suspensions, as emulsions, or in solid forms suitable for reconstitution in liquid prior to injection. The percentage of active compound contained in such parenteral compositions is highly dependent on the specific nature thereof, as well as the activity of the compound and the needs of the subject. However, percentages of active ingredient of 0.01% to 10% in solution are employable, and could be higher if the composition is a solid or suspension, which could be subsequently diluted to the above percentages.

[0623] In some embodiments, the injection can be an intra-tendon injection.

[0624] In some embodiments, the composition will comprise 0.1-10% of the active agent in solution.

[0625] In some embodiments, the composition will comprise 0.1-5% of the active agent in solution.

[0626] In some embodiments, the composition will comprise 0.1-4% of the active agent in solution.

[0627] In some embodiments, the composition will comprise 0.15-3% of the active agent in solution.

[0628] In some embodiments, the composition will comprise 0.2-2% of the active agent in solution.

[0629] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of 1-96 hours.

[0630] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of 1-72 hours.

[0631] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of 1-48 hours.

[0632] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of 1-24 hours.

[0633] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of 1-12 hours.

[0634] In some embodiments, the compositions are provided in dosage forms suitable for continuous dosage by intravenous infusion over a period of 1-6 hours.

[0635] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of 5 mg/m² to 300 mg/m².

[0636] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of 5 mg/m² to 200 mg/m².

[0637] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of 5 mg/m² to 100 mg/m².

[0638] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of 10 mg/m² to 50 mg/m².

[0639] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of 50 mg/m² to 200 mg/m².

[0640] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of 75 mg/m² to 175 mg/m².

[0641] In some embodiments, these compositions can be administered by intravenous infusion to humans at doses of 100 mg/m² to 150 mg/m².

[0642] In one preferred embodiment, the compositions can be administered to the respiratory tract (including nasal and pulmonary) e.g., through a nebulizer, metered-dose inhalers, atomizer, mister, aerosol, dry powder inhaler, insufflator, liquid instillation or other suitable device or technique.

[0643] In some embodiments, aerosols intended for delivery to the nasal mucosa are provided for inhalation through the nose. For optimal delivery to the nasal cavities, inhaled particle sizes of about 5 to about 100 microns are useful, with particle sizes of about 10 to about 60 microns being preferred. For nasal delivery, a larger inhaled particle size is desired to maximize impaction on the nasal mucosa and to minimize or prevent pulmonary deposition of the administered formulation. In some embodiments, aerosols intended for delivery to the lung are provided for inhalation through the nose or the mouth. For optimal delivery to the lung, inhaled aerodynamic particle sizes of equal or less than 10 µm are useful, with an aerodynamic particle size of about 0.1 to 10 microns being preferred. Inhaled particles may be defined as liquid droplets containing dissolved drug, liquid droplets containing suspended drug particles (in cases where the drug is insoluble in the suspending medium), dry particles of pure drug substance, drug substance incorporated with excipients, liposomes, emulsions, colloidal systems, coacervates, aggregates of drug nanoparticles, or dry particles of a diluent which contain embedded drug nanoparticles.

[0644] In some embodiments, compounds of Formula (I) disclosed herein intended for respiratory delivery (either systemic or local) can be administered as aqueous formulations, as non-aqueous solutions or suspensions, as suspensions or solutions in halogenated hydrocarbon propellants with or without alcohol, as a colloidal system, as emulsions, coacervates or as dry powders. Aqueous formulations may be aerosolized by liquid nebulizers employing either hydraulic or ultrasonic atomization or by modified micropump systems (like the soft mist inhalers, the Aerodose[®] or the AERx[®] systems). Propellant-based systems may use suitable pressurized metered-dose inhalers (pMDIs). Dry powders may use dry powder inhaler devices (DPIs), which are capable of dispersing the drug substance

effectively. A desired particle size and distribution may be obtained by choosing an appropriate device.

[0645] In some embodiments, the compositions of Formula (I) disclosed herein can be administered to the ear by various methods. For example, a round window catheter (e.g., U.S. Pat. Nos. 6,440,102 and 6,648,873) can be used.

[0646] Alternatively, formulations can be incorporated into a wick for use between the outer and middle ear (e.g., U.S. Pat. No. 6,120,484) or absorbed to collagen sponge or other solid support (e.g., U.S. Pat. No. 4,164,559).

[0647] If desired, formulations of the invention can be incorporated into a gel formulation (e.g., U.S. Pat. Nos. 4,474,752 and 6,911,211).

[0648] In some embodiments, compounds of Formula (I) disclosed herein intended for delivery to the ear can be administered via an implanted pump and delivery system through a needle directly into the middle or inner ear (cochlea) or through a cochlear implant stylet electrode channel or alternative prepared drug delivery channel such as but not limited to a needle through temporal bone into the cochlea.

[0649] Other options include delivery via a pump through a thin film coated onto a multichannel electrode or electrode with a specially imbedded drug delivery channel (pathways) carved into the thin film for this purpose. In other embodiments the acidic or basic solid gacyclidine can be delivered from the reservoir of an external or internal implanted pumping system.

[0650] Formulations of the invention also can be administered to the ear by intratympanic injection into the middle ear, inner ear, or cochlea (e.g., U.S. Pat. No. 6,377,849 and Ser. No. 11/337,815).

[0651] Intratympanic injection of therapeutic agents is the technique of injecting a therapeutic agent behind the tympanic membrane into the middle and/or inner ear. In one embodiment, the formulations described herein are administered directly onto the round window membrane via transtympanic injection. In another embodiment, the ion channel modulating agent auris-acceptable formulations described herein are administered onto the round window membrane via a non-transtympanic approach to the inner ear. In additional embodiments, the formulation described herein is administered onto the round window membrane via a surgical approach to the round window membrane comprising modification of the crista fenestrae cochleae.

[0652] In some embodiments, the compounds of Formula (I) are formulated in rectal compositions such as enemas, rectal gels, rectal foams, rectal aerosols, suppositories, jelly suppositories, or retention enemas, containing conventional suppository bases such as cocoa butter or other glycerides, as well as synthetic polymers such as polyvinylpyrrolidone, PEG (like PEG ointments), and the like. In suppository forms of the compositions, a low-

melting wax such as, but not limited to, a mixture of fatty acid glycerides, optionally in combination with cocoa butter is first melted.

[0653] Suppositories for rectal administration of the drug (either as a solution, colloid, suspension or a complex) can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at ordinary temperatures but liquid at the rectal temperature and will therefore melt or erode/dissolve in the rectum and release the drug. Such materials include cocoa butter, glycerinated gelatin, hydrogenated vegetable oils, poloxamers, mixtures of polyethylene glycols of various molecular weights and fatty acid esters of polyethylene glycol.

[0654] In some embodiments, the compositions can be administered by transdermal patch.

[0655] Other modes of deliveries include using biodegradable or non-biodegradable scaffolds.

[0656] It is to be noted that concentrations and dosage values may also vary with the severity of the condition to be alleviated. It is to be further understood that for any particular patient, specific dosage regimens should be adjusted over time according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions, and that the concentration ranges set forth herein are exemplary only and are not intended to limit the scope or practice of the claimed compositions.

[0657] Solid compositions can be provided in various different types of dosage forms, depending on the physicochemical properties of the drug, the desired dissolution rate, cost considerations, and other criteria. In one of the embodiments, the solid composition is a single unit. This implies that one-unit dose of the drug is comprised in a single, physically shaped solid form or article. In other words, the solid composition is coherent, which is in contrast to a multiple unit dosage form, in which the units are incoherent.

[0658] Examples of single units which may be used as dosage forms for the solid composition include tablets, such as compressed tablets, film-like units, foil-like units, wafers, lyophilized matrix units, and the like. In a preferred embodiment, the solid composition is a highly porous lyophilized form. Such lyophilizates, sometimes also called wafers or lyophilized tablets, are particularly useful for their rapid disintegration, which also enables the rapid dissolution of the active compound.

[0659] On the other hand, for some applications the solid composition may also be formed as a multiple unit dosage form as defined above. Examples of multiple units are powders, granules, microparticles, pellets, mini-tablets, beads, lyophilized powders, and the like. In one embodiment, the solid composition is a lyophilized powder. Such a dispersed lyophilized system comprises a multitude of powder particles, and due to the lyophilization process used in the formation of the powder, each particle has an irregular, porous microstructure through which the powder is capable of absorbing water very rapidly, resulting

in quick dissolution. Effervescent compositions are also contemplated to aid the quick dispersion and absorption of the compound.

[0660] Another type of multiparticulate system which is also capable of achieving rapid drug dissolution is that of powders, granules, or pellets from water-soluble excipients which are coated with the drug, so that the drug is located at the outer surface of the individual particles. In this type of system, the water-soluble low molecular weight excipient is useful for preparing the cores of such coated particles, which can be subsequently coated with a coating composition comprising the drug and, preferably, one or more additional excipients, such as a binder, a pore former, a saccharide, a sugar alcohol, a film-forming polymer, a plasticizer, or other excipients used in pharmaceutical coating compositions.

[0661] Also provided herein are kits. Typically, a kit includes one or more compounds or compositions as described herein. In certain embodiments, a kit can include one or more delivery systems, e.g., for delivering or administering a compound as provided above, and directions for use of the kit (e.g., instructions for treating a patient). In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with cancer. In another embodiment, the kit can include a compound or composition as described herein and a label that indicates that the contents are to be administered to a patient with one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing.

[0662] The actual dose of the active compounds of the present invention depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan.

Methods of Treatment

[0663] The compounds and compositions provided herein can be used as inhibitors and/or modulators of one or more components of the Wnt pathway, which may include one or more Wnt proteins, and thus can be used to treat a variety of disorders and diseases in which aberrant Wnt signaling is implicated. Non-limiting examples include one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease. In certain embodiments, the compounds and compositions provided herein can be used for promoting wound healing.

[0664] In some embodiments, the methods further include administering to a patient in need of such treatment an effective amount of one or more of the compounds of Formula (I), in combination (simultaneously or sequentially) with at least one other agent.

[0665] In some embodiments, the methods further include administering a pharmaceutical composition that includes a therapeutically effective amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient and optionally at least one other agent.

[0666] In some embodiments, the one or more diseases or conditions is a tendinopathy. In certain embodiments, the tendinopathy is tendinosis. In certain embodiments, the tendinopathy is tendinitis. In certain embodiments, the tendinopathy is tenosynovitis.

[0667] A tendon is a band of fibrous connective tissue that usually connects muscle to bone. Healthy tendons include parallel arrays of type I collagen fibers closely packed together, but also include a small amount of elastin and of proteoglycans. Tendons can be slow to heal if injured, and sometimes do not regain their original strength. Partial tears heal by the rapid production of disorganized type-III collagen, which is weaker than normal tendon. Recurrence of injury in the damaged region of tendon is common.

[0668] Tendons which may be treated by the methods of the invention include any tendon of the human or mammalian body. Non-limiting examples of tendons include the patellar tendon, the anterior tibialis tendon, the Achilles tendon, the hamstring tendon, the semitendinosus tendon, the gracilis tendon, the abductor tendon, the adductor tendon, the supraspinatus tendon, the infraspinatus tendon, the subscapularis tendon, the teres minor tendon, the flexor tendon, the rectus femoris tendon, the tibialis posterior tendon, and the quadriceps femoris tendon.

[0669] In some embodiments, the tendon is a tendon of the foot or ankle; e.g., the extensor hallucis longus, the flexor hallucis longus, the extensor digitorum longus, the extensor digitorum brevis, the peroneus longus, the peroneus brevis, the flexor hallucis brevis, the flexor digitorum longus, the posterior tibialis, the Achilles tendon, and the plantar fascia.

[0670] In some embodiments, the tendon is a tendon of the leg; e.g., the patellar tendon, the anterior tibialis tendon, the Achilles tendon, the hamstring tendon, the semitendinosus tendon, the gracilis tendon, the abductor tendon, the adductor tendon, the flexor tendon, the rectus femoris tendon, the tibialis posterior tendon, and the quadriceps femoris tendon.

[0671] In some embodiments, the tendon is a tendon of the shoulder; e.g., the supraspinatus tendon, the infraspinatus tendon, the subscapularis tendon, and the teres minor tendon (rotator cuff complex).

[0672] In some embodiments, the tendon is a tendon of the elbow; e.g., the biceps tendon, the triceps tendon, the extensor carpi radialis brevis, the common extensor tendon, the extensor digitorum, the extensor digiti minimi, the extensor carpi ulnaris, the supinator, the common flexor tendon, the pronator teres, the flexor carpi radialis, the palmaris longus, the flexor carpi ulnaris and the digitorum superficialis. In some embodiments, the tendon is a

tendon of the wrist. In some embodiments, the tendon of the wrist is selected from the group consisting of biceps tendon, the triceps tendon, the extensor carpi radialis brevis, the common extensor tendon, the extensor digitorum, the extensor digiti minimi, the extensor carpi ulnaris, the supinator, the common flexor tendon, the pronator teres, the flexor carpi radialis, the palmaris longus, the flexor carpi ulnaris, the digitorum superficialis, the flexor pollicis brevis, the flexor pollicis longus, the abductor pollicis brevis, the abductor pollicis longus, the flexor digitorum profundus, the flexor digitorum superficialis, the extensor pollicis brevis, and the extensor pollicis longus. In some embodiments, the tendon is a tendon of the hand. In some embodiments, the tendon of the hand is selected from the group consisting of the flexor pollicis brevis, the flexor pollicis longus, the abductor pollicis brevis, the abductor pollicis longus, the flexor digitorum profundus, the flexor digitorum superficialis, the extensor pollicis brevis, and the extensor pollicis longus.

[0673] Non-limiting examples of tendinopathies include: clavicular or patellar tendinopathy, patellar tendonitis; medial tibial stress syndrome; Achilles tendinopathy, lateral epicondylitis or "tennis elbow;" medial epicondylitis or "golfer's elbow;" plantar fasciitis; and rotator cuff tendinopathy.

[0674] In some embodiments, the tendinopathy is rotator cuff tendinopathy; e.g., supraspinatus tendinopathy, infraspinatus tendinopathy, subscapularis tendinopathy, and teres minor tendinopathy.

[0675] In some embodiments, the tendinopathy is lateral epicondylitis or "tennis elbow" at the extensor muscle group origin at the lateral humeral condyle insertion, principally in the extensor carpi radialis brevis (ECRB) tendon. In some embodiments, the tendinopathy is medial epicondylitis or "golfer's elbow" at the interface between the pronator teres and flexor carpi radialis origin of the medial humeral condyle.

[0676] In some embodiments, the tendinopathy is patellar tendinopathy. In some embodiments, the tendinopathy is Achilles tendinopathy. In some embodiments, the tendinopathy is plantar fasciitis. In some embodiments, the tendinopathy is medial plantar fasciitis. In some embodiments, the tendinopathy is lateral plantar fasciitis.

[0677] In some embodiments, the tendinopathy is tendinosis. In some embodiments, the tendinosis is selected from the group consisting of extensor hallucis longus tendinosis, flexor hallucis longus tendinosis, extensor digitorum longus tendinosis, extensor digitorum brevis tendinosis, peroneus longus tendinosis, peroneus brevis tendinosis, flexor hallucis brevis tendinosis, flexor digitorum longus tendinosis, posterior tibialis tendinosis, Achilles tendon tendinosis, and plantar fascia tendinosis. In some embodiments, the tendinosis is selected from the group consisting of patellar tendinosis, the anterior tibialis tendinosis, the hamstring tendinosis, semitendinosus tendinosis, gracilis tendinosis, abductor tendinosis, and adductor tendinosis. In some embodiments, the tendinosis is selected from the group consisting

of flexor tendinosis, rectus femoris tendinosis, tibialis posterior tendinosis, and quadriceps femoris tendinosis. In some embodiments, the tendinosis is selected from the group consisting of supraspinatus tendinosis, infraspinatus tendinosis, subscapularis tendinosis, and teres minor tendinosis.

[0678] In some embodiments, the tendinosis is selected from the group consisting of biceps tendinosis, triceps tendinosis, extensor carpi radialis brevis tendinosis, common extensor tendinosis, extensor digitorum tendinosis, extensor digiti minimi tendinosis, extensor carpi ulnaris tendinosis, supinator tendinosis, common flexor tendinosis, pronator teres tendinosis, flexor carpi radialis tendinosis, palmaris longus tendinosis, flexor carpi ulnaris tendinosis and digitorum superficialis tendinosis. In some embodiments, the tendinosis is selected from the group consisting of biceps tendinosis, triceps tendinosis, extensor carpi radialis brevis tendinosis, common extensor tendinosis, extensor digitorum tendinosis, extensor digiti minimi tendinosis, extensor carpi ulnaris tendinosis, supinator tendinosis, common flexor tendinosis, pronator teres tendinosis, flexor carpi radialis tendinosis, palmaris longus tendinosis, flexor carpi ulnaris tendinosis, digitorum superficialis tendinosis, flexor pollicis brevis tendinosis, flexor pollicis longus tendinosis, abductor pollicis brevis tendinosis, abductor pollicis longus tendinosis, flexor digitorum profundus tendinosis, flexor digitorum superficialis tendinosis, extensor pollicis brevis tendinosis, and extensor pollicis longus tendinosis. In some embodiments, the tendinosis is selected from the group consisting of flexor pollicis brevis tendinosis, flexor pollicis longus tendinosis, abductor pollicis brevis tendinosis, abductor pollicis longus tendinosis, flexor digitorum profundus tendinosis, flexor digitorum superficialis tendinosis, extensor pollicis brevis tendinosis, and extensor pollicis longus tendinosis.

[0679] In some embodiments, the tendinopathy is tendinitis. In some embodiments, the tendinitis is selected from the group consisting of extensor hallucis longus tendinitis, flexor hallucis longus tendinitis, extensor digitorum longus tendinitis, extensor digitorum brevis tendinitis, peroneus longus tendinitis, peroneus brevis tendinitis, flexor hallucis brevis tendinitis, flexor digitorum longus tendinitis, posterior tibialis tendinitis, Achilles tendon tendinitis, and plantar fascia tendinitis. In some embodiments, the tendinitis is selected from the group consisting of patellar tendinitis, the anterior tibialis tendinitis, the hamstring tendinitis, semitendinosus tendinitis, gracilis tendinitis, abductor tendinitis, and adductor tendinitis. In some embodiments, the tendinitis is selected from the group consisting of flexor tendinitis, rectus femoris tendinitis, tibialis posterior tendinitis, and quadriceps femoris tendinitis. In some embodiments, the tendinitis is selected from the group consisting of supraspinatus tendinitis, infraspinatus tendinitis, subscapularis tendinitis, and teres minor tendinitis.

[0680] In some embodiments, the tendinitis is selected from the group consisting of biceps tendinitis, triceps tendinitis, extensor carpi radialis brevis tendinitis, common extensor

tendinitis, extensor digitorum tendinitis, extensor digiti minimi tendinitis, extensor carpi ulnaris tendinitis, supinator tendinitis, common flexor tendinitis, pronator teres tendinitis, flexor carpi radialis tendinitis, palmaris longus tendinitis, flexor carpi ulnaris tendinitis and digitorum superficialis tendinitis. In some embodiments, the tendinitis is selected from the group consisting of biceps tendinitis, triceps tendinitis, extensor carpi radialis brevis tendinitis, common extensor tendinitis, extensor digitorum tendinitis, extensor digiti minimi tendinitis, extensor carpi ulnaris tendinitis, supinator tendinitis, common flexor tendinitis, pronator teres tendinitis, flexor carpi radialis tendinitis, palmaris longus tendinitis, flexor carpi ulnaris tendinitis, digitorum superficialis tendinitis, flexor pollicis brevis tendinitis, flexor pollicis longus tendinitis, abductor pollicis brevis tendinitis, abductor pollicis longus tendinitis, flexor digitorum profundus tendinitis, flexor digitorum superficialis tendinitis, extensor pollicis brevis tendinitis, and extensor pollicis longus tendinitis. In some embodiments, the tendinitis is selected from the group consisting of flexor pollicis brevis tendinitis, flexor pollicis longus tendinitis, abductor pollicis brevis tendinitis, abductor pollicis longus tendinitis, flexor digitorum profundus tendinitis, flexor digitorum superficialis tendinitis, extensor pollicis brevis tendinitis, calcific tendinitis, and extensor pollicis longus tendinitis.

[0681] In some embodiments, the tendinitis is caused by chronic overuse injuries of tendon failed healing.

[0682] In some embodiments, the injury or damage is localized very near the muscle-tendon junction (myotendinous junction).

[0683] In some embodiments, the tendinitis leads to scarring and fibrosis.

[0684] The methods of the invention may result in improvement in one or more of the following: decreasing pain of the affected joint or limb, decreasing stiffness of the affected joint or limb, increasing mobility of the affected joint or limb, increasing strength of the affected joint or limb, decreasing the rate of tendinopathy progression, decreasing inflammation, increasing the strength of the tendon, or improving the rate of tendon strength recovery. Various methods for measuring effectiveness of the treatment include, but are not limited to: Disabilities of the Arm, Shoulder and Hand Score (DASH), Visual Analog Score (VAS), and grip strength testing.

[0685] In some embodiments, the treatment results in increased strength of the tendon. In some embodiments, the treatment results in a more rapid rate of tendon strength recovery. In some embodiments, the treatment results in an increase in tendon strength of about 30%, about 40%, about 50%, about 60%, about 70%, about 80%, about 90% within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 days of administration of a compound of the invention, as compared to baseline.

[0686] The methods of the invention may include preventive treatments.

[0687] In some embodiments, the administering is by direct injection to the affected site. In some embodiments, the direct injection is accomplished using the "peppering technique" with or without ultrasound guidance. The "peppering technique" is an injection method whereby after the needle is inserted into the tender area, multiple small injections are performed by withdrawing, redirecting and reinserting the needle without emerging from the skin.

[0688] In some embodiments, the methods can further include administering one or more other therapeutic regimens and/or agents effective for treating a tendinopathy, e.g., palliative care, with treatment focusing on anti-inflammatory measures, including treatment with nonsteroidal anti-inflammatory drugs (NSAIDs), steroid injections, cortisone injections, platelet rich plasma (PRP) injections, physical therapy, shock wave therapy, low-level laser therapy (phototherapy), cell therapy, and sclerotherapy.

[0689] In some embodiments, the one or more diseases or conditions is psoriasis. Non-limiting examples include: psoriasis vulgaris (including nummular psoriasis and plaque psoriasis); generalized pustular psoriasis (including impetigo herpetiformis and von Zumbusch's disease); acrodermatitis continua; pustulosis palmaris et plantaris; guttate psoriasis; arthropathic psoriasis; other psoriasis (including inverse psoriasis).

[0690] In some embodiments, the one or more diseases or conditions is dermatitis. Non-limiting examples include: atopic dermatitis, contact dermatitis (e.g., allergic contact dermatitis, irritant contact dermatitis), stasis dermatitis, dermatitis that led up to steroid dermatitis, steroid-resistant dermatitis, dermatitis to which tacrolimus is not applicable, chronic dermatitis, erythroderma (e.g., erythroderma posteczematosa and erythroderma secondary to dermatoses, toxic erythroderma, infantile desquamative erythroderma, and paraneoplastic erythroderma), eczema, nummular eczema, dyshidrotic eczema, asteatotic eczema, seborrheic dermatitis, autosensitization dermatitis, stasis dermatitis, urticaria, drug eruption, dermal vasculitis, prurigo, pruritus cutaneus, erythema (e.g. nodosum or multiforme), rosacea, rosacea-like dermatitis, lichen planus, photo-induced dermatitis, or follicular keratosis. In certain embodiments, the dermatitis is contact dermatitis, e.g., allergic contact dermatitis, e.g., resulting from direct skin contact with a substance such as poison ivy, poison oak, or poison sumac.

[0691] In some embodiments, the one or more diseases or conditions is morphea.

[0692] In some embodiments, the one or more diseases or conditions is ichthyosis.

[0693] In some embodiments, the one or more diseases or conditions is Darier's disease.

[0694] In some embodiments, the methods can further include administering one or more other therapeutic regimens and/or agents effective in treating a skin disorder described herein, e.g., corticosteroids, immune modulators, vitamin D3 and its analogs, retinoic acids and their pharmaceutically active derivatives, or combinations thereof. Specific non-limiting

examples of drugs include betamethasone dipropionate, clobetasol propionate, halobetasol propionate, diflorasone diacetate, amcinonide, desoximethasone, fluocinonide, halcinonide, mometasone furoate, betamethasone valerate, fluocinonide, fluticasone propionate, triamcinolone acetonide, fluocinolone acetonide, flurandrenolide, desonide, hydrocortisone butyrate, hydrocortisone valerate, alclometasone dipropionate, flumethasone pivate, hydrocortisone, hydrocortisone acetate, prednisone, Benadryl, tacrolimus, picrolimus, tazarotene, isotretinoin, cyclosporin, anthralin, vitamin D3, cholecalciferol, calcitriol, calcipotriol, tacalcitol, calcipotriene, Gossypol, 4-hydroxyestradiol, 2-hydroxyestradiol, 2-hydroxyestrone, 2-benzimidazolylthioacetamide-N-ethyl-2-benzyl (KH7.102), an antibody, a nucleic acid, or combinations thereof.

[0695] In some embodiments, the one or more diseases or conditions is Raynaud's syndrome.

[0696] In some embodiments, the patient is a human.

[0697] In some embodiments, the compound of Formula (I) inhibits one or more proteins in the Wnt pathway.

[0698] In some embodiments, the compound of Formula (I) inhibits signaling induced by one or more Wnt proteins.

[0699] In some embodiments, the Wnt proteins are chosen from: WNT1, WNT2, WNT2B, WNT3, WNT3A, WNT4, WNT5A, WNT5B, WNT6, WNT7A, WNT7B, WNT8A, WNT8B, WNT9A, WNT9B, WNT10A, WNT10B, WNT11, and WNT16.

[0700] In some embodiments, the compound of Formula (I) inhibits a kinase activity.

[0701] In some embodiments, the compound of Formula (I) inhibits one or more Wnt proteins.

Evaluation of Biological Activity

[0702] The biological activity of the compounds described herein can be tested using any suitable assay known to those of skill in the art, e.g., WO 2001/053268 or WO 2005/009997. For example, the activity of a compound may be tested using one or more of the test methods outlined below.

[0703] In another example, one may utilize *in vitro* assays for Wnt biological activity, e.g. stabilization of β -catenin and promoting growth of stem cells. Assays for biological activity of Wnt include stabilization of β -catenin, which can be measured, for example, by serial dilutions of a candidate inhibitor composition. An exemplary assay for Wnt biological activity contacts a Wnt composition in the presence of a candidate inhibitor with cells, e.g. mouse L cells. The cells are cultured for a period of time sufficient to stabilize β -

catenin, usually at least about 1 hour, and lysed. The cell lysate is resolved by SDS PAGE, then transferred to nitrocellulose and probed with antibodies specific for β -catenin.

[0704] In a further example, the activity of a candidate compound can be measured in a *Xenopus* secondary axis bioassay (Leyns, L. *et al. Cell* (1997), 88(6), 747-756).

Example 8.

[0705] Another screening assay for Wnt activity is described as follows. Reporter cell lines can be generated by stably transducing cells of cancer cell lines (e.g., colon cancer) with a lentiviral construct that include a Wnt-responsive promoter driving expression of the firefly luciferase gene.

[0706] Lentiviral constructs can be made in which the SP5 promoter, a promoter having eight TCF/LEF binding sites derived from the SP5 promoter, is linked upstream of the firefly luciferase gene. The lentiviral constructs can also include a hygromycin resistance gene as a selectable marker. The SP5 promoter construct can be used to transduce SW480 cells, a colon cancer cell line having a mutated APC gene that generates a truncated APC protein, leading to de-regulated accumulation of β -catenin. A control cell line can be generated using another lentiviral construct containing the luciferase gene under the control of the SV40 promoter which does not require β -catenin for activation.

[0707] Cultured SW480 cells bearing a reporter construct can be distributed at approximately 10,000 cells per well into 96 well or 384 well plates. Compounds from a small molecule compound library can then be added to the wells in half-log dilutions using a ten micromolar top concentration. A series of control wells for each cell type receive only buffer and compound solvent. Twenty-four to forty hours after the addition of compound, reporter activity for luciferase can be assayed, for example, by addition of the BrightGlo luminescence reagent (Promega) and the Victor3 plate reader (Perkin Elmer). Readings can be normalized to DMSO only treated cells, and normalized activities can then be used in the EC₅₀ calculations. Table 2 shows the activity of selected indazole-3-carboxamide analogs.

Table 2.

Compound	EC₅₀ (nM)	Compound	EC₅₀ (nM)
1	175 nM	2	5,000 nM
3	200 nM	4	160 nM
5	10,000 nM	6	270 nM
7	110 nM	8	130 nM
9	10,000 nM	11	10,000 nM
12	63 nM	13	1,250 nM
14	106 nM	15	37 nM
16	10,000 nM	18	122 nM
19	107 nM	20	118 nM
23	120 nM	26	210 nM
32	1,250 nM	36	275 nM
37	1,120 nM	38	120 nM
39	65 nM	40	65 nM

41	67 nM	42	500 nM
43	63 nM	44	158 nM
45	110 nM	46	15 nM
47	71 nM	48	10,000 nM
49	57 nM	50	71 nM
51	26 nM	52	57 nM
53	63 nM	54	158 nM
55	44 nM	56	160 nM
57	10,000 nM	58	71 nM
59	3,100 nM	60	10,000 nM
61	239 nM	62	16 nM
63	100 nM	64	6 nM
65	101 nM	66	10,000 nM
67	10,000 nM	68	48 nM
69	50 nM	70	41 nM
71	25 nM	72	215 nM
73	322 nM	74	65 nM
75	40 nM	76	850 nM
77	2,650 nM	78	239 nM
79	123 nM	80	158 nM
81	77-142 nM	82	143-188 nM
83	2,500-3,400 nM	84	822-898 nM
86	66 nM	87	2,440 nM
106	33 nM	124	67 nM
126	22 nM	162	426 nM
163	15,400 nM	168	66 nM
169	49 nM	170	43 nM
172	60 nM	173	36 nM
174	48 nM	175	25 nM
176	30 nM	177	183 nM
178	297 nM	179	30 nM
180	13 nM	181	38 nM
182	35 nM	183	49 nM
184	40 nM	185	27 nM
186	460 nM	187	215 nM
188	9 nM	189	85 nM
190	1,200 nM		

Example 9.

[0708] Representative compounds were screened using primary human mesenchymal stem cells (hMSCs) to determine their ability to induce tenocyte differentiation (process by which tendon is developed).

[0709] *Human Mesenchymal Stem Cell Culture:* Primary human mesenchymal stem cells (hMSCs) were purchased from Lonza (Walkersville, MD) and expanded in Mesenchymal Stem Cell Growth Media (Lonza). Cells between passage 3 and 6 were used for the experiments.

[0710] *Compound Screening:* Each compound was dissolved in DMSO as a 10mM stock and used to prepare compound source plates. For the tenocyte differentiation assay, serial dilution (1:2, 10-point dose-response curves from 10 μ M to 19.5 nM) and compound transfer was performed using the ECHO 550 (Labcyte, Sunnyvale, CA) into 384-well black clear bottom assay plates (Greiner Bio-One) with appropriate DMSO backfill for a final DMSO concentration of 0.17%. hMSCs were plated at 3,000 cells/well in 70 μ L/well Dulbecco's modified Eagle's medium (DMEM, Life Technologies, Carlsbad, CA) with 1% Fetal Bovine Serum (FBS, Life Technologies). Bone Morphogenic Factor (BMP) and Fetal Growth Factor (FGF) (10 ng/ml each, Peprotech, Inc., Rocky Hill, NJ) were used as a positive-

controls for differentiation while negative control wells were treated with 120 nL DMSO for normalization and calculating EC₅₀ values. Cells were incubated at 37°C and 5% CO₂ for 4 days. Cells were fixed using 4% formaldehyde (Electron Microscopy Sciences), and stained with anti-Scleraxis (anti-SCXA) antibodies (Abgent, San Diego, CA) [Webb S., *et.al.*, Retinoic acid receptor signaling preserves tendon stem cell characteristics and prevents spontaneous differentiation *in vitro*, *Stem Cell Research & Therapy* 2016, 7:45] overnight at 4°C. The cells were washed with Phosphate Buffered Saline (PBS, Life Technologies) and incubated with anti-rabbit Alexa-flor 647 secondary antibodies (Life Technologies) and DAPI (Life Technologies) for 1 hour at room temperature. Cells were washed using PBS, and imaged using the CellInsight CX5 (Life Technologies, 594/633nm filter). Number of cells positive for SCXA in each well was quantified using the CellInsight CX5. Data was normalized to the average of 12 DMSO treated wells on the same plate using Dotmatics Studies module. The normalized averages (fold change over DMSO) of 3 replicate wells for each compound concentration were calculated. Due to solubility limitations of some of the compounds, values for higher doses were manually corrected and curve fitting and EC₅₀ determinations were performed using Dotmatics Studies.

[0711] EC₅₀ for each compound is reported. Table 3 shows the measured activity for representative compounds of Formula I as described herein.

Table 3.

Compound	EC ₅₀ (μM)	Compound	EC ₅₀ (μM)
1	>100uM	65	>100uM
2	>100uM	66	>100uM
3	>100uM	67	>100uM
4	4.552	68	4.613
5	>100uM	69	12.481
6	92.468	70	10.850
7	6.942	71	>100uM
8	4.983	72	>100uM
9	>100uM	73	>100uM
11	>100uM	74	10.180
12	4.998	75	12.373
13	>100uM	76	2.667
14	50.395	77	6.075
15	4.804	78	>100uM
16	35.772	79	>100uM
18	5.378	80	>100uM
19	>100uM	81	>100uM
20	11.982	82	>100uM
23	>100uM	83	>100uM
26	>100uM	84	>100uM
32	>100uM	86	5.273
36	>100uM	87	1.584
37	>100uM	106	5.545
38	2.839	124	>100uM
39	>100uM	126	5.537

40	5.174	162	>100uM
41	8.118	163	5.086
42	5.137	168	>100uM
43	5.019	169	4.905
44	25.061	170	>100uM
45	9.750	172	>100uM
46	5.056	173	>100uM
47	>100uM	174	5.539
48	>100uM	175	10.377
49	>100uM	176	4.654
50	>100uM	177	5.174
51	>100uM	178	>100uM
52	>100uM	179	1.115
53	>100uM	180	>100uM
54	>100uM	181	>100uM
55	>100uM	182	8.039
56	0.625	183	>100uM
57	>100uM	184	>100uM
58	>100uM	185	6.442
59	14.560	186	>100uM
60	>100uM	187	>100uM
61	12.268	188	1.212
62	>100uM	189	>100uM
63	10.243	190	>100uM
64	7.661		

Example 10.**Wnt Signaling inhibition**

[0712] **Cell Culture.** SW480 cells (ATCC) were cultured in Dulbecco's modified Eagle's medium (DMEM, ThermoFisher) with 1% Glutamax (Life Technologies), 1% Penicillin-Streptomycin (Life Technologies), 150ug/ml Hygromycin (Life Technologies) with 10% fetal bovine serum (FBS) (Hyclone) at 37°C, 5% CO₂.

[0713] **Wnt Reporter Assay.** Human colorectal cancer cell line SW480, stably expressing the Wnt responsive promoter linked to luciferase gene, was plated overnight at 4 x 10⁴ cells/well in DMEM, high glucose, no glutamine, no phenol red (Life Technologies), 1% Glutamax (Life Technologies), 1% Sodium Pyruvate (Life Technologies), 1% Penicillin-Streptomycin (Life Technologies) with 1% Fetal Bovine Serum (Hyclone). Cells were then treated with DMSO (vehicle control) or COMPOUND 175 at 10 µM top concentration and half a log dilution up to 10 concentrations (10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001 and 0.0003 µM). Cells were incubated for 48 hours at 37°C. 15 µl of Bright-Glo (Bright-Glo™ Luciferase Assay System, Promega) was added to the cells and luminescence was measured using the Cytation 3 plate reader (Biotek). Data was normalized using the DMSO control and inhibition profile and EC₅₀ was calculated using Prism 4 (GraphPad Software Inc, La Jolla, CA, USA). Prism 4.0 was used to calculate the EC₅₀ of the Wnt reporter inhibition assay.

[0714] Exposure of the SW480 cells to compound 175 at concentrations of 10, 3, 1, 0.3, 0.1, 0.03, 0.01, 0.003, 0.001 and 0.0003 µM showed that compound 175 inhibited Wnt

pathway activity in these cells in a dose-dependent manner with EC₅₀ of ~ 152.9 nM (see FIG. 1).

Example 11.

Tendon Differentiation

[0715] Cell Culture. Primary human mesenchymal stem cells (hMSCs; Lonza Inc) were cultured in MSCGM™ Mesenchymal Stem Cell Growth Medium, with 10% FBS (Lonza) 10% fetal bovine serum (FBS) (Hyclone) at 37°C, 5% CO₂. hMSCs were used between passage 2 and 6 and were never allowed to reach confluence to maintain a naive state.

[0716] Tenocyte Differentiation Assay. For tenocyte differentiation, hMSCs were plated in 384-well plates at 1 x 10⁴ cells/well in Dulbecco's modified Eagle's medium (DMEM, ThermoFisher) with 1% fetal bovine serum (FBS) (Hyclone). Cells were then treated with DMSO (vehicle control) or compound **175** at 750 nM top concentration and 2-fold dilution up to 8 concentrations (750, 333.3, 166.6, 83.3, 41.7, 21.7, 10.8 and 5.8 nM) and incubated for 7 days at 37°C. A combination of BMP and FGF (10ng/ml each, Peprotech, Inc.) was used as a positive control. At the end of 7 days, cells were fixed using 4 % methanol-free formaldehyde (Electron Microscopy Sciences) for 10 min, washed with phosphate buffered saline (PBS) 3 times, permeabilized with PBS containing 0.3% triton X-100 (Sigma) for 5 min, blocked with PBST (PBS containing 0.3% triton X-100) with 3% bovine serum albumin (BSA; Sigma) for 1 h at room temperature, followed by incubation with primary antibodies in PBST + BSA overnight at 4°C. Cells were rinsed 3 times with PBS and incubated with fluorophore-conjugated secondary antibody in PBST + BSA and DAPI for 1 h at room temperature and washed with PBS 3 times. Plates were imaged using a CX5 high-content imager (ThermoFisher) and the % of cells stained positive were determined using a cell scoring algorithm (ThermoFisher). Data was plotted and EC₅₀ was calculated using Prism 5 (GraphPad Software Inc, La Jolla, CA, USA). Prism 5.0 was used to calculate the EC₅₀ of the Tenocyte differentiation assay.

[0717] Exposure of the hMSCs to compound **175** at concentrations of 750, 333.3, 166.6, 83.3, 41.7, 21.7, 10.8 and 5.8 nM showed that COMPOUND 175 induced the expression of SCXA, TenascinC and Tenomodulin, in a dose-dependent manner with an EC₅₀ between 139- 189 nM (see FIGS. 2A-C and 3), indicating a differentiation of hMSC into tenocytes.

Anti-inflammation

[0718] Cell Culture. THP-1 cells (Catalog # TIB-202, ATCC, Manassas, VA) were cultured in Roswell Park Memorial Institute (RPMI) 1640 Medium (Catalog # 21870-100, Buffalo, NY) with 1% L-glutamine, 1% HEPES, 1% Sodium Pyruvate, 2% Sodium Bicarbonate supplemented with 100 units/mL penicillin, 50 µg/mL streptomycin, 2-

mercaptoethanol (0.05mM) [basal medium] and 10% fetal bovine serum (Catalog # 16140089, Life Technologies, Carlsbad, CA) at 37°C and 5% CO₂.

[0719] Cytokine Production Assay. THP-1 cells were cultured in basal media with 1% FBS for 24 hours before the start of the assay. THP-1 cells were plated at 6×10^4 cells/well and treated with DMSO (vehicle control) or compound **175** at 10 μ M highest test concentration and 2 to 3.5-fold serial dilutions up to 8 concentrations (10, 3.5, 1, 0.5, 0.1, 0.035, 0.01, 0.005 μ M). For the TNF α assay, 50 ng/mL of LPS was added to the wells after 2 hours to induce cytokine production, and cells were incubated for 5 hours at 37°C. For the IL6 assay, 500 ng/ml of LPS was added after 2 hours and cells were incubated for 22 hours at 37°C. Plates were spun in a centrifuge for 1 minute at 10,000 rpm and supernatants were collected for ELISA. Supernatants were diluted 1:1 for the TNF α assay and 1:4 for the IL6 assay using the assay medium. ELISA was performed using Human TNF- α ELISA MAXTM Deluxe (Catalog #430204, Biolegend, San Diego, CA) and Human IL-6 ELISA MAXTM Deluxe (Catalog # 430504, Biolegend, San Diego, CA) kits. Briefly, 96-well plates were coated with the appropriate capture antibody overnight and washed to remove excess antibody. Blocking buffer was added and incubated for 1 hour to prevent non-specific binding. Diluted supernatants were incubated in the coated plates for 2 hours at room temperature. Following washes to remove unbound proteins, biotinylated detection antibody was added and incubated for 30 mins at room temperature, followed by washes to remove unbound excess antibody. Avidin-HRP was then added and incubated for 30 mins at room temperature. Following several washes to remove unbound avidin-HRP, the TMB substrate was added and the plates were read on the Cytation 3 plate reader (Biotek Inc., Winooski, VT) at an absorbance of 450 nm with correction at 570 nm. All samples were processed in triplicate. Inhibition profile and EC₅₀ was calculated using Prism 5 (GraphPad Software Inc, La Jolla, CA, USA). Prism 5.0 was used to calculate the EC₅₀ of the TNF α and IL6 inhibition assays.

[0720] Exposure of THP-1 cells to LPS induced the production of both TNF α and IL6. Compound **175** treatment inhibited the LPS-induced cytokine production in these cells in a dose-dependent manner with average EC₅₀ ranging from 342 - 547 nM for TNF α and 356 - 629 nM for IL6 (see **FIGS. 4A-B**), with results generated from two independent assays and three replicates per assay.

Example 12.

Rat Tendinopathy Model (1)

[0721] Rat Model of Collagenase-induced Tendonitis. Fifty (50 μ l) of Collagenase Type IA (10 mg/ml in PBS, pH 7.4, approximately 469 units/mg) (Catalog #C5138, Sigma, St. Louis, MO) was injected into the Achilles tendon of both ankles near the

osteotendinous junction of male Sprague Dawley CD [®]IGS rats (CRL, Inc.), using insulin syringes with 28.5 G needle.

[0722] Delivery of compound 175 by Topical Application. Rats were divided into 6 groups with 5 animals per group: Group 1 (sham injection); Group 2 (Collagenase-Vehicle); Group 3 (Collagenase- compound 175 10 mg/mL with 1% BA) and Group 4 (Collagenase-COMPOUND 175 10 mg/mL with 0.5% Tween 80). COMPOUND 175, formulated in 1% HPMC 40-0101/20% PG/1% BA or 1% HPMC 40-0101/20% PG/0.5% Tween 80, or vehicle (1% HPMC 40-0101/20% PG/1% BA) was applied at a dose volume of 30 $\mu\text{L}/\text{cm}^2$ to cover a 2 cm^2 dose area to the skin near the Achilles tendon region of both ankles of the collagenase-injected rats using an applicator and rubbed into the skin for 10 seconds. All rats were periodically observed for any pain, illnesses or abnormalities. At various time points, blood was collected for plasma in lithium heparin coated tubes by saphenous vein bleeding. For histology, rats were euthanized using isoflurane, tendons were isolated (n=6 tendons/group), fixed in 10% buffered formalin (Catalog # SF93-4, Fisher, Pittsburgh PA) and H & E histology staining was performed at a secondary site (Pacific Pathology, San Diego, CA). For biochemical analysis, tendons were isolated (n=4 tendons/group), flash frozen in liquid nitrogen and then stored at -80°C for subsequent biochemical analysis (not reported).

[0723] Histology Scoring of Tendons. There is biological variability in response to collagenase when injected directly into the tendons. This results in varying degrees of severity and location of inflammation as well as tendon degeneration (Urdzikova et al., Human multipotent mesenchymal stem cells improve healing after collagenase tendon injury in the rat. *Biomed Eng Online*. 2014 Apr 9; 13:42). Therefore, the entire tendon was isolated and placed in a tissue cassette and embedded in paraffin. Five (5) μm sections were generated and an average of 3 sections were fixed on one slide, with a minimum of eight (8) slides per tendon and subjected to Hematoxylin & Eosin (H&E) staining. Slides were viewed under an upright light microscope (EVOS AMEX-1200) at a 10X magnification and scored blinded using a 1-4 scoring system of severity: 1 - representing severe damage and 4 - representing normal tendon, for Linearity of the fiber structure, Shape of the tendon cells, Density of the tendon cells, Inflammation, and Hemorrhage for a total score of twenty (20) using a modification of that described previously (Urdzikova et al., 2014 - see Table 3). After the analysis was completed, the scorer was unblinded and scores for each criterion was annotated, totaled and total scores from each section were averaged together to generate a final score for each rat followed by averaging of scores for a given treatment group.

[0724] Biomarker Assays in Plasma. Following manufacturer's instructions, KC/GRO plasma levels were determined using the KC/GRO Immunoassay kit (Catalog# 900-K57, Peprotech, Rocky Hill, NJ). Briefly, 96-well plates were coated with the anti-rat KC/GRO capture antibody overnight and washed to remove excess antibody. Plasma samples were

incubated in the coated plates for 2 hours at room temperature. Following washes to remove unbound proteins, biotinylated anti-rat KC/GRO detection antibody was added and incubated for 30 mins at room temperature. Following washes to remove unbound excess antibody, avidin-HRP was added and incubated for 30 mins at room temperature. Following washes to remove unbound Avidin-HRP, the ABTS substrate was added and the plates were read on the Cytation 3 plate reader (Biotek Inc., Winooski, VT) at an absorbance of 525 nm with correction at 450 nm. All samples were processed in triplicate.

[0725] Data Analysis. For tendon scoring, each section was analyzed following a 1-4 point scoring system as previously described (Urdzikova et al., 2014) with the exclusion of one variable, the Thickness of the epitenon, due to the difficulty in discerning the epitenon layer in histology sections. Table 4 below briefly summarizes the scoring system.

Table 4.

Variable ^a	Score and Criteria
Linearity of the fiber structure	1 = no linear areas 2 = 20-50% linear 3 = > 50% linear 4 = linear (normal)
Shape of the tendon cells	1 = predominantly round 2 = moderately round 3 = slightly oval 4 = linear (normal)
Density of the tendon cells	1 = sheets of cells 2 = moderate increase 3 = slight increase 4 = sparse(normal)
Inflammation	1 = severe increase 2 = moderate increase 3 = slight increase 4 = none
Hemorrhage	1 = predominant hemorrhage 2 = multiply areas in each field 3 = sparse or patchy 4 = none

[0726] ^aHistology Scoring was modified by Samumed to exclude one variable, Thickness of the epitenon.

[0727] In this study, a total of 64 sections were scored for Group 1 (sham injection group) and approximately 96 sections each for Group 2 (Collagenase-Vehicle), Group 3 (Collagenase-compound 175 with BA preservative) group and Group 4 (Collagenase-compound 175 without preservative). To determine statistical significance between groups, student's t-test was performed with $p < 0.05$ considered as significant for histology scoring and biomarker assay.

[0728] Compound 175 Ameliorates Collagenase-Induced Tendinopathy. Collagenase induced Tendinitis in rats recapitulates acute tendon injury in humans with inflammation resulting within a few hours (Urdzikova et al., 2014). Using an interventional approach, topical formulation of compound 175 was administered 24 hours post collagenase injection into the Achilles tendon. The Collagenase-injected rats were dosed with vehicle alone

or compound **175** (10 mg/mL) formulated with or without BA as a preservative for 21 consecutive days. Group 1 rats that received sham injections served as a control for no disease induction.

[0729] As shown in **FIG. 5**, a significant presence of inflammatory cells was evident in the Collagenase-vehicle group. Consequently, there was evidence of tendon degeneration and damage in the Collagenase-vehicle group compared to normal tendons found in the sham control group. Amelioration of inflammation as well as tendon degeneration by compound **175** is demonstrated in **FIG. 5**. The histopathology of the tendon from the treatment groups revealed tendons with decreased inflammation as well as improved structure of the fibers and tendon cells with respect to linearity, shape and density. This observation was further confirmed by blinded Histology scoring. As shown in **FIG. 6**, upon topical treatment with compound **175**, both compound **175** treatment groups demonstrated statistically significant increases in the tendon scores, achieving a score of 14.0 (± 0.217) in Group 3 (Collagenase-compound **175** with BA) and a score of 12.2 (± 0.284) in Group 4 (Collagenase-compound **175** without BA), compared to a score of 9.14 (± 2.43) in Group 2 (Collagenase-vehicle), with a p-value of <0.01 and <0.05 , respectively by student's t test.

[0730] **Compound 175 Reduces Plasma Biomarker KC/GRO in the Collagenase-induced Tendon Injury Model.** KC/GRO is an inflammatory biomarker reported to be associated with the development of tendonitis. In this study, plasma concentrations of KC/GRO were investigated at various timepoints of the study. As shown in Table 4 and **FIG. 7**, KC/GRO levels were elevated in the Group 2 (Collagenase-vehicle) on Days 5-21, ranging from 814 - 1483 pg/mL, while both the COMPOUND 175-treated groups, with or without BA, had lower levels of KC/GRO in plasma, ranging from 400 – 480 pg/mL and 347 - 451 pg/mL, respectively. Both compound **175**-treated groups (Groups 3 and 4) demonstrated a statistically significant decrease in plasma KC/GRO levels compared to Collagenase-vehicle control on Days 7 and 21 ($p<0.05$ by student's t test, Table 5). Overall, the decrease of a plasma biomarker of inflammation corroborates the ability of compound **175** to ameliorate tendonitis.

Table 5.

Day	Plasma KC/GRO Concentration (pg/mL)		
	Group 2	Group 3	Group 4
	Vehicle (0 mg/mL)	Compound 175 (10 mg/mL with 0.5% BA)	Compound 175 (10 mg/mL without BA, with 0.5% Tween 80)
0	228 $\pm$ 57.4	332 $\pm$ 51.3	530 $\pm$ 31.4
1	574 $\pm$ 106	521 $\pm$ 23.9	637 $\pm$ 120
3	376 $\pm$ 156	813 $\pm$ 61.4	541 $\pm$ 58.9
5	1185 $\pm$ 485	480 $\pm$ 48.7	410 $\pm$ 86.0
7	1483 $\pm$ 286 ^a	421 $\pm$ 57.2 [*]	451 $\pm$ 76.6 [*]
14	1356 $\pm$ 367 ^a	400 $\pm$ 10.3	424 $\pm$ 76.2
21	814 $\pm$ 92.4 ^a	408 $\pm$ 83.3 [*]	347 $\pm$ 111 [*]

[0731] ^aMean values were above quantitation limit (AQL>1000 pg/mL) and are reported as estimated.

[0732] * p<0.05 (student's t test) in Compound 175-treated groups (Groups 3 and 4) as compared to Group 2 (Vehicle) on Days 7 and 21.

[0733] Tendinopathy is an acute injury of the tendon that involves inflammation and tendon damage. If left untreated, repeated injury can lead to tendon ruptures and require surgery. The presence or absence of the preservative benzyl alcohol has no effect on the efficacy of compound 175. Treatment with compound 175 ameliorates tendinopathy as assessed by blinded histological scoring of the tendon. To further confirm this finding, it has shown that compound 175 also results in a decrease of an inflammatory plasma biomarker, KC/GRO.

Example 13.

Rat tendinopathy model (2)

[0734] Fifty (50 µl) of Collagenase Type IA (10 mg/ml in PBS, pH 7.4, approximately 469 units/mg) (Catalog #C5138, Sigma, St. Louis, MO) was injected into the Achilles tendon of both ankles near the osteotendinous junction of male Sprague Dawley CD®IGS rats (CRL, Inc.), using insulin syringes with 28.5 G needle.

[0735] **Delivery of compound 175 by Topical Application.** Rats were divided into 6 groups, with 6 animals per group except 8 animals in Group 2: Group 1 (sham injection), Group 2 (Collagenase-Vehicle with 0.5% Phx), Group 3 (Collagenase-compound 175 3 mg/mL with 0.5% BA), Group 4 (Collagenase-compound 175 10 mg/mL with 0.5% BA), Group 5 (Collagenase-compound 175 3 mg/mL with 0.5% Phx) and Group 6 (Collagenase-compound 175 10 mg/mL with 0.5% Phx). COMPOUND 175, either at 3 or 10 mg/ml, prepared in either 1% HPMC 40-0101/20% PG/0.5% BA or 1% HPMC 40-0101/20% PG/0.5% Phx or vehicle (1% HPMC 40-0101/20% PG/0.5% Phx) was applied at 30 µL/cm² over a 2 cm² area to the skin near the Achilles tendon region of both ankles of the collagenase-injected rats using an applicator, and rubbed into the skin for 10 seconds. All rats were periodically observed for any pain, illnesses or abnormalities. At various time points, blood was collected for plasma in lithium heparin coated tubes by saphenous vein bleeding. For histology, rats were euthanized using isoflurane, tendons were isolated (n=8 tendons/group), fixed in 10% buffered formalin (Catalog #SF93-4, Fisher, Pittsburgh, PA) and H & E histology staining was performed at a secondary site (Pacific Pathology, San Diego, CA). For biochemical analysis, tendons were isolated (n=4 tendons/group), flash frozen in liquid nitrogen and then stored at -80°C for subsequent biochemical analysis (not reported). Additionally, one (1) day after collagenase injection, 4 tendons were collected from Group 2 (vehicle) to observe the induction of inflammation (not reported).

[0736] There is biological variability in response to collagenase when injected directly into the tendons. This results in varying degrees of severity and location of inflammation as well as tendon degeneration (Urdzikova et al., 2014). Therefore, the entire tendon was isolated and placed in a tissue cassette and embedded in paraffin. Five (5) μ m sections were generated with an average of 3 sections being fixed on one slide with a minimum of eight (8) slides per tendon and subjected to Hematoxylin & Eosin (H&E) staining. Slides were viewed under an upright light microscope (EVOS AMEX-1200) at a 10X magnification and scored blinded using a 1-4 scoring system of severity: 1- representing severe damage and 4 - representing normal tendon, for Linearity of the fiber structure, Shape of the tendon cells, Density of the tendon cells, Inflammation, and Hemorrhage for a total score of twenty (20) using a modification of that described previously (Urdzikova et al., 2014 – see Table 3). After the analysis was completed, the scorer was unblinded and scores for each criterion was annotated, totaled and total scores from each section were averaged together to generate a final score for each rat followed by averaging of scores for a given treatment group.

[0737] **Biomarker Assays in Plasma.** Following manufacturer's instructions, KC/GRO plasma levels were determined using the KC/GRO Immunoassay kit (Cat# 900-K57, Peprotech, Rocky Hill, NJ). Briefly, 96-well plates were coated with the anti-rat KC/GRO capture antibody overnight and washed to remove excess antibody. Plasma samples were incubated in the coated plates for 2 hours at room temperature. Following washes to remove unbound proteins, biotinylated anti-rat KC/GRO detection antibody was added and incubated for 30 mins at room temperature. Following washes to remove unbound excess antibody, avidin-HRP was added and incubated for 30 mins at room temperature. Following washes to remove unbound avidin-HRP, the ABTS substrate was added and the plates were read on the Cytation 3 plate reader (Biotek Inc., Winooski, VT) at an absorbance of 525 nm with correction at 450 nm. All samples were processed in triplicate.

[0738] **Data Analysis.** For tendon scoring, each section was analyzed following a 1-4 point scoring system as previously described (Urdzikova et al., 2014) with the exclusion of one variable, Thickness of the epitenon, due to difficulty in discerning the epitenon layer in the histology sections. Table 2 below briefly summarizes the scoring system. In this study, a total of 94 sections were scored for Group 1 (sham injection, control group) and between 92-116 sections for Group 2 (Collagenase-Vehicle with 0.5%Phx); Group 3 (Collagenase-compound 175 3 mg/mL with 0.5% BA), Group 4 (Collagenase-compound 175 10 mg/mL with 0.5% BA), Group 5 (Collagenase-compound 175 3 mg/mL with 0.5% Phx) and Group 6 (Collagenase-compound 175 10 mg/mL with 0.5% Phx).

[0739] **Compound 175 Ameliorates Collagenase-Induced Tendinopathy.** Collagenase-induced tendonitis in rats recapitulates acute tendon injury in humans with inflammation resulting within a few hours (Urdzikova et al., 2014). Using an interventional

approach, topical formulation of compound **175** was administered one day (~24 hours) after the injection of collagenase into the Achilles tendon. The collagenase-injected rats were dosed with vehicle alone (containing 0.5% Phx) or compound **175** (3 or 10 mg/mL) formulated with either 0.5% BA or 0.5% Phx as a preservative for twenty-one (21) consecutive days. Group 1 rats (sham injections) served as control animals for no disease induction.

[0740] As shown in **FIG. 8**, a significant presence of inflammatory cells was evident in the Collagenase-vehicle group (Group 2). Consequently, there was evidence of tendon degeneration and damage in the Collagenase-vehicle group compared to normal tendons found in the sham control group (Group 1). Amelioration of inflammation as well as tendon degeneration by compound **175** is demonstrated in **FIG. 8**. The histopathology of the tendon from the compound **175**-treated groups revealed tendons with decreased inflammation as well as improved structure of the fibers and tendon cells with respect to linearity, shape and density. This observation was further confirmed by blinded Histology scoring. As shown in **FIG. 9**, upon topical treatment with compound **175**, all four (4) compound **175**-treated groups demonstrated statistically significant increases in the tendon scores, achieving a score of 14.5 (± 1.15) in Group 3 (Collagenase-compound **175** 3 mg/mL with 0.5% BA), a score of 14.8 (± 0.968) in Group 4 (Collagenase-compound **175** 10 mg/mL with 0.5% BA), a score of 15.1 (± 0.506) in Group 5 (Collagenase-compound **175** 3 mg/mL with 0.5% Phx) and a score of 13.2 (± 0.855) in Group 6 (Collagenase-compound **175** 10 mg/mL with 0.5% Phx), compared to a score of 8.57 (± 0.672) in Group 2 (Collagenase-vehicle), with p-values of <0.001 (Groups 3, 4 and 5) and <0.01 (Group 6) versus Group 2, by student's t test.

[0741] **Compound 175 Reduces Plasma Biomarker KC/GRO in the Collagenase-induced Tendon Injury Model.** KC/GRO is an inflammatory biomarker reported to be associated with the development of tendonitis. In this study, plasma concentrations of KC/GRO were investigated at various timepoints of the study. As shown in Table 5 and **FIG. 10**, KC/GRO levels were elevated in Group 2 (Collagenase-vehicle with 0.5% Phx) on Days 5-21, ranging from 488 - 778 pg/mL, while all four compound **175**-treated groups had decreased levels of KC/GRO in plasma, ranging from 150-561 pg/mL. Compound **175** at both 3 and 10 mg/mL dose concentrations, with either BA or Phx as preservative (Groups 3-6), demonstrated a statistically significant decrease in plasma KC/GRO levels compared to vehicle control (Group 2) on Days 5, 7 and 21 ($p<0.05$, by student's t test) as indicated in Table 6. Overall, the decrease of a plasma biomarker of inflammation corroborates the ability of compound **175** to ameliorate tendonitis.

Table 6.

Day	Plasma KC/GRO Concentration (pg/mL)				
	Vehicle	Compound 175-Treated Groups			
	Group 2	Group 3	Group 4	Group 5	Group 6
	0	3 mg/mL	10 mg/mL	3 mg/mL	10 mg/mL

	0.5% Phx	0.5% BA		0.5% Phx	
0	219 ± 94.9	78.2 ± 14.9	224 ± 40.1	112 ± 74.0	254 ± 60.6
1	450 ± 53.1	472 ± 47.2	360 ± 31.4	416 ± 47.9	375 ± 44.4
3	451 ± 50.2	449 ± 53.9	454 ± 52.2	374 ± 89.1	405 ± 42.1
5	778 ± 56.9	561 ± 97.2	327 ± 49.9*	431 ± 24.5**	328 ± 37.1**
7	708 ± 95.5	445 ± 54.5	396 ± 92.4	422 ± 47.9	299 ± 53.9*
14	704 ± 170	319 ± 57.7	343 ± 59.4	505 ± 41.0	265 ± 20.8
21	488 ± 98.8	150 ± 53.8*	350 ± 25.6	226 ± 37.3	342 ± 39.7

[0742] * $p < 0.05$ (student's t test) on Day 7 (Group 6) and on Day 21 (Group 3) compared to Group 2 (Vehicle) on Days 7 and 21.

[0743] ** $p < 0.01$ (student's t test) on Day 5 compound 175-treated groups (Groups 4, 5 and 6) compared to Group 2 (Vehicle).

[0744] Tendinopathy is an acute injury of the tendon that involves inflammation and tendon damage. If left untreated, repeated injury can lead to tendon ruptures and require surgery. Both doses of compound 175 (3 and 10 mg/ml with either BA or Phx preservatives) were efficacious in the rat tendonitis model. Based on the foregoing results, neither preservative, BA or Phx, appeared to improve the efficacy of compound 175. The results demonstrate that treatment with compound 175 ameliorated tendinopathy as assessed by blinded histological scoring of the tendon. To further confirm this finding, it has been shown that compound 175 also results in a decrease of an inflammatory plasma biomarker, KC/GRO.

Example 14.

Pharmacokinetics

[0745] Thirty (30) naïve male Sprague Dawley rats were divided into three dose groups (Groups 1-3; 10 animals/group). compound 175 was formulated in 1% hydroxypropyl methylcellulose (HPMC) 40-0101/20% propylene glycol at 1 or 10 mg/mL containing 1% benzyl alcohol (BA) as preservative (Groups 1 and 2) or at 10 mg/mL containing 0.5% Tween 80 (used in earlier rat studies) without BA preservative (Group 3). The compound 175 formulation was applied once topically to each ankle of the hind leg of each animal at 60 μL volume ($30 \mu\text{L}/\text{cm}^2 \times 2 \text{ cm}^2$) over the area of the Achilles tendon. The study design is presented in Table 7 below.

Table 7.

Group	N/Sex	Cmpd 175 Conc. (mg/mL)	Preservative ^b	Left and Right Hind limb ^a			
				Dose Volume ($\mu\text{L}/\text{cm}^2$)	Dose Area (cm^2)	Dose per Unit Area (mg/cm^2)	Total Dose Volume (μL)
1	10/M	1	BA	30	2	0.03	60
2	10/M	10				0.3	
3	10/M	10	No preservative			0.3	

[0746] ^a Topical application to left and right ankles of the hind limbs over the area of the Achilles tendon

[0747] ^b Compound 175 topical formulations: 1% HPMC 40-0101/20% propylene glycol containing 1% benzyl alcohol (BA) as preservative (Groups 1 and 2), and without BA preservative but with 0.5% Tween 80 (Group 3).

[0748] **Blood Sample Collection.** Blood samples (~0.5 mL) were collected via cardiac puncture, into tubes containing K₂EDTA as anticoagulant, at 1, 2, 4, 7 and 24 hours post-dose from 2 animals per timepoint (n=2). Plasma was harvested and frozen at -80°C for bioanalysis.

[0749] **Tissue Sample Collection.** The Achilles tendons from both ankles were collected following euthanasia at 1, 2, 4, 7 and 24 hours post-dose from 2 animals per timepoint (n=4) from all groups. Skin tissue samples were collected from the dose-site at 7 and 24 hours post-dose from 2 animals per timepoint (n=4) in Group 2. Tissues were frozen at -80°C for bioanalysis. Blood and tissue collection schedule is outlined in Table 8 below.

Table 8.

Group	Cmpd. 175 Conc. (mg/mL)	Preservative	Blood Collection Timepoints (h) ¹⁾	Tendon Collection Timepoints (h) ^b	Skin Collection Timepoints (h) ^b
1	1	BA	1, 2, 4, 7 and 24	1, 2, 4, 7 and 24	NS
2	10				7 and 24
3	10	No preservative			NS

[0750] NS = No samples collected.

[0751] ¹⁾ n=2/timepoint/group for blood collection.

[0752] ^b n=4/timepoint/group for tendon and skin collection (2 animals per timepoint x 2 ankles).

[0753] **Experimental Procedures.** Skin tissue samples were processed using the following procedures: 1) Weigh tissue and homogenize using cryoPrep (Covaris); 2) Add 9x volume of Acetonitrile:Methanol (70:30) and vortex for one hour; 3) Aliquot 100 µL of tissue homogenate into 96 microtube polypropylene plate; 4) Add 10 µL of working standard to each standard; 5) Add 10 µL of methanol in all samples and blanks; 6) Add 10 µL of internal standard (IS) to all tubes except blanks; 7) Spin in centrifuge at 3000 rpm for 10 minutes; and 8) Transfer 100 µL of supernatant into 96-well plate containing 150 µL of water. Cap and vortex for LC/MS/MS analysis.

[0754] **Bioanalytical and Pharmacokinetic Analysis.** The chromatograms of the samples were integrated and calibrated using Analyst 1.6.2 (AB Sciex, Redwood City, CA). Linear regression with 1/x² weighting and internal standardization was used for standard calibration, with an acceptance criterion of ±30% of nominal standard concentration. The lower

limit of quantitation (LLOQ) was 2.00 ng/mL (plasma), 6.00 ng/g (tendon) and 25.0 ng/g (skin). Pharmacokinetic parameters were estimated by noncompartmental analysis from individual concentration versus time profiles using Pheonix WinNonlin version 6.3 (Certara, Inc., Princeton, NJ). The time to maximum concentration ($t_{\max}$) and the maximum concentration ($C_{\max}$) were determined based on measured plasma and tissue concentrations. The area under the curve ($AUC_{0-\text{last}}$) was calculated using the linear trapezoidal rule.

[0755] Systemic Exposure. Systemic exposure to compound 175 was low compared to tendon and skin tissues after a single topical administration of a 1 or 10 mg/mL formulation, with either BA or Tween 80. Plasma exposure in Groups 1 and 2 (1 and 10 mg/mL formulation containing BA) were: 1.30 and 10.6 ng/mL $C_{\max}$ and 0.650 and 36.1 h·ng/mL $AUC_{(0-\text{last})}$, respectively, showing a dose-proportional increase in $C_{\max}$ and greater than dose-proportional increase in total exposure ($AUC_{(0-\text{last})}$). Exposure in Group 3 (10 mg/mL formulation without BA but containing Tween 80) was 1.94 ng/mL $C_{\max}$ and 6.79 h·ng/mL $AUC_{(0-\text{last})}$, which was ~0.2x of Group 2 (10 mg/mL with BA).

[0756] Tendon Exposure. Compound 175 Achilles tendon exposure in Groups 1 and 2 (1 and 10 mg/mL formulation containing BA) was 519 and 1930 ng/g $C_{\max}$ and 2164 and 7270 h·ng/g $AUC_{(0-\text{last})}$, respectively, indicating a less than dose-proportional increase in exposure: 3.4x increase in $AUC_{(0-\text{last})}$ for a 10x dose-increment. Group 3 (10 mg/mL without BA) tendon exposure was 7053 ng/g $C_{\max}$ and 28077 h·ng/g $AUC_{(0-\text{last})}$, which was ~4x of Group 2 (10 mg/mL with BA). Tendon to plasma ratios ($AUC_{(0-\text{last})}$) were 3329 and 202 in Groups 1 and 2 (1 and 10 mg/mL formulations containing BA) and 4135 in Group 3 (10 mg/mL without BA).

[0757] Skin concentrations in Group 2 (10 mg/mL containing BA) were reported as estimated as all values were above quantitation limit ($AQL > 25000$ ng/g). Mean skin concentrations at 7 and 24 hours post-dose were ~208600 and 113375 ng/g, roughly 1000x tendon concentrations at these timepoints. Plasma, Tendon and Skin PK parameters are presented below in Table 9 and concentration-time profiles are displayed in FIG. 11.

Table 9.

Group	Dose Conc. (mg/mL)	Preservative	Tissue	$t_{\max}$ (h)	$C_{\max}$ (ng/g or ng/mL)	t_{last} (h)	$AUC_{(0-\text{last})}$ (h·ng/g or h·ng/mL)	Tissue/Plasma AUC Ratio
1	1	1% BA	Plasma	1.00	1.30	1.00	0.650	3329
			Tendon	1.00	519	24.0	2164	
2	10	1% BA	Plasma	4.00	10.6	7.00	36.1	202
			Tendon	1.00	1930	24.0	7270	
			Skin	7.00	208600 ¹⁾	24.0	NC	NC
3	10	No preservative	Plasma	7.00	1.94	7.00	6.79	4135
			Tendon	1.00	7053	24.0	28077	

[0758] Total dose volume = 60 μ L/ankle of hind limb; n=2 (plasma), n=4 (tendon, skin; 2).

[0759] NC = not calculated due to lack of sufficient timepoints for AUC calculation.


[0760] ¹⁾ Above quantitation limit (AQL>25000 ng/g) - value reported as estimated.

[0761] Systemic exposure to compound 175 in rats after a single topical administration was low in all dose groups compared to tendon exposure, with tendon to plasma ratios ranging from 202 to 4135 across groups. A dose dependent increase in plasma and tendon exposure was seen between the 1 and 10 mg/mL formulations containing BA. While the 10 mg/mL formulation without BA (containing Tween 80) showed lower systemic exposures (0.2x) compared to the formulation containing BA, the tendon exposure was 4 fold higher than the 10 mg/mL formulation containing BA.

[0762] The term “comprising” as used herein is synonymous with “including,” “containing,” or “characterized by,” and is inclusive or open-ended and does not exclude additional, unrecited elements or method steps.

WHAT IS CLAIMED IS:

1. A method of treating of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease, the method comprising administering to a subject (e.g., a subject in need thereof) a compound or pharmaceutically acceptable salt thereof having the structure of Formula I:



wherein:

R^1 , R^2 and R^4 are independently selected from the group consisting of H, C_{1-9} alkyl, halide, $-N(R^{10})_2$, $-XR^{10}$, CN, $-OCF_3$ and $-CF_3$;

R^3 is selected from the group consisting of carbocyclyl R^6 , heterocyclyl R^6 , aryl R^6 and heteroaryl R^6 ;

R^5 is selected from the group consisting of $-(C_{1-9} \text{ alkyl})_n$ carbocyclyl R^7 , $-(C_{1-9} \text{ alkyl})_n$ heterocyclyl R^7 , $-(C_{1-9} \text{ alkyl})_n$ aryl R^7 and $-(C_{1-9} \text{ alkyl})_n$ heteroaryl R^7 ;

each R^6 is 1-5 substituents each selected from the group consisting of H, C_{1-9} alkyl, halide, amino, $-OCF_3$, $-CF_3$, $-CN$, $-XR^{10}$, $-(C_{1-9} \text{ alkyl})_n$ carbocyclyl R^8 , $-(C_{1-9} \text{ alkyl})_n$ heterocyclyl R^8 , $-(C_{1-9} \text{ alkyl})_n$ aryl R^8 , $-(C_{1-9} \text{ alkyl})_n$ heteroaryl R^8 , $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$;

each R^7 is 1-5 substituents each selected from the group consisting of H, C_{1-9} alkyl, halide, amino, $-OCF_3$, $-CF_3$, $-CN$, $-XR^{10}$, $-(C_{1-9} \text{ alkyl})_n$ carbocyclyl R^9 , $-(C_{1-9} \text{ alkyl})_n$ heterocyclyl R^9 , $-(C_{1-9} \text{ alkyl})_n$ aryl R^9 , $-(C_{1-9} \text{ alkyl})_n$ heteroaryl R^9 , $-C(=O)R^{11}$, $-N(R^{10})C(=O)R^{11}$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})SO_2R^{11}$ and $-SO_2R^{11}$;

each R^8 is 1-5 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, OCF_3 , $-CF_3$, $-CN$, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1-9} \text{ alkyl})_nN(R^{12})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$;

each R^9 is 1-5 substituents each selected from the group consisting of H, C_{1-3} alkyl, halide, amino, $-OCF_3$, $-CF_3$, $-CN$, $-XR^{12}$, $-C(=O)R^{13}$, $-N(R^{12})C(=O)R^{13}$, $-(C_{1-9} \text{ alkyl})_nN(R^{12})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{12})SO_2R^{13}$ and $-SO_2R^{13}$;

each R^{10} is independently selected from the group consisting of H, C_{1-9} alkyl, $-(C_{1-9} \text{ alkyl})_nN(R^{14})_2$, $-(C_{1-9} \text{ alkyl})_n$ carbocyclyl R^8 , $-(C_{1-9} \text{ alkyl})_n$ heterocyclyl R^8 , $-(C_{1-9} \text{ alkyl})_n$ aryl R^8 and $-(C_{1-9} \text{ alkyl})_n$ heteroaryl R^8 ;

each R^{11} is independently selected from the group consisting of C_{1-9} alkyl, $-N(R^{14})_2$, $-(C_{1-9} \text{ alkyl})_n\text{carbocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n\text{heterocyclyl}R^8$, $-(C_{1-9} \text{ alkyl})_n\text{aryl}R^8$ and $-(C_{1-9} \text{ alkyl})_n\text{heteroaryl}R^8$;

each R^{12} is independently selected from the group consisting of H, C_{1-9} alkyl, $-(C_{1-9} \text{ alkyl})_nN(R^{14})_2$, $-(C_{1-9} \text{ alkyl})_n\text{carbocyclyl}$, $-(C_{1-9} \text{ alkyl})_n\text{heterocyclyl}$, $-(C_{1-9} \text{ alkyl})_n\text{aryl}$ and $-(C_{1-9} \text{ alkyl})_n\text{heteroaryl}$;

each R^{13} is independently selected from the group consisting of C_{1-9} alkyl, $-N(R^{14})_2$, $-(C_{1-9} \text{ alkyl})_n\text{carbocyclyl}$, $-(C_{1-9} \text{ alkyl})_n\text{heterocyclyl}$, $-(C_{1-9} \text{ alkyl})_n\text{aryl}$ and $-(C_{1-9} \text{ alkyl})_n\text{heteroaryl}$;

each R^{14} is independently selected from the group consisting of H, C_{1-3} alkyl, carbocyclyl and aryl;

each X is selected from the group consisting of a bond, -O- and -S-; and

each n is 0 or 1.

2. The method of claim 1, wherein R^1 , R^2 and R^4 are H.
3. The method of claim 2, wherein R^3 is 3-pyridyl R^6 .
4. The method of claim 2, wherein R^3 is 5-pyrimidinyl R^6 .
5. The method of claim 2, wherein R^3 is 4-pyridazinyl R^6 .
6. The method of claim 3, wherein R^6 is one substituent and is $-N(R^9)C(=O)R^{10}$.
7. The method of claim 3, wherein R^6 is one substituent and is $-(CH_2)\text{heterocyclyl}R^8$.


8. The method of claim 7, wherein the R^6 heterocyclyl is independently selected from the group consisting of azetidiny R^8 , pyrrolidinyl R^8 , piperidinyl R^8 , piperazinyl R^8 , and morpholinyl R^8 .


9. The method of claim 2, wherein R^5 is 3-pyridyl R^7 .
10. The method of claim 3, wherein R^5 is 3-pyridyl R^7 .
11. The method of claim 2, wherein R^5 is 5-pyrimidinyl R^7 .
12. The method of claim 2, wherein R^5 is 4-pyridazinyl R^7 .
13. The method of claim 9, wherein R^7 is one substituent and is selected from the group consisting of halide, $-OCF_3$, $-CF_3$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})SO_2R^{11}$ and $-N(R^{10})C(=O)R^{11}$.


14. The method of claim 10, wherein R^7 is one substituent and is selected from the group consisting of halide, $-OCF_3$, $-CF_3$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})_2$, $-(C_{1-9} \text{ alkyl})_nN(R^{10})SO_2R^{11}$ and $-N(R^{10})C(=O)R^{11}$.


15. The method of claim 9, wherein R^7 is one substituent and is selected from the group consisting of $-OR^{10}$ and $-C(=O)R^{11}$ where R^{11} is $-N(R^{10})_2$, and each R^{10} is independently selected from the group consisting of H, methyl and $-(C_{1-9} \text{ alkyl})_n\text{carbocyclyl}R^8$ where n is 0 and each R^8 is 1-2 substituents independently selected from H or halide.


17. The method of claim 1, the compound having a structure selected from the group consisting of:
































18. The method of claim 17, the compound having a structure selected from the group consisting of:







19. The method of claim 17, the compound having a structure selected from the group consisting of:






20. The method of claim 17, the compound having a structure selected from the group consisting of:








pharmaceutically acceptable salt thereof.





22. The method of claim 17, the compound having a structure selected from the group consisting of:





, , and , or a pharmaceutically acceptable salt thereof.

23. The method of claim 17, the compound having a structure selected from the group consisting of:











25. The method of claim 17, the compound having a structure selected from the group consisting of:



26. A method of treating of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease, the method comprising administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of a compound or pharmaceutically acceptable salt thereof having the structure of Formula Ia:



Ia


wherein:

R^3 is 3-pyridyl R^6 ;

R^5 is selected from the group consisting of pyridyl R^7 , -pyrimidinyl R^7 , and -pyridazinyl R^7 ;

R^6 is $-\text{CH}_2\text{heterocyclyl}R^8$;

R^7 is 1-2 substituents each independently selected from the group consisting of H, F,




R^8 is 1-2 substituents each independently selected from the group consisting of H and halide.

27. The method of claim 26, wherein the R^6 heterocyclyl is selected from the group consisting of azetidiny R^8 , pyrrolidinyl R^8 , piperidinyl R^8 , piperazinyl R^8 , and morpholinyl R^8 .

28. The method of claim 26, wherein R^6 is $-\text{CH}_2\text{piperidinyl}R^8$.

29. The method of claim 26, wherein R^7 is selected from the group consisting of




30. The compound of claim 27, wherein R^8 is H.

31. The compound of claim 28, wherein R^8 is H.48.


32. A method of treating of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease, the method comprising administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of a compound or

pharmaceutically acceptable salt thereof having the structure of:




33. A method of treating of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease, the method comprising administering to a subject

(e.g., a subject in need thereof) a therapeutically effective amount of a compound or



pharmaceutically acceptable salt thereof having the structure of:

34. A method of treating of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease, the method comprising administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of a compound or



pharmaceutically acceptable salt thereof having the structure of:

35. The method of any one of claims 1-34, wherein the one or more diseases or conditions is a tendinopathy.

36. The method of claim 35, wherein the tendinopathy is tendinosis.

37. The method of claim 35, wherein the tendinopathy is tendinitis.

38. The method of claim 35, wherein the tendinopathy is tenosynovitis.


39. The method of any one of claims 1-34, wherein the one or more diseases or conditions is dermatitis.

40. The method of claim 39, wherein the dermatitis is contact dermatitis.



41. The method of claim 39, wherein the dermatitis is atopic dermatitis.

42. The method of any one of claims 1-34, wherein the one or more diseases or conditions is psoriasis.

1/12

**FIG. 1**

2/12

**FIG. 2A****FIG. 2B**

3/12




FIG. 2C

4/12




FIG. 3

5/12




FIG. 4A






FIG. 4B


6/12




7/12

**FIG. 6**

8/12

**FIG. 7**

9/12

**FIG. 8**

10/12





FIG. 9

11/12

KC/GRO**FIG. 10**




FIG. 11




FIG. 1